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Abstract 
Mastitis is one of the most economically important diseases of dairy cattle in 
Australia causing an annual loss of more than $130 million per year. 
Staphylococcus aureus is the predominant contagious pathogen causing clinical 
bovine mastitis in Australia. The only effective treatment available against S. 
aureus-associated mastitis is treatment with antibiotics. However, due to emergence 
of antibiotic resistance by S. aureus strains and ability of the pathogen to develop 
biofilm in mammary gland, there is only 0-52% cure rate of mastitis in lactating 
animals. In the given scenario, there is an urgent need of an effective vaccine, 
which could facilitate prevention of bovine mastitis caused by S. aureus, 
particularly where herd management is failing. 
  
The ultimate objective of this project was to develop an effective vaccine for 
prevention of bovine mastitis in cows taking into consideration the virulence factors 
and biofilm forming properties of S. aureus isolated from cases of bovine mastitis 
in cows. A total of 154 isolates of S. aureus from Victoria and Queensland were 
used in the study. Detection of biofilm formation by 154 S. aureus strains was 
accomplished using CRA and TCP methods which revealed the superiority of TCP 
method. TCP method could determine biofilm forming ability of 100% of the 
strains whereas only 31.17% of strains producing biofilm could be determined by 
CRA method. Amplification of icaA and icaD genes by conventional PCR showed 
that approximately 66.23% of the S. aureus isolates expressed icaA and icaD genes, 
respectively. However, only 2 (1.3%) strains were positive for the bap gene. No 
apparent relationship between biofilm formation by bovine S. aureus isolates and 
presence of ica loci, bap gene or agr types was evident in the current study, 
although  a possible correlation between blaZ gene and penicillin resistance was 
evident. The antimicrobial susceptibility study of the 154 S. aureus strains against 
12 different antimicrobial agents revealed that 100% of the strains were sensitive to 
cefoxitin and co-trimoxazole. Only 1 (0.65%) strain each was found resistant 
against cephalexin, tetracycline, vancomycin, rifampicin and linezolid, respectively. 
None of the S. aureus isolates were found to be resistant to methicillin as judged by 
the absence of mecA gene. Studies on the development of persistent antibiotic 
resistance by S. aureus revealed that the selected strains used in this study 
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developed resistance to more than one antibiotic after formation of biofilm. The 
resistance persisted as long as 4 weeks and then reverted back to antibiotic 
susceptibility when grown as planktonic cultures.   
  
Detection of virulence factors of 154 S. aureus isolates of bovine mastitis origin has 
revealed that clfA (91.56%), clfB (92.86%), spa (87.7%), fnbpA (54.5%), isdA 
(98.1%), isdB (100%), sdrD (98.1%) and sdrE (95.5%) were the predominant 
MSCRAMMS, with α-toxin (94.16%), β-toxin (83.12%) being the predominant 
cytotoxins. A total of 4 (2.6%) isolates were found to carry the pvl gene. The 
potentially superantigenic enterotoxins produced by S. aureus isolates were seh 
(32.5%), sec (23.4%), seg (17.5%) and sei (13%).  
  
Both genotyping and serotyping studies have revealed that 64.29% of S. aureus 
isolates were encapsulated with CP8 (31.82%) and CP5 (23.38%) being the 
predominant capsular types. Thirty percent of Australian S. aureus isolates from 
bovine origin were found to be non-typeable. There was a strong correlation 
between both the methods of CP typing for detection of CP types 1, 5 and 8, and 
the non-typeable S. aureus isolates. 
  
A non-invasive mouse mastitis model, involving inoculation of S. aureus into 
mammary gland via mammary duct without traumatising the mammary gland 
surface epithelium or glands was established to enable evaluation of the 
immunogenicity and protective potential of vaccine candidates used in this study. 
Potential association of icaA and icaD genes and strength of biofilms of S. aureus 
in damage of mammary tissue was apparent in the investigation. Mice infected with 
encapsulated (CP8) strong biofilm forming S. aureus produced more severe mastitis 
lesions with evidence of necrosis in the mammary glands than in mice infected with 
CP8 encapsulated but weak biofilm forming S. aureus strain. This study also 
demonstrated the potential role of the pro-inflammatory cytokines, TNF-α in the 
tissue damage caused by S. aureus to the mammary glands. The level of TNF-α was 
significantly higher in sera sample of mice inoculated with the strong biofilm 
forming S. aureus than the weak biofilm forming strain even at 48 h post infection.  
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Mice infected with two different non-typeable S. aureus strains via intraductal route 
of mammary glands demonstrated minimal inflammatory infiltrates and tissue 
damage in the mammary glands. But the mice died within 24-36 h of post infection 
with S. aureus. Analysis of sera samples using collected from mice immediately 
before death showed significantly higher levels of pro-inflammatory cytokines 
particularly IL-6 suggestive of cytokine storm as the potential cause of death of 
mice. The potential role of IL-6 in the early mortality observed in mice was 
confirmed by the fact that administration of anti IL-6 and anti IL-6Rβ antibodies 
delayed the mortality for up to 13h 15 min. Severity of mastitis was also reduced in 
terms of clinical symptoms and bacterial loads from the mammary glands. The 
study highlights the potential importance of using anti-cytokine antibodies in the 
treatment of bovine mastitis and other S. aureus-associated infections. 
  
Mice immunized with formalin killed whole cell of S. aureus residing in biofilm 
and delivered via i/mam route developed cell mediated immune response (CMI) as 
measured by IFN-γ as an indirect indicator of CMI. Mice immunised with this 
biofilm vaccine significantly reduced colonization of S. aureus in mammary gland, 
severity of clinical symptoms and tissue damage in mammary gland in comparison 
with the mice immunized with formalin killed whole cell of planktonic S. aureus. 
The planktonic vaccine administered by s/c route produced significantly higher 
humoral immune response than the biofilm vaccine. However, considering the 
tissue damage, clinical severity and colonisation of S. aureus in mammary gland the 
biofilm vaccine performed better when administered by i/mam route. 
  
Protein A (spa), being prevalent in 87.7% of the isolates of S. aureus collected from 
bovine mastitis cases in Australia was used as a potential vaccine candidate against 
bovine mastitis using the mouse mastitis model established in this investigation. A 
moderate level of humoral antibody (IgG, IgG1 and IgG2a) response were 
produced in mice immunised by the s/c route, with lower level produced in mice 
immunised by the i/mam route. However, no significant difference in the CMI 
responses of mice immunised with planktonic vaccine was observed regardless of 
the route of immunisation. Furthermore, there was no difference in the clinical 
symptoms, bacterial loads or histopathological damage in mice immunised by s/c 
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versus i/mam route pointing out the unsuitability of Protein A as a component of 
any cocktail bovine mastitis vaccine. 
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Chapter 1: Literature review 
 
1.1 Bovine mastitis 
Mastitis (Mast: breast, itis: inflammation) is an inflammatory reaction of the 
mammary gland which may result from bacterial, thermal or physical causes. 
Mastitis leads to changes in the physical and chemical quality of milk and 
pathological changes in the mammary gland tissue. There are changes in the colour 
and consistency of milk from udder of cows suffering from mastitis. Milk from 
mastitis udder contains increased levels of serum albumin, immunoglobulins, 
somatic cells and decreased levels of casein, lactose and potassium (Auldist and 
Hubble, 1998). Pathological changes in the mammary gland of cow suffering from 
mastitis broadly include infiltration of inflammatory cells, abscess formation and 
degeneration of mammary tissue including necrosis (Gudding et al., 1984). 
 
1.1.1 Classification of bovine mastitis  
Mastitis can be classified as clinical or subclinical mastitis. There are visible 
abnormalities in milk and udder in clinical mastitis. The commonly observed 
abnormalities are swelling, heat, hardness and pain in udder and clots, blood, flakes 
in milk making it look watery. On the basis of level of severity, clinical mastitis can 
be further classified as sub-acute clinical, acute clinical, per-acute clinical and 
chronic clinical mastitis (Blood and Rodostits, 1989). In sub-acute clinical mastitis, 
there are very limited abnormalities including appearance of flakes in milk in initial 
ejections, slight swelling and reduction in milk production and microscopic changes 
in quality of milk. Acute clinical mastitis is always accompanied by redness, 
swelling, pain in the udder. There are prominent changes in the quality and quantity 
of milk with the manifestations of fever, anorexia and dehydration in cows. The most 
severe form of clinical mastitis is per-acute form where there is sudden death of the 
animal resulting from systemic infection and extensive damage of udder tissue. The 
chronic clinical form of mastitis results due to inadequate treatment of acute forms of 
mastitis. 
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In subclinical mastitis there are no any visible changes in udder or milk. The milk 
appears to be normal and the udder looks healthy. The only prominent observation is 
the sudden reduction in milk yield and quality of milk as judged by increased number 
of somatic cell count (SCC). Subclinical mastitis can be divided into two groups; 
infectious or non-infectious subclinical mastitis. The causative agent of infectious 
sub-clinical mastitis is a bacterial pathogen and there is elevation in the level of 
somatic cell count (SCC) in milk accompanied by reduction in milk production. The 
non-infectious sub clinical mastitis is due to other conditions such as age, trauma, 
season and there is absence of a pathogenic bacterium in milk. The SCC is elevated 
and there is reduction in milk yield from the udder. The udder is occasionally 
swollen and there is formation of fibrous tissue in the udder. There is absence of 
systemic changes in the cow and milk may contain some white flakes or bloody 
clots. 
 
1.2 Economic implications of bovine mastitis 
Mastitis is one of the most economically devastating diseases of dairy cattle 
particularly for the back yard farmers in developing world, with different levels of 
economic losses reported by different countries. As it is a production related disease 
the loss associated with bovine mastitis are reduction in milk production, poor 
quality of milk and milk-products, preventive measures of mastitis, treatment cost 
including cost of drug, veterinary services, culling of infected cows, cost of labour 
(Hogeveen and Osteras, 2005). Per-acute cases of mastitis may lead to sudden death 
of cows causing maximum loss to dairy farmers (Menzies et al., 1995). The total 
annual loss due to bovine mastitis is estimated to be $35 billion all over the world 
(Ratafia, 1987). The cost of mastitis involving various factors may differ from 
country to country, but the economic principles involved for loss are similar in all 
countries (Hogaveen and Osteras, 2005; Halasa et al., 2007). A comparative data 
compiling the loss due to mastitis in different countries is presented in Table 1.1. 
 
1.3 Epidemiology of bovine mastitis 
1.3.1 Etiology of bovine mastitis 
Major advances in the fields of animal breeding, animal nutrition and husbandry 
practices have played a significant role in increasing the global milk yield over the  
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               Table 1.1: Comparative Data on loss due to mastitis in different countries 
 
Rank 
 
Country 
 
 
Milk 
production 
(million MT)* 
 
Losses due to mastitis 
Annual 
(US$ 
equivalent, 
million) 
 
Per cow per 
year (US$ 
equivalent) 
 
Year of 
estimate 
 
Reference 
 
1 
India 107.03 
1150-1200  2001 Dua, 2001 
320  1994 Singh and Singh, 
1994 
2 United States 
of America 
85.88 
1700-1800 185 1996 Bramley et al., 
1996 
3 
China 38.51 
 160 1991 Fang et al., 1991 
4 
Pakistan 33.61 
NA NA   
5 Russian 
Federation 
32.33 
NA NA   
6 
Brazil 30.00 
 95-142 2005 Swinkels et al., 
2005 
7 
Germany 29.20 
 285 2001 Hamann, 2001 
8 
France 22.65 
 102.42 2006 Fourichon et al., 
2001 
9 
New Zealand 15.67 
 67.70 1993 Holdaway, 1993 
 72.56 1990 Scharenraad and  
Dijkhuizen, 1990 
10 
United 
Kingdom 
13.24 
NA 191.26 
 
1999 
 
Bennett et al., 
1999 
 
75-131 1993 Esslemont and  
Peeler, 1993 
11 
Poland 12.45 
NA 22-257 2011  
12 
Turkey 11.61 
NA 72.56 1990  
13 
Netherlands 11.47 
   Hogeveen et al., 
2011 
   Scharenraad and  
Dijkhuizen, 1990 
14 
Ukraine 11.36 
NA    
15 
Mexico 10.55 
NA    
16 
Italy 10.70 
NA    
17 
Argentina 10.37 
NA    
18 
Australia 9.39 
130 200 2011 Dairy Australia, 
2011 
19 
Canada 8.21 
 19.6 1996 Dekkers et al., 
1996 
20 
Japan 7.91 
NA    
                                   NA=Not available   *Combined output from cows and buffaloes as of 2009         
   (FAO:http://faostat.fao.org/site/339/default.aspx).  
 
last 2 decades (Shook, 2006) meeting the overwhelming demand for milk and milk 
products. There have been continuous changes in the predominance of etiological of 
mastitis (Zadoks and Fitzpatrick, 2009), greater understanding of the host responses 
to intra-mammary infections (Oviedo-Boyso et al., 2007; Attalla et al., 2010) and 
treatment regimens leading to adoption of various control and prevention measures. 
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Regardless, the problem of mastitis continues to pose the greatest challenge to the 
dairy industry worldwide. As many as 137 species and subspecies of microbes can be 
associated with mammary infection (Watts, 1988). The predominant causal organism 
is bacteria; however, instances of Mycoplasma, yeast and algal infection have also 
been reported (Wilson et al., 1997; Barkema et al., 1998; Fox et al., 2005). 
Mycoplasma species associated with mastitis in cows are Mycoplasma bovis, 
Mycoplasma bovigenitalium, Mycoplasma canadense, Mycoplasma californicum and 
Mycoplasma alkalescens. Prototheca, a group of yeast-like micro-algae that have 
been described as a cause of mastitis in Japan, Europe and North and South America 
(Ruth et al., 2011). 
 
Mastitis in dairy herds is generally of two types: Environmental mastitis and 
contagious mastitis. They differ in their causal factors. 
 
Environmental mastitis is caused by the coliform bacteria that enter through the teat 
canal contacted through contaminated environment (Boyer, 1997). As coliform 
bacteria are normal inhabitants of soil, digestive tract and manure, they multiply in 
contaminated bedding and a substantial proliferation in their numbers (to the tune of 
1000,000 or more per gram of bedding) increase the probability of infection and 
clinical mastitis (Bradley and Green, 1997). Coliforms particularly Escherichia coli, 
Enterobacter aerogenes, Klebsiella pneumonia and Serratia marcescens and a 
Streptococcus sp, Streptococcus uberis, are the chief organisms found to cause 
environmental mastitis. The cases of environmental mastitis however rarely exceed 
10% of the total cases even though there is an increasing body of evidence 
suggesting the contrary (Boyer, 1997; Bradley and Green, 1997; Edmondson, 1997; 
Bradley and Green, 2001; Bradley et al., 2007; Dairy Australia, 2011) particularly 
with regards to mastitis associated with S. uberis infection.  
 
Contagious mastitis is caused by bacteria that thrive on the skin of the teat or inside 
of the udder and is transmitted by milking. The pathogens mainly associated with 
contagious mastitis are Staphylococcus aureus, Streptococcus dysgalactiae and 
Streptococcus agalactiae. However, the most recognised pathogen in majority of 
clinical and subclinical mastitis cases (40.5%) in most countries is S. aureus 
(Workineh et al., 2002; Middleton, 2008; Pereira et al., 2011). These bacteria are of 
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immense importance because though their prevalence seldom exceeds 25% in intra-
mammary infections; their effect clearly affects the milk quality premiums and 
account for a considerable portion of clinical cases (Owens et al., 1988). They are 
considered the emerging pathogens of bovine mastitis as they are the most 
commonly isolated ones (Pyolara and Taponen, 2009; Pereira et al., 2011). In cattle, 
mastitis is the only disease associated with S. agalactiae infection and transmission 
within the herds occurs due to inadequate hygiene in the farm (Ruth et al., 2011). S. 
aureus is a versatile organism and it also demonstrates strain-specific associations 
with somatic cell count, milk yield, biofilm production, clinical signs, persistence 
and treatment response (Ruth et al., 2011). 
 
In addition to Staphylococcus sp, Corynebacterium sp constitute some of the 
emerging pathogens causing bovine mastitis. Corynebacterium bovis is frequently 
isolated from milk in many dairy farms and causes moderate inflammation of the 
mammary gland (Hommez et al., 1999; Haltia et al., 2006). These infections result in 
a slight increase in bulk tank somatic cell counts, changes in the composition of milk, 
sudden reduction in milk production and clinical mastitis (Harmon, 1994). Four 
species of non-lipophilic Corynebacteria found to cause clinical and sub-clinical 
mastitis are C. amycolatum, C. ulcerans, C. pseudotuberculosis, and C. 
minutissimum (Hommez et al., 1999). Other species of Corynbacterium isolated from 
cases of clinical mastitis in sheep are C mastiditis and C. camporealensis 
(Fernandez-Garayzabal, 1997a, b).  
 
Recent studies have revealed that coagulase negative staphylococci (CoNS) isolated 
from teat skin, teat canal, and vagina as well as from the coat and the nostril 
comprises an area of interest as causal organisms of bovine mastitis (Pittkala et al., 
2004; Tenhagen et al., 2006). Mastitis in heifers at calving is mainly caused by 
CoNS. More than 50 species and subspecies of coagulase negative staphylococci are 
included in this group (Pyolara and Taponen, 2009), Staphylococcus epidermidis, 
Staphylococcus simulans, Staphylococcus saprophyticus, Staphylococcus hyicus, 
Staphylococcus warneri, Staphylococcus chromogenes, Staphylococcus scrimi and 
Staphylococcus xylosus being the commonly encountered species of CoNS in bovine 
mastitis (Rupp et al., 2000). The various species of CoNS isolated from bovine 
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mastitis cases show varied pathogenicity, antimicrobial susceptibility and virulence 
factors (Zadoks and Schukken, 2006; Taponen and Pyolara, 2009).  
 
Mastitis caused by fungi and yeast is uncommon. The fungi commonly associated 
with mastitis are Candida sp, Trichosporon sp, Saccharomyces sp and Aspergillus sp 
(Chahota et al., 2001). A very rare case of mastitis caused by yeast like fungus, 
Geotrichum candidum has also been reported (Chahota et al., 2001). Though the 
incidence of mycotic mastitis is very low, serious problems may arise when it occurs 
in enzootic form (Sharma et al., 2012).  
 
1.3.2 Factors affecting occurrence of bovine mastitis 
1.3.2.1 Host factors associated with bovine mastitis 
The large number of predisposing factors that contribute to the emergence of mastitis 
in dairy cattle may be physiological, genetic, pathological or environmental 
(Sordillo, 2005) are described below:  
 
1.3.2.1.1 Age of the cow 
 It has been demonstrated that occurrence of mastitis in infected quarters increases 
with age in cows (Emanuelson and Persson, 1984; Harmon, 1994; Busato et al., 
2000; Sharma et al., 2007; Sharma and Maiti, 2010), being the highest at 7 years of 
age (Schukken et al., 1989). This may be due to an increased cellular response to 
intramammary infection or due to permanent udder tissue damage resulting from the 
primary infection. Efficient innate host defence mechanisms of the younger animals 
are one possibility that makes them less susceptible to infection (Dulin et al., 1988). 
However, at least one study conducted using 4133 cattle including both cross-bred 
and non-descriptive breeds, revealed the highest risk of occurrence of mastitis to be 
between the ages of 4-6 years, followed by the age group between 2-4 years, with the 
least occurrence noted between 6-8 years of age (Mahajan et al., 2011). Interestingly 
it was noted in this study that the cross bred animals were 2.55 times more 
susceptible to mastitis than the non-descript or indigenous ones. 
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1.3.2.1.2 Inherited features of the bovine 
 Various genetic traits may also have a considerable impact upon the susceptibility of 
the animal to mastitis. These genetic traits include the natural resistance, teat shape 
and conformation, positioning of udders, relative distance between teats, milk yield 
and fat content of milk. High milk yielders with higher than average fat content are 
reported to be more susceptible to mastitis (Grohn et al., 1990; Rajala and Grohn, 
1999; Lactation Resource Library, 2009). The conformation of the udder and shape 
of the teat are inherited characteristics that may also affect susceptibility to mastitis. 
Cows with elongated teats are more vulnerable to mastitis infection than cows with 
inverted teat ends (Rathore, 1976; Seykora and McDaniel, 1985). Broad udders, 
lower hind-quarters and teats placed widely help the infectious agent and should be 
selected against (Thomas et al., 1984). Another important predisposing factor for 
mastitis is super numerous teats, which provide additional reservoirs for potential 
pathogens leading to manifestation of mastitis.  
 
1.3.2.1.3 Stage of lactation: 
 The incidence of mastitis is reported to be higher immediately after parturition, early 
lactation and during the dry period, especially the first 2-3 weeks (Schukken et al., 
1989; Ellis, 2005; Corbett, 2009; Fadlelmula et al., 2009) due probably to increased 
oxidative stress and reduced antioxidant defence mechanisms during early lactation 
(Sharma et al., 2011). An increase in somatic cell numbers or count (SCC) which is 
mainly neutrophils is observed immediately after parturition, which remains high for 
a few weeks irrespective of the presence or absence of infection (Plastridge, 1958; 
Bradley and Green, 2005). This increased SCC is the cow’s natural first line of 
defence to prepare for the onset of the new lactation. Relatively recent studies have 
revealed that cows in late lactation always show a higher than average SCC than that 
seen at other stages of the lactation period (Peeler et al., 2000), potentially 
representing increased subclinical infection, leading to a fall in milk production. Milk 
somatic cells are primarily leukocytes or white blood cells including macrophages, 
lymphocytes and neutrophils, which serve as a defence mechanism to fight infection 
and assist in repairing damaged tissue. 
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1.3.2.1.4 Mammary regression: 
 There are significant functional changes in the udder during the early and late 
lactation and dry period, which affect the cow’s susceptibility to infections (Giesecke 
et al., 1994; Capuco et al., 2003). Lactating cows under stress show premature 
mammary regression. Such a condition compromises udder’s natural defence 
mechanisms (Giesecke et al., 1994; Capuco et al., 2003) leading to invasion of the 
teat canals by potential pathogens. The same condition prevails during the healing 
process of lesions because the resistance to causal agents remains less effective.  
 
1.3.2.2 Environmental factors associated with mastitis 
1.3.2.2.1 Milking machine 
Extraneous factors such as the milking habits of farmers and faulty milking machines 
favour the pathogens to gain access to mammary gland and proliferate, potentially 
leading to mastitis (Mein et al., 2004). In farms where machines are employed for 
milking it is important to maintain physiologically optimal pressure [50 kPa for most 
machines], because pressures in excess of this may lead to injury in the teat (Blood 
and Rodostits, 1989). Fluctuations in the pressure due to inadequate vacuum reserve 
must be avoided to prevent occurrence of mastitis. Proper installation as well as the 
correct maintenance of milking machines is important to avoid an inadequate 
vacuum level, teat and tissue damage and incomplete milking (International Dairy 
Federation, 1987). The vacuum level created by the vacuum pump is another 
important factor for complete and high quality milking. Experiments have shown that 
a teat subjected to a vacuum level of 10.5-12.5 inches at the time of peak milk flow 
results in rapid, complete and high quality milk yield, and the teat suffers minimum 
physical pressure (Jones, 2009a). Two-chambered teat cups are found to be better 
than single chambered teat cups in regard to achieving complete milking as well as 
fewer incidences of teat injuries (Mein and Schuring, 2003). However, there is a 
report of increased risk of both contagious and environmental mastitis causing 
pathogen due to machine induced changes, which widen the orifice of the teat canal 
in cows (Mein et al., 2001).  
 
1.3.2.2.2 Nutrition 
 The quality and plan of nutrition appears to be an important factor that influences 
clinical manifestation of mastitis in heifers and cows (Heinrichs, 2009) although no 
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relationship between the incidence of mastitis and either high energy or high protein 
feed in cows has been reported (Madsen and Nielsen, 1981; Rodenburg, 2012). 
  
Vitamin E is one of the important supplements in dairy feed to boost the immune 
response of cows (Spears and Weiss, 2008) as it has been reported to enhance the 
neutrophil function as well as the phagocytic properties of neutrophils after 
parturition (Hogan et al., 1992). Vitamin E is often combined with selenium, which 
acts as an anti-oxidant by preventing oxidative stress (Chamberlain and Wilkenson, 
1996; Mustacich and Powis, 2000). A number of investigations have demonstrated 
that neutrophils of selenium fed cows are more effective at killing mastitis causing 
microorganism such as E. coli than those not supplemented with selenium 
(Underwood and Suttle, 1999).  
 
Beta-carotene and Vitamin A have also been found to be effective in preventing the 
occurrence of mastitis, most probably due to their antioxidant and immune-
enhancing properties and contribution mucosal surface integrity of the mammary 
gland respectively (Sordillo et al., 1997). Zinc and copper are also important 
nutritional elements that contribute mammary gland health by promoting cellular 
repair, wound healing and reduction in SCC (Prasad et al., 2004; Bruno, 2010) aided 
by increases in metallothionein synthesis with antioxidant potential. Various studies 
have shown that feed supplemented with copper and fed to heifers reduces the 
severity of subclinical mastitis as well as clinical mastitis induced by Escherichia 
coli (Scaletti et al., 2003; Upadhayay et al., 2009).  
 
1.3.2.2.3 Weather and Climate 
 The incidence of mastitis is greatly influenced by the weather conditions and 
prevailing climatic conditions. Heat, humidity, cold and draught are the important 
predisposing factors (Jones, 2001; Dhakal et al., 2007; Akyuz et al., 2010; Reneau, 
2012). A higher incidence of mastitis has been reported to occur particularly during 
summer rainy months (Ribeiro et al., 2001; Akyuz et al., 2010; Reneau, 2012; 
Sentitula et al., 2012); as heat and humidity increases, so does the bacterial 
multiplication as well as the load of pathogens in the environment (Godden et al., 
2003). Conversely, an alternative study has reported a higher incidence of coliform 
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mastitis during the cold months of the year when the temperature was reported to be 
less than 21°C (Shathele, 2009; Ranjan et al., 2011).  
 
1.3.2.2.4 Hygiene 
The important sources of bacteria causing mastitis are the infected udder, teat canal, 
bedding material, manure, water, feed and milking machine. Environmental mastitis 
caused by the coliform bacteria is generally transmitted through contaminated 
environment (Boyer, 1997). Various researchers have demonstrated that there is 
incidence of clinical mastitis in cows reared in dirty barn and bedding material 
containing increased colony counts (Bramley and Neave, 1975). Coliforms and 
environmental streptococci enter into the mammary gland during the dry period and 
produce clinical mastitis during lactation. Contagious mastitis causing organisms are 
spread from infected quarter to healthy ones during milking via milker’s hands, 
clothes used to wipe udders, teat cup liners and milking machine. Splashes and 
aerosol of milk also play indirect role to transmit infection. A study conducted in 
NIRD, England demonstrated that 50% of milker’s hands before milking and 100% 
of milker’s hands after milking were contaminated with mastitis causing organisms 
(Dodd et al., 1966). 
 
 1.4 Mammary gland immunity and bovine mastitis  
In the last two decades there has been immense development in the area of mammary 
gland immunity and its function. Identification of leukocyte subpopulation by flow 
cytometry analysis, studies of bovine cytokines and their roles mammary gland 
defence, development of recombinant cytokines as disease control tool has given 
new dimension to the area of mammary gland immunity. Mammary gland immunity 
can be defined as the protection developed by the body against various infectious 
agents by using variety of immune and non- immunological factors (Sordillo and 
Streicher, 2002). The immune components are capable of recognizing and 
differentiating the foreign agents and body’s own molecules and upon recognition, 
the infection is attempted to eliminate by both cellular and soluble factors. The non-
immune components comprise various protection mechanisms which are non-
specific to particular causative agent.  
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1.4.1 Immune defence mechanisms of mammary gland 
There are two distinct forms of defence mechanisms which protect the mammary 
gland against variety of microorganisms. They are innate or nonspecific immunity 
and acquired or specific immunity. Innate immunity is activated at the early stage of 
infection by various stimuli and most of the infections are eliminated if this 
immunity is functioning adequately. However, it does not recognize any specific 
antigenic determinant of the causative pathogen. The various components of innate 
immunity are teat canal, neutrophils, macrophages, natural killer cells and cytokines. 
The acquired immunity is triggered when the innate immunity fails to eliminate the 
infection. The major functions of acquired immune system are recognition of specific 
pathogen by antigenic presentation process, elimination of the pathogen or pathogen 
infected cells and development of immunological memory by T cell receptors for 
future infections by the same pathogen. Due to development of immunological 
memory, there will be faster and stronger response against the pathogen in its 
subsequent encounters. 
 
The mammary defence mechanisms can be further characterized as anatomical, 
cellular and soluble factors against variety of mammary gland infections which are 
discussed below. 
 
1.4.1.1 Anatomical defence mechanisms 
Teat canal plays an important role in the defence mechanism of udder against variety 
of pathogens. Teat canal, a cylinder shaped body opening prevents leakage of milk 
and gain entry of microorganisms into the udder. The sphincter muscle of teat keeps 
the teat orifice tightly closed to prevent penetration of any mastitis causing bacteria 
and thus acts as a mechanical barrier. The teat canal is lined by a stratified squamous 
epithelium or keratin which prevents or limits the entry of bacteria into the teat 
cistern by its variety of physical, chemical, bacteriostatic and bactericidal properties. 
Accumulation of keratin acts as a physical barrier to the pathogens and in non-
lactating cows the teat canal is completely blocked to prevent entry of any foreign 
substances (Nickerson, 1987). The esterified and nonesterified fatty acids component 
of keratin layer including myristic acid, palmitoleic acid, linoleic acid exhibit 
bacteriostatic effects. Certain cationic proteins present in keratin exert bacteriostatic 
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effect which alter cell wall of invading bacteria after binding electrostatically and 
lead to death of the organism (Hogan et al., 1987). 
 
1.4.1.2 Cellular defence mechanisms 
If the mastitis-causing bacteria can invade the teat canal, they need to evade the 
cellular defence mechanism of mammary gland. This mechanism consists of 
neutrophils, macrophages and lymphocytes which lead to either innate or acquired 
immunity (Sordillo and Streicher, 2002).  
 
1.4.1.2.1 Neutrophils  
Neutrophils are the predominant cell type present in mammary tissue during early 
stage of infection. There is constant supply of neutrophils in sterile mammary gland 
as milking stimulus induces migration of neutrophils from blood to the mammary 
tissue (Paape et al., 1992).  But after reaching the alveolar lumen and ingesting on fat 
and casein, they lose the phagocytic property and die and these dead neutrophils are 
removed by milking and replaced by healthy neutrophils (Paape and Wergin, 1977). 
In healthy animal udder the production and destruction of neutrophils are regulated 
in such fashion that there is constant maintenance of particular number of neutrophils 
in blood, milk and mammary tissue (Jain, 1986). There is rapid migration of 
neutrophils once there is infection in the mammary gland which is mediated by the 
chemotactic components released by the causative agent and other variety of 
components of immune system. The number of neutrophils constitute as high as 90% 
of the total leukocyte population in the mammary gland during mammary gland 
infections. Neutrophils exert bactericidal effect through respiratory burst and further 
produces antibacterial peptides and defensins which kill wide range of mastitis 
causing pathogens (Sordillo and Streicher, 2002; Paape et al., 2002; Mehrzad et al., 
2010). 
 
1.4.1.2.2 Macrophages 
Healthy and lactating mammary gland generally contains macrophages which can 
regulate both innate and acquired immunity. The nonspecific function of 
macrophages is to phagocytize bacteria and kill them with proteases and reactive 
oxygen species.  However, the number of macrophages in the infected mammary 
. 
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gland is lower possessing less Fc receptors leading to deceased rate of phagocytosis. 
The important function of macrophages in infected mammary gland is to recognize 
the pathogen and release pro-inflammatory cytokines which induce neutrophil 
recruitment to the site of infection. Besides, activated macrophages release 
prostaglandins, leukotrienes, and cytokines which can enhance local inflammatory 
response (Kampenand and Mallard, 1997; Kehrli et al., 1999). 
 
1.4.1.2.3 Lymphocytes 
If the invading pathogen survives the phagocytosis by neutrophils, the neutrophil 
infiltration is then replaced by T and B lymphocytes and monocytes (Wagstrom et 
al., 2000). Lymphocyte subset comprises of two main groups- T and B lymphocytes. 
T lymphocytes are responsible for cell mediated immunity and B lymphocytes are 
primarily responsible for humoral immunity. B lymphocytes are developed in bone 
marrow in adults. When a pathogen enters into the body of host, B lymphocytes uses 
specific receptors to connect to the antigen. Upon activation by T lymphocytes it 
proliferates into plasma and B memory cells. Plasma cells produce antibody specific 
to the antigen which is responsible to kill the antigen. Memory cells can remember 
the specific antigen and if the same antigen invades the host next time, it activates 
the immune system much faster than previous time and the antigen is destroyed.  
 
T lymphocytes are produced in liver or bone marrow and later moved to the thymus 
mature. Similar to B lymphocytes, T lymphocytes also contain specific receptors 
which can recognize variety of antigens. T lymphocytes can be classified into two 
major groups:  αβ T lymphocytes and γδ T lymphocytes. The αβ T lymphocytes 
include helper T cells (CD4+) and cytotoxic or regulatory T cells (CD8+). The 
primary function of T helper cells is to activate B lymphocytes and killer T cells. The 
killer T cells are expert in killing virus, bacteria and even cancer cells once it is 
activated. In healthy bovine mammary gland, the prevailing type of T lymphocytes is 
αβ T lymphocytes predominantly expressing CD8+ phenotype. However, during 
mastitis the predominant phenotype of αβ T lymphocytes is CD4+ (Asai et al., 1998; 
Wagstrom et al., 2000). γδ T lymphocytes have not been well characterised and their 
biological functions are not yet clear. However, limited data have suggested that this 
class of lymphocytes may act as cytotoxic and may contribute in defence mechanism 
of body against bacterial infections (Sordillo and Streicher, 2002). 
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Natural killer cells have cytotoxic activity similar to cytotoxic T cells. However, they 
do not have any T cell receptors to produce antibody, but can distinguish infected 
and cancerous cells from normal cells to destroy them. Research findings have 
indicated that natural killer cells can kill both gram positive and gram negative 
bacteria and thus highlights its importance in prevention of mastitis (Shafer-Weaver 
and Sordillo, 1997). 
 
1.4.1.3 Soluble defence mechanisms 
1.4.1.3.1 Antibodies 
The primary soluble defence mechanisms in colostrum/milk are antibodies of 
different isotypes and cytokines released by macrophages. Antibodies in milk 
contribute the body’s humoral to defense against pathogens in two different ways: by 
preventing entry of the pathogen by binding to specific epitopes, followed by 
removal of antigen-antibody complexes by macrophages and triggering killing of the 
pathogen by stimulating one or more complement pathways (Beck et al., 2010). Four 
different types of antibody isotypes which may be associated with the defence 
mechanism during mammary gland infections viz. IgG1, IgG2, IgM and IgA (Guidry 
and Miller, 1986). The highest level of immunoglobulins is recorded in the 
mammary gland secretion during the release of colostrum and during mammary 
gland inflammation due to infections. IgG1 and IgG2 are reported to present in high 
concentrations in normal and infected mammary gland secretions, respectively. The 
primary function of IgG1, IgG2 and IgM in the mammary gland is to increase 
phagocytosis by neutrophils (Mukkur and Inmam, 1989) and macrophages by acting 
as opsonins. On the other hand, secretory IgA is present in small quantities only 
raising doubts on its role in defence against mammary gland infections (Mukkur and 
Tewari, 1975). It causes agglutination of bacteria entered into the mammary gland to 
prevent colonization of bacteria and it does not act as opsonins. 
 
1.4.1.3.2 Complement, lysozyme and lactoferrin 
In addition to antibodies, the other important soluble defence mechanisms are 
complement, lysozyme and lactoferrin.  Complement system is composed of several 
small proteins which are synthesized by liver and are present in milk and blood. The 
functions of complement are cell lysis, opsonization, clumping of antigen bearing 
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agents and attraction of macrophages and neutrophils for chemotaxis. Complement is 
the predominant proinflammatory mediator in mastitis caused by E. coli (Rainard 
and Poutrel, 1995; Riollet et al., 2000). Highest concentration of complement has 
neen reported during mastitis in contrast to the lowest concentration in healthy 
mammary gland during lactation (Rainard and Poutrel, 1995). Lysozyme and 
lactoperoxidase are the enzymes present in normal milk have bactericidal and 
bacteriostatic activities against both gram positive and gram negative bacteria, 
respectively. However, both enzymes are present in lower concentrations in bovine 
milk which limits their effectiveness in protection of bovine mastitis. 
 
1.4.1.3.3 Cytokines 
Cytokines acts as mediators as well as regulators of immune response (Belardelli and 
Ferrantini, 2002). The variety of cytokines reported to be present in healthy and 
infected mammary gland are interleukins (IL), colony stimulating factors (CSF), 
interferon gamma (IFN-γ) and tumour necrosis factor (TNF) [Alluwaimi, 2004]. The 
interleukins which are associated with bovine mammary gland infections are IL1, 
IL2, IL6 and IL8 (Alluwaimi, 2004). Of all the interleukins associated with bovine 
mastitis, IL2 is most extensively studied and characterized (Alluwaimi, 2004). IL2 is 
produced by T lymphocytes during immune response. IL2 is necessary for 
maturation of regulatory T cells and development of T lymphocytes immunologic 
memory. There are reports that administration of IL2 via intramammary route can 
enhance both cell mediated and humoral immune response in S. aureus infected 
quarters (Nickerson et al., 1989). Administration of IL2 therapeutically by 
intramammary route can protect infection of mammary gland against S. aureus 
infection. However, it failed do so in case of already existing infections of mammary 
gland in cows (Daley et al., 1991). Due to the influence of colony stimulating factors 
(CSF) on phagocytic cell populations, various researchers suggest their importance in 
clinical applications to treat bovine mastitis (Daley, et al., 1993). Interferon gamma 
(IFN-γ) plays a critical role in both innate and acquired immunity against bacterial 
and viral infections by activating the macrophages may play an important tool in the 
prevention and control of bovine mastitis (Sordillo and Babiuk, 1991). Tumor 
necrosis factor (TNF) is a member of group of cytokines which is primarily produced 
by activated macrophages and can also be produced by NK cells and CD4+ 
lymphocytes. This factor regulates immune cells by taking active part in neutrophil 
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recruitment. In acute mastitis caused by E. coli, TNF-α was reported to be the 
predominant cytokine during early stage of infection (Slebodzinski et al., 2002). If 
the production of TNF-α could be modulated during coliform mastitis, there is a fair 
chance to reduce the infection rate of bovine mastitis caused by E. coli. 
 
     1.5 Current status of different strategies used for therapy 
and prevention of bovine mastitis 
     1.5.1 Antibiotics 
      Antibiotics ranging from narrow to broad have been used extensively over the past 
40 years in the control of bovine mastitis (Barkema et al., 2006). However, because 
of the emerging antibiotic resistance believed to be probably due to their overuse 
(Pearson, 2002; Shi et al., 2010; Shittu et al., 2011; Park et al., 2012) and the 
induction of prolonged persistent antibiotic resistance in biofilms by many mastitis-
causing pathogens, as demonstrated recently for S. aureus isolated from cases of 
bovine mastitis in the bovine mammary gland (Babra et al., 2013), effectiveness of 
antibiotic therapy has been compromised. As such the control of bovine mastitis has 
become one of the most challenging problems on dairy farms today. Cows suffering 
from mastitis are culled due to high SCCs and repeated occurrence of clinical 
mastitis. Although culling and selective antibiotic therapy have been found to cause a 
reduction in the manifestation of clinical mastitis (Petersson-Wolfe et al., 2010), 
dairy farmers are often reluctant to cull affected cows due to the devastating financial 
impact on backyard farmers due to losses in milk production as is often the case in 
developing countries. 
 
Intra-mammary infections have been traditionally treated with systemic or intra-
mammary antibiotic therapy (Barlow, 2011). Despite scheduling treatment regimens 
to prolong the availability of appropriate antibiotics for an extended period of time in 
the infected area (Erskine, 2001), the cure rates of mastitis particularly for S. aureus 
infections have been reported to vary from 0% to 80% (Erskine, 2001; Timms, 2001; 
Gruet et al., 2001). This is presumably due to the induction and persistence of 
biofilm-associated antibiotic resistance (Babra et al., 2013) depending upon the 
intensity of infection as reflected by SCC counts and management practices (Serieys 
et al., 2005; Petrovski, 2007). Milking animals with a SCC of less than 1 million 
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showed greatest success of antibiotic therapy (Cattell and  Belschner, 1997) while 
those with a higher count responded poorly (Timms, 2001). This is notwithstanding 
the fact that some antibiotics including penicillin, oxytetracycline, lincomycin and 
neomycin may affect the phagocytic properties of polymorphonuclear leukocytes 
(PMN) by altering the oxidative burst property of PMN (Paape et al., 2003) leading 
to a recurrence of intra-mammary infections.  
 
1.5.2 Bacteriophage therapy for mastitis associated infections 
Given the problems associated with antibiotic therapy of mastitis, development of 
alternative treatment strategies for management of clinical and sub-clinical mastitis 
are warranted. One such alternative treatment is bacteriophage therapy, which uses 
pathogen specific bacteriophages in the treatment of a bacterial infection. Recent 
interest in phage therapy in veterinary medicine was sparked by some early success 
in the treatment of E. coli infections in animal models including a chicken model for 
respiratory infections (Huff et al., 2002), a mouse model for meningitis (Smith and 
Huggins, 1982) and a calf model for diarrhoea (Smith and Huggins, 1987). However, 
the few studies that have been carried out using bacteriophages to treat mastitis 
caused by S aureus infection have yielded variable results. While intra-mammary 
infusion of bacteriophage into S aureus infected quarters of lactating dairy cattle did 
not show significant protection (Gill et al., 2006 a, b). Kwiatek and co-workers in 
2011 isolated and characterised a bacteriophage from the milk of cows suffering 
from mastitis with broad-spectrum activity against methicillin- resistant S aureus 
(MRSA). It is suggested that additional research is required to explore the therapeutic 
potential of bacteriophages to treat clinical and subclinical mastitis associated 
bacterial infections.  
 
      1.5.3 Genetic selection of cattle for resistance to clinical mastitis  
Breeding production animals for resistance to infectious diseases is not new (Adams 
and Templeton, 1998), but generally the breeding of farm animals has been confined 
to enhancement of production traits such as increased milk production. Such 
selection, while enhancing milk production, has been reported to increase the 
incidence of many infectious diseases including bovine mastitis (Simianer et al., 
1991; Heringstad et al., 2007). In attempts to overcome this problem, a strategy 
based on enhancing the overall immune response including antibody-mediated 
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immune response (AMIR) and cell-mediated immune response (CMIR) has been 
proposed (Thompson-Crispi et al., 2012). However, a negative genetic correlation 
between AMIR and CMIR (Heriazon et al., 2009) has been recorded, making a 
balanced genetic selection more complicated and so requiring further investigation. 
 
1.5.4 Ancillary non-specific strategies for prevention of mastitis 
1.5.4.1 Non-specific immunostimulants against mastitis 
      In the absence of the availability of effective commercial vaccines for prevention of 
mastitis caused by multiple pathogens, attempts are continually being made to 
evaluate the potential of non-specific immunostimulants for prevention of bovine 
mastitis (Eid et al., 1995). Lysate of Corynebacterium cutis has been considered as 
one of the non-specific immune stimulants against mastitis. There are reports of a 
reduction in SCC (Lee et al., 1996) in the milk of dairy cows receiving a 
subcutaneous injection of lysate of C. cutis. Intramuscular injection of C. cutis to 
pregnant ewes resulted in an increased level of IgG in serum on the 140
th
 day and in 
colostrum up to 3 days post-parturition (Yilmaz et al., 2011). Clearly, further studies 
on the potential of the non-specific immunostimulants are warranted.  
 
    1.5.4.2 Lactation therapy 
      Treatment of mastitis during lactation with antibiotics is referred to as “lactation 
therapy”, which is used by many producers to reduce the clinical signs of mastitis 
and bring back the normal milk production of cows. This therapy has proven useful 
in reducing the SCC in milk and thereby maintains the quality of milk (Oliver et al., 
2004; Pyorala, 2009). However, lactation therapy for subclinical mastitis is not 
suggested as it is not economically viable and shows poor efficacy (Pyorala, 2009). 
Factors such as SCC in milk during treatment, stage of lactation, immune status of 
the animal, age of the cow and type of pathogen also play an important role in the 
success or failure of lactation therapy (Hillerton and Berry, 2003; Hektoen et al., 
2004). New intra-mammary infections in cows have been shown to respond better to 
antibiotic therapy than chronic infections (Pinzon-Sanchez et al., 2010), and young 
animals show better response to treatment than older animals (Sol et al., 2000; 
McDougall et al., 2007a, b). Spontaneous cure by lactation therapy for clinical as 
well as subclinical mastitis caused by S. aureus is very rare (Oliver et al., 2004; Zhen 
et al., 2009). Lactation therapy in chronic clinical cases of mastitis caused by S. 
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aureus has been found equally ineffective (Petersson-Wolfe et al., 2010). However, 
an extended period of treatment with antibiotics at therapeutic levels has been 
reported to yield better cure rates for clinical mastitis caused by S. aureus (Sol et al., 
2000). A serious drawback of this therapy is the loss of milk because of antibiotic 
residues.  
 
     1.5.4.3   Dry cow therapy 
Dry cow therapy with antibiotics has been suggested as one of the options to control 
intra-mammary infections and prevent development of mastitis (Oliver and Sordillo, 
1988). During the dry period, the cow is at the greatest risk of acquiring new intra-
mammary infections with both gram-positive and gram-negative environmental or 
contagious pathogens (Todhunter et al., 1991). It has been reported that about 61% of 
new infections are acquired during this period (Todhunter et al., 1991). Treatment 
during dry period is advantageous because it allows treatment of infections with 
antibiotics without the need to discard milk from treated quarters. Antibiotics are 
administered towards the end of lactation (Janosi and Huszenicza, 2001) and may 
remain in the udder in concentrations high enough to kill pathogenic bacteria for 20-
70 days, depending upon the kind of formulations that are used. The antibiotic has an 
enhanced penetration due to prolonged exposure and the probability of curing intra-
mammary infections increases markedly, unless resistance to new antibiotics is 
acquired by the invading pathogen’s biofilm formation in the udder (Babra et al., 
2013). Dry cow therapy has been reported to eliminate almost 100% of mastitis 
caused by S. agalactiae (Oliver and Sordillo, 1988). However, dry cow therapy is 
comparatively less successful to prevent S. aureus mastitis than streptococcal 
mastitis (Ziv et al., 1981). The cure rate of dry cow treatment against S. aureus 
mastitis was reported as approximately 50% and vaccination against this pathogen 
during the dry period may enhance the antibiotic efficacy (Todhunter et al., 1991). 
Dry cow therapy for a period of two weeks showed significant reduction in the 
number of clinical mastitis cases due to infection with S. dysgalactiae and S. uberis 
(Hassan et al., 1999).   
 
1.5.4.5 Teat sealer 
The development of internal and external teat sealants for use during the dry period 
is a promising progress towards control of mastitis and its aftermath (Twomey et al., 
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2000; Sanford et al., 2004; Ruciman et al., 2010; Izak et al., 2012). External teat 
sealants such as DryFlex and Delaval also showed potential in reducing new 
infections of the mammary gland during the dry period (Timms, 2001). However, 
lack of persistence is the main drawback of external teat sealers (Hayton and 
Bradley, 2001). Bismuth subnitrate as an internal teat sealer used in field conditions 
was reported to reduce new infections up to ten fold (Huxley et al., 2002). Internal 
teat sealer used with long acting antibiotics during the dry period showed a 30% and 
33% reduction in new intra-mammary infections and incidence of clinical mastitis, 
respectively (Sordillo et al., 1997). Bismuth subnitrate combined with cloxacillin as 
dry cow therapy demonstrated reduction in both clinical and subclinical cases of 
mastitis (Ruciman et al., 2010; Izak et al., 2012).There are several studies that have 
demonstrated the usefulness of OrbeSeal, an internal sealer in reducing new 
infections of the mammary gland in lactating animals (Cook et al., 2004; Sanford et 
al., 2004).  
 
1.6 Bovine mastitis in Australia 
The Dairy industry is the third largest rural industry in Australia after beef and wheat 
industry providing direct employment in the dairy farms to approximately 43,000 
people. The national dairy herd is composed of 1.65 million cows producing 9,200 
million litres of milk. Australian Dairy industry in is the major export industry 
generating a total of $2.76 billion per annum and contributing 7% to the World Dairy 
Trade (Dairy Australia, 2013). Dairying is the prominent industry in the temperate 
and sub-tropical zones of Australia. All states of Australia produce and supply fresh 
milk and milk-products including custard, cheese and yoghurt to the nearby towns 
and cities. However, the south-east seaboard states produce the highest amount of 
milk in Australia. 
 
Mastitis continues to be one of the most economically devastating diseases of dairy 
cattle in Australia. More than $130 million is lost by the Australian dairy farmers 
($A200/cow/year) every year due to poor udder health caused by mastitis resulting in 
reduction of milk production, increase in treatment costs, veterinary consultation 
fees, number of cow culls (Dairy Australia, 2011). A herd without an effective 
mastitis control programme may witness morbidity as high as 40% with infection, on 
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an average of two quarters of the mammary gland (Dairy Australia, 2011). Of the 
various clinical manifestations, subclinical mastitis is economically the most 
important due to its long term effects on milk yields and needs specific tests for 
detection (Gogoi, 1997; Zafalon et al., 2007).   
 
It is difficult to establish the true incidence of mastitis in Australia as there are 
variations in geographical locations, type of farming, management and herd size in 
different states of the country.  A survey in one district cannot represent another 
district (Frost et al., 1966). Moreover, incidence of mastitis and cell counts in milk 
has been reported to be higher in the flood hit areas and during rainy season. It is 
even complicated due to subclinical mastitis which is often invisible and un-noticed. 
The trend of aetiology of mastitis has been variable in Australia. Since 1960 to 1990 
the predominant causative agent of mastitis was S. aureus and S. agalactiae. The less 
common mastitis pathogens were S. dysgalactiae and S. uberis. According to a report 
of the Australian Veterinary Journal most herds were infected with S. aureus. 
However, there was variation of infected cows among the infected herds. A total of 
100% of herds in Brisbane Milk Supply area were infected by S. aureus comprising 
46% infected cows. In New South Wales the percentage of herd infection was lower 
in Camden and Laidley but it was as high as 86% in Moss Vale District. The 
incidence of S. agalactiae infection was 86% in herds including 29.7% infection in 
cows, 90.7% herd infection in Moss Vale, 15% in Camden and Laidley, respectively. 
Western Australia has as low as approximately 2% cows infected with S. agalactiae 
(Frost et al., 1966). 
 
In the last 10-20 years there has been a change in the trend of occurrence of bovine 
mastitis in Australia. Environment pathogens have become more prominent causative 
agents of bovine mastitis in most herds throughout the country. S. uberis has topped 
the list of environmental pathogens causing mastitis followed by Pseudomonas, 
Bacillus cereus and E. coli (Mein et al., 2011). A recent study on the prevalence of 
mastitis causing organisms in intensive dairy herds in New South Wales revealed a 
shocking 91% of environmental pathogens which included 41.6% environmental 
Streptococcus and 33.6% coliforms (Shum et al., 2009). S. uberis was the 
predominant environmental Streptococcus followed by Strep. dysgalactiae and E. 
coli being the most common coliform in those dairy herds. However, prevalence of 
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the contagious pathogens, S. aureus and S. agalactiae, still remains an unsolved 
battle in many dairy herds in Australia, S. aureus being the predominant causative 
agent of clinical bovine mastitis.  Moreover, overuse or misuse of antibiotics to treat 
S. aureus mastitis has led to the development of a new genre of S. aureus which is 
multi-drug resistant including Methicillin called MRSA (Methicillin Resistant 
Staphylococcus aureus). Given the recent reports that even MSSA (Methicillin 
Sensitive Staphylococcus aureus ) can become resistant to certain antimicrobials 
when presented as biofilms adds another dimension to bovine mastitis caused even 
by MSSA (Babra et al., 2013).  
 
The first widely adopted Mastitis Control Program in Australia was “Five Point 
Plan” consisting the original five points to reduce the number of prevalent and new 
mastitis infections. The plan lasted for 30 successful years and after 30 years it 
became less viable and less cost-effective in pasture based dairy herds and the plan 
failed to control the prevalence of mastitis caused by environmental pathogens. After 
“Five Point Plan”, important step implemented towards the control of mastitis in 
Australia was “Farm Guidelines for Mastitis Control” which was developed by 
Countdown Downunder technical group and first published in 1998 by Dairy 
Research and Development Corporation. Every effort was made to distribute the 
guidelines to dairy farmers. This programme has been a success in Australia with its 
associated problems with implementation. The current management practices 
followed to control mastitis in Australia are aimed at reducing the level of herd 
infection, achieving a bulk milk cell count (BMCC) below 400,000 cells/ml, 
improving quality of milk in terms of its composition, improving udder health and 
recognizing and controlling pain and inflammation caused by mastitis. 
 
1.7 Significance of Staphylococcus aureus in bovine mastitis 
Staphylococci in human pus were described for the first time by Robert Koch in 
1878 and the name “Staphylococcus” was first suggested by Alexander Ogston in 
1884. Two different coloured colonies namely yellow and white produced by 
Staphylococci were first described by Rosenbach in 1884 suggesting the 
nomenclatures S. aureus and S. albus which was later renamed as S. epidermidis.  
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Staphylococci are gram positive non-motile, non-spore forming facultative 
anaerobes. They are about 1µm in diameter cocci and form grape like clusters. 
 
Human is the main reservoir of S. aureus organisms (Banwart, 1979). As these 
organisms are present on hands, skin, anterior nares, infected wound, pimples, nose 
and throat discharges of human, the health, hygiene and work habit of milkers, 
animal attendants can influence the level of contamination of milk. The persistent 
and intermittent colonization of S. aureus in anterior nares of healthy people are 
reported to be as high as 20% and 70%, respectively (Kluytmans et al., 1997) which 
may lead to staphylococcal infections (Saginur et al., 1996). In healthy dairy animals 
S. aureus is present in almost all external surfaces (Roberson et al., 1998) which can 
multiply and persist for short period (Kloos, 1997). However, udder has been the 
most preferred site of S. aureus colonization in dairy animals (Jorgensen et al., 2005) 
and transmission usually takes place during milking (Roberson et al., 1994). There 
are also reports of S. aureus surviving in feed material, dust, bedding which can 
serve as a source of infection (Matos et al., 1991).  
 
Despite advances in the area of prevention and control of mastitis, S. aureus is the 
leading cause of contagious bovine mastitis worldwide (Athar, 2007; Dingwell et al., 
2003; Keefe et al, 1997). It causes contagious mastitis resulting either clinical or 
subclinical mastitis with increase in the number of somatic cell count (SCC) in milk. 
It has been reported to cause more than 80% of subclinical mastitis cases in bovines 
causing a loss of US $ 300 per animal per year (Wilson et al., 1997; Karahan et al., 
2011). S. aureus enters the mammary gland via teat orifice. Chapped or injured teats 
are most likely to be affected. Once the organism enters into the mammary gland, it 
adheres to epithelial lining and invades the host immune system by variety of 
antiphagocytic factors including capsule, proteinA, fibronecting binding proteins. 
Once intra-mammary infection is established, damage to the mammary gland 
epithelial lining is initiated by ulceration and occlusion of lactiferous ducts and 
alveoli, infiltration of inflammatory cells in the parenchyma. Mammary tissue 
damage is further complicated by various toxins produced by S. aureus which act as 
super antigens. 
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The success rate of treatment against S. aureus mastitis is rare and it relapses in most 
of the cases (Barkema et al., 2006). There is heavy reliance on the use of antibiotics 
to control bovine mastitis as there are no prophylactic accredited vaccines against the 
malady nor are there any preventive measures which are fully dependable. As such 
there is an abundance of literature concerning susceptibility of mastitis pathogens 
against a large spectrum of antimicrobial agents. However, worldwide changes in 
resistance patterns to antimicrobial agents of S. aureus strains isolated from clinical 
sites have been observed (Ross et al, 1974; Eykyn, 1988). Misuse or overuse of 
antimicrobial agents and introduction of resistant strains into countries have been 
responsible for an increase in the prevalence of strains resistant to antibiotics (Ross et 
al, 1974; Gogoi and Dutta, 2001) including methicillin, a penicillinase resistant 
antibiotic, the first case of MRSA being reported from England (Jevons, 1961). 
Within the past decade MRSA has emerged as a problematic pathogen in hospitals as 
well as in the dairy industry. As a result, vancomycin is currently being used 
effectively against MRSA, the first case of vancomycin resistance being reported by 
Pearson (2002). Given the recent reports that even MSSA can become resistant to 
certain antimicrobials when presented as biofilms adds another dimension to bovine 
mastitis caused even by MSSA (Babra et al., 2013). 
 
1.7.1 Virulence factors of S. aureus 
S. aureus produces a variety of virulence factors by which it causes damage to host 
leading to signs and symptoms of disease. These virulence factors permit the 
pathogen to evade host immune mechanisms by adhering to eukaryotic membrane, 
resisting phagocytosis and killing eukaryotic cells. Broadly, the virulence factors of 
S. aureus can be classified into two groups-(a) Virulence factors involved in 
establishment of infection and (b) Virulence factors involved in maintenance of 
infection (Haveri et al., 2007). 
 
1.7.1.1 Staphylococcus aureus virulence factors involve in establishment of 
infection 
The first step in establishing infection is the initial attachment of S. aureus to 
eukaryotic membrane followed by colonization and subsequent infection (Brouillette 
et al., 2003). Colonization is commonly associated with a variety of adherence 
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factors or adhesins which are known as microbial surface component recognizing 
adhesive matrix molecules (MSCRAMMs).These surface molecules attach to 
components of host tissue or plasma (Gordon & Lowy, 2008; Bien, et al., 2011).  
There are over 20 different MSCRAMMs identified which can be expressed in S. 
aureus (Walsh, et al., 2008) and they mediate attachment to surface proteins of host 
cells including collagen, elastin, fibrinogen, thrombospondin, fibronectin, bone 
sialoprotein and laminin ( Bartlett and Hulten, 2010). Major adhesins in this group 
that mediate the initial attachment of bacteria to the bovine mammary gland, 
providing the first critical step for establishing infection (Foster and Hook, 1998) are 
S. aureus Protein A, clumping factors A and B (ClfA and ClfB), protein A, Collagen 
adhesion (CNA) and the fibronectin binding proteins A and B (FnBPA and FnBPB) 
[Cucarella et al., 2001; Gordon and Lowy, 2008; Plata et al., 2009] 
 
1.7.1.1.1 Protein A (Spa) 
Protein A is one of many surface proteins produced by S. aureus which has been 
considered to have antiphagocytic properties based on its ability to bind the Fc 
portion of immunoglobulin G (IgG). It consists of a single polypeptide chain of 
molecular weight 42,000 and contains little or no carbohydrate (Bjork, 1972; 
Sjoquist, 1972). It has the ability to interact with several host components, possibly 
indicating a role as a virulence factor in S. aureus infections. More than 7200 
different spa types have been reported due to the variable number of repeats in spa 
region (http://spaserver.ridom.de/).The virulence factor of Spa in S. aureus has been 
proved in murine septic arthritis (Palmqvist et al., 2002).  
 
1.7.1.1.2 Clumping factors /Fibrinogen binding proteins (Clf) 
Clumping factor (ClfA and ClfB), a fibrinogen-binding protein anchored to the S. 
aureus cell wall, is a virulence factor contributing to murine septic arthritis 
(Josefsson, 2001) in mice and rat endocarditis (Moreillon et al., 1995). The 
fibrinogen molecule contains two sites available which interact with clumping factor. 
ClfA binds to C terminus of γ-chain (Hartford et al., 1997; Hawiger et al., 1982; 
McDevitt et al., 1997) and ClfB binds to α-chain (Walsh et al., 2008). The 
characteristic clumping of S. aureus cells in fibrinogen-containing medium is 
mediated by this binding interaction. It has been shown that ClfA through its 
fibrinogen-binding function is a mediator of S. aureus -induced platelet aggregation 
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(Bayer et al., 1995; O’Brien et al., 2002). ClfB is one of the determinants of nasal 
persistence of S. aureus. Mice immunized with recombinant ClfB via intranasal route 
have demonstrated reduction of colonisation and persistence of S. aureus in nares of 
mice (Schaffer et al., 2006). 
 
1.7.1.1.3 Fibronectin binding proteins (FnBP) 
Fibronectin (Fn) is a 440-kDa glycoprotein found in the extracellular matrix and 
body fluids of animals. It was the first ECM (Extracellular matrix protein) shown to 
act as substrate for the adhesion of eukaryotic cells (Hynes, 1990). The fibronectin-
binding proteins A and B (FnBP-A and FnBP-B),
 
encoded by the fnbpA and fnbpB 
loci, respectively, were identified
 
as the main adhesins that bind purified fibronectin 
(Jonsson et al., 1991; Signas et al., 1989).
 
At least one of the FnBP genes is found in 
the vast majority
 
of S. aureus strains (Smeltzer et al., 1997). Pathogen adherence to 
the teat canal
 
of the udder is believed to be the first step of mammary gland
 
infection, 
and FnBPs have been proposed as virulence factors
 
in bovine mastitis (Sutra and 
Poutrel, 1994). Mamo et al., (1994) reported that mice immunized with FnBP were 
partially protected against intra-mammary challenge. 
 
1.7.1.2 Virulence factors involve in maintenance of infection 
S. aureus produces a variety of virulence factors which evade the tissue and host 
immune system and thereby maintain infection. These virulence factors are capsular 
polysaccharides, enzymes, cytotoxins, superantigens. 
 
1.7.1.2.1 Capsular polysaccharides 
The capsular polysaccharide or capsule is a cell wall bacterial component that 
protects bacteria from phagocytic uptake and enhances microbial virulence. S. aureus 
isolated from human infections have been shown to produce 12 polysaccharide 
serotypes (11 different capsular serotypes) and one surface polysaccharide 336 
(Guidry et Al., 1998). The majority of clinical isolates were reported to express a 
surface polysaccharide of either serotype 5 or 8, representing 70-80% of the isolates 
from all sources (Arbeit et al., 1984; Hochkeppel et al., 1987; Poutrel et al., 1988). 
However, the percentage distribution of these capsular types appears to vary in 
different countries (Arbeit et al., 1984; Hochkeppel et al, 1987; Poutrel et al, 1988; 
Roghmann et a.l, 2005; Han et al, 2000; Sompolinsky et al, 1985). More recently, it 
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has been suggested that there are only four types of CPs (Lee, 2002), all other 
reported types representing mutated versions, details of which has not been 
elucidated. CPSs from serotypes 1, 2, 5, and 8 have been purified and characterized
 
(Fattom et al., 1996; Liau and Hash 1977; Murthy et al., 1983; O’Riordan and Lee, 
2004; Jones, 2005). Purified capsular polysaccharides are non-immunogenic in mice 
(Fattom et al, 1990) but which become immunogenic upon linking to carrier proteins 
to produce and induce T-cell dependent immune responses.  
 
1.7.1.2.2 Virulence-associated enzymes 
Most S. aureus strains express Staphylokinase which acts as plasminogen activator 
(Gogoi Tiwari and Tiwari, 2006; Kwiecinski et al., 2010) Staphylokinase forms a 
complex with plasminogen which activates proteolytic activity leading to dissolving 
of fibrin clots. Other enzymes produce by S. aureus are lipase to digest lipids, 
deoxyribonuclease (DNAse) to break down DNA, coagulase to clot plasma, 
hyaluronidase to break down hyaluronic acid, beta lactamase for penicillin resistance 
and fatty acid modifying enzyme (FAME) to provide nutrient to S. aureus and anti-
bacterial lipids (Cheesbrough, 1995). 
 
1.7.1.2.3 Cytotoxins 
A large number of cytotoxins are produced by S. aureus which form pores in the cell 
membrane causing osmotic swelling leading to cell death. These cytotoxins include 
leukocidins, phenol soluble modulins (PSMs) and cytolysins. The cytolysins of S. 
aureus are α-, β-, γ-, and δ-toxins, of which α-toxin is well characterised and most 
potent toxin (Wadstrom 1983). β-toxin is a sphingomyelinase C and 95% of S. 
aureus isolates from bovine mastitis cases produce this toxin (Tollersrud, 2001) 
which causes damage to epithelial lining of mammary gland. γ-toxin is produced by 
coagulase positive S. aureus causes tissue damage by stimulating degranulation of 
neutrophils. Delta toxin is responsible for lysis of cells in different species (Hirsh et 
al., 2004). Leukocidins target the phagocytic cells and cause pore in the membrane of 
PMNs and interfere with the function of neutrophis (Rainard et al., 2003). The 
members of Leukocidin family are Panton Valentine Leukocidin (PVL), LukR-PV, 
LukM/FPV, LukE/D, γ-haemolysin and Leukocidin. Phenol soluble modulins 
(PSMs) are the peptides produced by S. aureus which are cytotoxic and 
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proinflammatory (Surewaard et al., 2012).  Recent finding has demonstrated that it 
plays a part in the formation of S. aureus biofilm (Periasamy et al., 2012). 
 
1.7.1.2.4 Superantigens 
S. aureus produces a number of superantigens including enterotoxins (SEs), Toxic 
Shock Syndrome toxin and exfoliative toxins. Enterotoxins of S. aureus include the 
classical enterotoxins A to E and the recently identified and characterised SEG-SEU 
toxins (Dinges et al., 2000; Smyth et al., 2005). These antigens are considered 
superantigens due to their ability to induce release of cytokines from both T cells and 
macrophages by binding to outer surface of MHC class II proteins and T cell 
receptors (Marrack and Kappler, 1990; Balaban and  Rasooly, 2000; Ulrich, 2000; 
Schlievert, 2008). 
 
1.7.2 Biofilm formation by S. aureus and bovine mastitis 
1.7.2.1 Biofilm  
Bacterial growth can be classified into two types: single cells and aggregated cells. 
Single cell growth is known as planktonic and the aggregated cells are known as 
biofilm. Definition of biofilm according to Bjarnsholt, 2013 is “A coherent cluster of 
bacterial cells embedded in a matrix, which is more tolerant of most antimicrobials 
and host defences compared with planktonic bacterial cells”. The first ever 
publication on biofilm was published by Hoiby in 1977 who described aggregates of 
Pseudomonas aeruginosa in lungs of cystic fibrosis patients. However, the term 
“Biofilm” was first used in 1981 by Costerton et al. to describe bacteria embedded in 
extracellular matrix (McCoy, 1981). Since then there has been vast research on 
biofilms formed by different bacteria (Nickel et al., 1989; Post et al., 1996; Erdos et 
al., 2003; Stoodley et al., 2005; Hiller et al., 2007, Babra et al., 2013 and Bjarnsholt, 
2013) describing its potential role in the establishment of  80% of infections (Davies, 
2003). 
 
1.7.2.2 Implication of biofilm in various infections 
Complexity and severity of various human and animal infections are contributed by 
biofilm formation by the respective causative organism. Biofilms of Staphylococcal 
and Streptococcal species complicates endocarditits, biofilms of S. aureus, 
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Haemophilus influenza and Pseudomonas aeruginosa complicates cystic fibrosis, S. 
aureus and S. epidermidis cause complications in implant related infections (Hall-
Stoodley et al., 2004). These complications arise due to tolerance to phagocytosis 
(Matz et al., 2004; Matz et al., 2005; Bjarnsholt, 2013) and decreased susceptibility 
to antimicrobial agents (Bjarnsholt, 2013). Quorum sensing demonstrated by 
biofilms (Manefeld and Turner, 2002) also contributes to pathogenesis of disease. 
Quorum sensing is a biofilm dependant trait which involves cell to cell 
communication (Fuqua et al., 1994) and detachment of biofilm lead to septicaemia 
and colonisation.  
 
1.7.2.3 Development of biofilm by S. aureus  
S. aureus biofilms are considered major facilitators of different animal and human 
infections contributing 80% of all infections (National Nosocomial Infections 
Surveillance, 1999). Development of biofilm by S. aureus occurs in three steps. First 
step involves adherence of S. aureus cells to surface by physicochemical interactions. 
Various adhesion proteins of S. aureus including FnBPA, FnBPB, ClfA, ClfB, CNA 
and Bone sialo binding protein (BBP) play role in the adherence of S. aureus to 
extracellular matrix of host tissue (Patti et al., 1992; Mc Devitt et al., 1994; Tung et 
al., 2000 and O’Neill et al., 2008). The second step involves multiplication of S. 
aureus and cell to cell interaction and leading to formation of slimy layer like 
structure. The major component of S. aureus biofilms is an exopolysaccharide, Poly-
β-1, 6-linked N-acetylglucosamine (PNAG) [Sadovskaya et al., 2007]. Four proteins 
including IcaA, IcaD, IcaB and IcaC encoded by the icaADBC operon are associated 
with the production of PNAG. IcaA and IcaD are the most important proteins for the 
production of PNAG (Otto, 2009). Besides PNAG, some other proteins of S. aureus 
have been described to be involved in cell to cell interaction and biofilm formation. 
These proteins include Bap, ProteinA, Agr, SasC and SasG (Lasa and Penades, 2006; 
Corrigan et al., 2007; Merino et al., 2009; Schroeder et al., 2009; Boles and Horswill 
2011). Extracellular DNA (eDNA) has also been demonstrated to play an important 
role in biofilm formation during the attachment stage of biofilm (Archer et al., 2011). 
The third step involves detachment of biofilm. An accessory gene agr encoding 
agrA, agrB, agrC and agrD is responsible for detachment of biofilm helping in 
dissemination S. aureus resulting in chronic mastitis. The quorum sensing of S. 
aureus during biofilm formation is regulated by agr gene (Archer et al., 2011; Boles 
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and Horswill, 2011; Otto, 2013). It upregulates the enzyme responsible for degrading 
components of extracellular matrix and down regulates adhesive protein genes which 
maintain attachment of biofilm (Boles and Horswill, 2011; Otto, 2013), thus 
facilitating detachment of biofilm. It is also responsible for transient upregulation of 
certain genes which are responsible for production of toxins such as δ-toxin, capsule 
and protease (Boles and Horswill, 2008) thus allowing biofilm to neutralise kill 
neutrophils (Anwar et al., 2009). 
 
1.7.2.4 Biofilm and S. aureus bovine mastitis 
After entry into the mammary gland, S. aureus attaches to mammary gland epithelia 
and forms colonies which are surrounded by extracellular matrix leading to biofilm 
formation. Chronic persistence of infection is characteristic of biofilm related 
infection which is promoted due to resistance to phagocytosis and antibiotic therapy 
conferred by biofilm formation by S. aureus (Monzon et al., 2002). 
 
Numerous investigators have demonstrated the ability of S. aureus to form biofilm in 
vitro by using various methods including Congo red agar plates and tissue culture 
method (Vasudevan et al., 2003; Oliveira et al., 2007; Dhanawade et al., 2010; Babra 
et al., 2013). However, there are also demonstrations of biofilm formation by S. 
aureus in the mammary gland (Perez et al., 2009; Prenafeta et al., 2010). Production 
of extracellular matrix was demonstrated by Watson et al. as early as 1989 by using 
electron microscopy. They termed it as pseudo capsule which was observed in S. 
aureus isolated from clinical mastitis cases in cows and ewes. In vivo production of 
extracellular matrix by S. aureus was demonstrated indirectly by establishing 
production of antibodies against PNAG (Perez et al., 2009) and slime associated 
antigenic complex (SAAC) [Prenafeta et al., 2010] in experimental production of 
mastitis in sheep and cows.  
 
1.8 Current status of vaccine development against bovine 
mastitis 
Mastitis is caused by variety of pathogens and as such various efforts have been 
made to develop vaccine against mastitis caused by various organisms. It is beyond 
the scope of this review to describe detailed experimental approaches used in the 
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development of vaccines against bovine mastitis caused by the major bacterial 
pathogens. As such, a brief description of the vaccines, including the approaches 
currently used in practice or promising prototype vaccine candidates, is presented. 
The use of vaccination particularly with autogenous killed whole cell vaccines to 
control infectious diseases on-farm in dairy cattle is common, and vaccination 
against mastitis pathogens is no exception. Several efforts have been made to 
develop a vaccine against mastitis, but few have claimed satisfactory outcomes (Lee 
et al., 1988; Mamo et al., 1994; Leitner et al., 2000 and 2003; Tenhagen et al., 2001; 
Nour El-Din et al., 2006; Pellegrino et al., 2010; Xu et al., 2011) in the field or 
backyard farms. It is clear that a single vaccine will not prevent mastitis caused by 
the plethora of pathogens and their different mechanisms of pathogenesis (Health, 
2011).   
 
1.8.1 Vaccines against coliform bacteria 
Coliforms (E. coli, Klebsiella sp.) are etiological agents of environmental mastitis. 
Coliform mastitis generally causes clinical mastitis mostly during the peri-parturient 
period (Hogan and Smith, 1987; Jones 2009b). Early investigations used 
heterogeneous oligosaccharide antigens derived from E. coli to develop a vaccine 
against coliform mastitis. These vaccines were administered during the non-lactating 
period with the aim of preventing mastitis in subsequent lactations (Wilson 1972; 
Wilson et al., 1972). These vaccines reduced the severity of infection initially, but 
their effect gradually diminished over time (Dosogne et al., 2002). J-5 Bacterin, 
Mastiguard™ and J Vac® are the three vaccines available in the market against 
coliform mastitis (Ruegg, 2005). Startvac (Hipra) has been made available in the 
market targeting not only coliforms but also coagulase-negative staphylococci and S. 
aureus. J-5 Bacterin also known as the E. coli J5 vaccine is composed of the J5 
mutant strain of E. coli. Cows vaccinated with this vaccine showed a significant 
reduction of clinical mastitis cases under field conditions (Gonzalez et al., 1989; 
Hogan et al., 1992). Only 20% of the vaccinated animals showed clinical infections, 
although there was no difference in the incidence of new coliform mastitis cases 
among the vaccinated compared to the non-vaccinated animals (Hogan et al., 1992). 
However, no vaccines against mastitis caused by K. pneumoniae are available in the 
marketplace. 
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  1.8.2   Vaccines against Streptococcus uberis 
The high global incidence of clinical mastitis due to S. uberis, an environmental 
pathogen, has warranted the development of vaccines to prevent mastitis caused by 
this specific etiological agent (Leigh, 2000). Repeated immunisation in experimental 
animals with killed S. uberis vaccine resulted in a significant reduction in the number 
of bacteria in milk but failed to reduce the SCC count (Finch et al., 1994). 
Vaccination with this bacterin was reported to offer protection against mastitis 
caused by the homologous S. uberis strain but failed to protect against a heterologous 
strain (Finch et al., 1997). In another study, plasminogen activator derived from S. 
uberis showed promising results in reducing the severity of infection (Leigh, 1999 
and 2000). In a recent study, cows vaccinated with a recombinant adhesion molecule 
of S. uberis (rSUAM) by the subcutaneous route showed an increased antibody titre 
in milk and serum, which was found to reduce adherence and internalisation of the 
organism into the epithelial cells of the mammary gland under in vitro conditions 
(Prado et al., 2011). 
 
      Numerous efforts to develop S. uberis vaccines to prevent mastitis have not proven 
successful and no commercial vaccines for prevention of this infection are available 
in the market. No immune response is induced in the mammary gland even after 
intra-mammary infection with S. uberis, which further complicates the development 
of a vaccine (Schukken et al., 2009). Sortase-anchored proteins derived from S. 
uberis may be potential candidates for vaccine as they are potential virulence 
antigens contributing to the pathogenesis of bovine mastitis (Leigh et al., 2010). 
Recently, Denis et al., 2011 reported that cows suffering mastitis after environmental 
exposure to S. uberis developed bactericidal antibodies and T cells in blood and milk. 
This resulted in an increased level of interferon-gamma (IFN-γ) that was specific for 
in-vitro killing of S uberis (Denis et al., 2011). Clearly, research on the development 
of an effective vaccine against S. uberis-associated mastitis is highly warranted. 
 
1.8.3 Vaccines against Streptococcus agalactiae and Streptococcus 
dysgalactiae 
      S. agalactiae is an important pathogen for humans (infants, pregnant women and 
immunocompromised elderly patients) has nine serotypes (Health, 2011), each 
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having a serologically distinct polysaccharide capsule; a capsular conjugate vaccine, 
using the capsule of predominant serotypes, has been evaluated in Phase 2 trials with 
encouraging results. However, this pathogen causes mastitis in cattle with little 
information available on the capsular types prevalent in the dairy population. 
Furthermore, no commercially attractive prototype vaccine candidates are available 
against mastitis caused by S. agalactiae or S. dysgalactiae despite the fact that many 
attempts have been made to develop an effective vaccine against these pathogens 
(Keefe, 1997; Gillen 2007). Recently, a recombinant vaccine composed of S. aureus 
cluming factor A (ClfA) and surface immunogenic protein (rSip) of S. agalactiae 
was shown to increase the serum IgG1 antibody titre in experimental mice 
immunised by an intra-mammary route (Xu et al., 2011). Not much effort in 
developing a vaccine against bovine mastitis due to S. dysagalactiae has been made 
either. However, the surface proteins GapC and Mig of S. dysagalactiae were 
reported to be potential protective antigens against bovine mastitis (Bolton et al., 
2004).  
 
1.9 History of vaccine development against bovine mastitis 
caused by S. aureus  
 
The high antibiotic cost, antibiotic residues in milk and severe consequences of 
infection and drug resistance against S. aureus highlight the importance of 
prevention. Availability of an effective vaccine is one of the alternative methods to 
prevent mastitis. Many investigators have tried to develop an effective vaccine 
against mastitis, but none have yet yielded satisfactory outcomes (Lee et al., 1988; 
Greenberg et al., 1989; Mamo et al., 1994; McKenney et al., 1999; Leitner et al., 
2000; Tenhagen, 2001; Leitner et al., 2003). Several approaches for vaccine 
development that have been undertaken have claimed to reduce the clinical severity 
but not prevent intra-mammary infection (IMI), of are as follows: 
 
1.9.1 Use of whole organism as vaccine 
These vaccines comprise killed bacteria or lysates emulsified either in alum-based or 
oil-based adjuvant. Watson for the first time in 1981 has suggested that S. aureus 
produces additional antigen in vivo which can be used to develop a vaccine against 
bovine mastitis.  A heat killed S. aureus vaccine composed of capsular 
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polysaccharide of S. aureus and CP of S. epidermidis was studied for its protective 
potential against bovine mastitis in two herds in USA (Yoshida et al., 1984). There 
was remarkable decrease in leukocyte count of milk and increase in resistance to 
mastitis infection post vaccination for 4 months. Besides, the loss of milk production 
was also reduced in the vaccinated group. One of the commercially available whole 
organism vaccines since the 70’s is lysigin that contains whole cell lysates of five S. 
aureus strains of CPS serotypes 5, 8 and 336 (Middleton, 2008) which reduces the 
clinical severity of mastitis. Formalin-killed autogenous vaccines have also been 
used over the last few decades although the results have tended to vary depending 
upon the virulence attributes of the endemic S. aureus strains involved (cited from 
Middleton, 2008). A field trial using a killed S. aureus vaccine with toxoid and 
composite immunological adjuvant was performed to prevent bovine mastitis in 
Australia (Watson and Schwartzkoff, 1990). Intramuscular administration of the 
vaccine in cows 8 weeks prior to calving reduced overall incidence of mastitis to 45-
52% including 25% of subclinical mastitis caused by S. aureus. Tollersrud et al 
(2001) compared the immunogenicity of S. aureus type 5 CPS-conjugate vaccine 
with the killed whole cell vaccine and reported better performance for the whole cell 
vaccine in respect to humoral immune response.  Leitner et al. (2003a) developed a 
vaccine, MASTIVAC 1, which after demonstrating its protective potential in non-
mastitic mouse model (2003a) was evaluated its protective potential in dairy cattle in 
a challenge (Leitner et al., 2003b) and field trial (Leitner et al., 2003c). While the 
protection against one of the parent strains in the challenge trials was reported to 
provide significant protection, difference between the immunity efficacy of 
vaccinates versus the controls in the field trial was statistically insignificant. 
Furthermore, no analysis of the capsular types of the selected vaccine strains was 
carried out. Athar (2007) studied four different formalin inactivated S. aureus 
vaccines against mastitis in lactating buffaloes. These vaccines consisted of formalin 
inactivated S. aureus vaccine adjuvanted with dextran sulphate, aluminium 
hydroxide or both dextran sulphate plus aluminium hydroxide. Intramuscular 
administration of the vaccines reduced the incidence of subclinical mastitis caused by 
S. aureus accompanied by significant increase of antibody in serum and whey, 
increase milk yield and decreased somatic cell count. 
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1.9.2 Live attenuated vaccines 
Another approach that has yielded interesting results is the generation of live 
attenuated (aroA) S. aureus that has been reported to induce significant protection in 
mice (Buzzola et al., 2006). Live vaccine triggered specific antibody and enhanced 
phagocytic activity of neutrophils by stimulating IgG1 and IgG2 in a study using both 
live and killed S. aureus (Davidson, 1987). A study including four S. aureus vaccines 
consisting live attenuated, dextran sulphate adjuvanted, oil adjuvanted and simple 
bacterin demonstrated significant reduction in somatic cell count (Shakoor et al., 
2006). These vaccines included live attenuated, plain bacterins of S. aureus and two 
killed S. aureus vaccines with different adjuvants including dextran sulphate and 
mineral oil. Partial protection against mouse mastitis was reported by Buzzola et al. 
(2006) against challenge with the homologous parent strain although no information 
on the mutant S. aureus phenotype or resistance against challenge with various 
capsular types was reported.  
 
1.9.3 Capsular polysaccharide vaccines 
Yoshida et al. (1984) demonstrated that an S. aureus mastitis vaccine composed of 
capsular polysaccharide of S. aureus in combination with capsular polysaccharide 
from S. epidermidis increased resistance to infection upto 4 months of vaccination. 
Another study with S. aureus vaccine comprising pseudocapsule, alpha and beta 
toxoids of S. aureus with mineral oil adjuvant prevented clinical mastitis caused by 
S. aureus in the first lactation of the heifers (Nordhaug et al., 1994a). Guidry et al., 
1997 suggested that regional variation in prevalence of S. aureus capsular 
polysaccharides should be considered while formulating capsular polysaccharide 
based mastitis vaccines. S. aureus isolated from human infections have been shown 
to produce 12 polysaccharide serotypes (11 different capsular serotypes) and one 
surface polysaccharide 336 (Guidry et al., 1998). However, only polysaccharides of 
serotypes 1, 2, 5 and 8 have been purified and characterized (O’Riordan and Lee, 
2004; Jones, 2005). The majority of clinical isolates were reported to express a 
capsular polysaccharide of either serotype 5 or 8, representing 70-80% of the isolates 
from all sources (Arbeit et al., 1984; Hochkeppel et al., 1987; Poutrel et al., 1988), 
the rest being non-typeable. Guidry et al., 1998 reported that non-typeable bovine 
isolates belonged to serotype 336. The 336 antigen was characterized as polyribitol-
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phosphate-N-acetylglucosamine, a component of cell wall teichoic acid (Verdier et 
al., 2007) but no data on its vaccine potential is available at present. A trivalent S. 
aureus mastitis vaccine containing formalin inactivated S. aureus strains belonging 
to serotypes 5, 8 and 336 with and without adjuvants was evaluated for its immune 
response in dairy cattles (Lee et al., 2005). These vaccine formulations stimulated 
antigen-specific IgG1 and IgG2 production in serum. Vaccine formulations with 
adjuvant (either alum or Freund’s incomplete) stimulated even more IgG2 
production. A trademarked vaccine, StaphVAX (Nabi Biopharmaceuticals, Inc) was 
prepared by conjugating purified CP5 and CP8 antigens to mutant nontoxic 
recombinant P. aeruginosa exotoxin A (rEPA).The Phase III trials of this vaccine to 
prevent S. aureus infections in humans have been stalled due to unfavourable 
outcomes (Middleton, 2008).  
 
1.9.4 Surface and cell wall associated virulent factors as vaccines 
This approach has involved use of surface proteins particularly clumping factor (Clf) 
A, fibronectin-binding protein (FnBP) A, protein A and a collagen-binding protein 
(CNA) as vaccine candidates. Mamo et al., (1994) reported that mice immunized 
with FnBPA were partially protected against intra-mammary challenge. However, 
combination of FnBP fusion protein with staphylococcal -toxoid did not increase 
the efficacy of the vaccination either. Similarly, vaccination of mice with the CNA-
FnBP proteins reduced the post-challenge mortality (Zhou et al., 2006) whereas dairy 
heifers vaccinated with these proteins alone or in combination were not effective in 
countering challenge with the parent strain. However, when the fusion protein was 
incorporated in immunostimulating complexes (ISCOMs), no clinical cases of 
mastitis post-intramammary challenge with 1,000 CFU of the parent strain were 
recorded (Nelson et  al., 2006; cited from Middleton, 2008), thus raising the 
important question on the selection of an appropriate adjuvant for immunization of 
dairy cattle for effective protection against mastitis. 
 
1.9.5 Genetic immunization  
It is an attractive advancement in vaccine development that has been used to elicit 
potentially protective antibodies and cell-mediated immune responses in a variety of 
animal models of viral and bacterial diseases (Donnelly et al., 1999; Tuteja, 1999). 
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One of the claimed advantages of this method is that the antigen is produced in vivo 
and hence may induce both arms of the immune response (Condon et al., 1996). One 
recent report on the immunogenicity of a naked DNA encoding penicillin-binding 
protein, PBP2a, revealed the generation of a non-dose dependent antibody response 
to MRSA (Roth et al., 2006) in mice. A DNA vaccine encoding the clumping factor 
A was recently reported to yield high antibody titres in dairy cattle (Nour El-Din et 
al., 2006) but no challenge data was presented. However, Castagliuolo et al. (2006) 
reported success in providing significant protection against mastitis in the mouse 
model following intranasal immunization with four, rather than one, adhesins 
including fibrinogen-binding protein, fibronectin binding protein, clumping factor A 
and collagen-binding adhesion as target in a DNA vaccine. Intranasal immunization 
with a pDNA mixture coding the four adhesins, triggered significant levels of 
specific serum and mucosal Ig that inhibited S. aureus adhesion to cow mammary 
gland epithelial cells in vitro.  
 
1.9.6 Toxoids as vaccine 
There have been various efforts to develop vaccine using toxoids to prevent S. 
aureus mastitis. Kume and Murase (1976) studied the protective potential of S. 
aureus vaccine composed of bacterial toxin and reported to be effective in preventing 
clinical mastitis in cows. An animal trial in cows and buffaloes using alum-cell-
toxoid and aluminium hydroxide gel-cell toxoid of S. aureus resulted prevention of 
subclinical mastitis in vaccinated animals (Pal and Pathak, 1977). Formulation of 
vaccine against S. aureus mastitis by using S. aureus toxoids with adjuvant was first 
suggested by Watson, 1984. A more recent approach has reported prevention of 
subclinical mastitis by immunizing dairy cattle by immunization with an inactivated 
recombinant staphylococcal enterotoxin (a superantigen) type C (SEC) single mutant 
vaccine administered by the intramuscular route (Chang et al., 2008). An SEC-
specific ELISA test conducted at 4 wk post-immunization confirmed the presence of 
a high antibody titre against SEC in all vaccinated cattle. The somatic cell counts 
from the vaccinated group remained relatively low, whereas those of control group 
increased significantly after challenge with S. aureus. After challenge, S. aureus was 
not isolated from any cattle in the vaccinated group, whereas it was isolated from 
75% of the cattle in the control group. Another study has reported success in 
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achieving protection against intravenous challenge with S. aureus in mice immunized 
with a double mutant of staphylococcal enterotoxin C (dmSEC) devoid of 
superantigenic activity in combination with cholera toxin as adjuvant by the 
intranasal route (Hu et al., 2006). 
 
1.9.7 Non-capsular surface polysaccharide of S. aureus as vaccine 
candidate 
The use of a surface polysaccharide, poly- N-acetyl glucosamine (PNAG), a putative 
biofilm-forming antigen, and demonstrated to provide at least partial protection 
against staphylococcal infections in mice (Maitran et al., 2004). A vaccination study 
using bacterins and PNAG to protect S. aureus mastitis in sheep demonstrated 
antibody production against PNAG and prevented mastitis against S. aureus and 
suggested use of PNAG as important candidate of vaccine against bovine mastitis 
(Perez et al., 2009).  
 
1.10 Prospect of vaccine development against S.aureus 
considering the mode of growth 
Amongst the two modes of growth by S. aureus, the biofilm versus planktonic, the 
former is difficult to treat and control as it is 50-500 times more resistant to 
antibiotics (Stewart and Costerton, 2001). Innate immune system of host can assist in 
the elimination of the planktonic form of S. aureus which is considered a transient 
state. In an in vitro experiment it was demonstrated that human leukocyte 
(lymphocytes) can actively phagocytose planktonic form of S. aureus, but was 
unsuccessful to do the same to biofilm form of S. aureus (Leid et al., 2002). 
Planktonic S. aureus usually stimulates antibody production in host. But due to 
formation of deeper layers antibodies are ineffective against biofilm. Further it leaves 
the immune complex of adjacent tissues damaged enough to produce antibodies 
(Cochrane et al., 1998). The infections caused by biofilm form of S. aureus are not 
countered by the defense mechanisms even in healthy individuals owing to this 
reason. 
 
Most of the vaccine development programmes have focused on infections induced by 
planktonic S. aureus (Stranger-Jones et al., 2006; Kim et al., 2010). These vaccines 
39 
 
have reduced the clinical severity of S. aureus infections, but failed to prevent new 
infections (Middleton, 2008). Most of these vaccines have targeted one or a few 
virulence factors related to S. aureus infections. S. aureus produces almost 70 
virulence factors and biofilm being one of the potent virulence factors (Costerton et 
al., 1999; Harro et al., 2010). Targeting to neutralize the effect of one or few 
virulence factors is unlikely to assist in the control of S. aureus infections. Besides, 
S. aureus once enters into a host is either removed by host immune mechanism or 
form biofilm after attaching to extracellular matrix of host. In the biofilm form, 
proteome of S. aureus is transformed into biofilm phenotype which is different from 
the planktonic phenotype (Brady et al., 2007). Therefore a host vaccinated against 
planktonic S. aureus antigens may eradicate only a part of biofilm and hence the 
inefficiency associated with the planktonic vaccines. Brady et al. (2011) developed a 
vaccine which is composed of four immunogenic cell-wall associated antigens which 
were upregulated during biofilm formation of S. aureus in rabbit’s skin infections. 
The vaccine reduced radiographic scores of infection, but, failed to reduce clinical 
signs and clear the infection. A new approach of vaccine development against S. 
aureus should consider antigens which are common in both planktonic and biofilm 
mode of growth of S. aureus (Harro et al., 2010). It is important to choose the right 
components of biofilm while formulating an anti-biofilm S. aureus vaccine. Biofilm 
is mainly composed of two components: Biofilm matrix and S. aureus cells within 
biofilm. Most of the anti-biofilm vaccines have used biofilm matrix as candidates for 
vaccine formulation (Schaffer and Lee, 2008), PNAG being the commonest one. 
PNAG has shown promising results against S. aureus mastitis in animal models 
(Perez et al., 2009) and S. aureus abscess formation (Gening et al., 2010). However, 
more studies need to be conducted to establish efficacy of PNAG against S. aureus 
biofilm infections. Since the extracellular matrix of the biofilm assists the pathogen 
to evade immune defense mechanisms of the host, in many conditions it is produced 
and sloughed off (Harro et al., 2010). Thus it can be concluded that a potent anti-
biofilm S. aureus vaccine should be composed of both the extracellular matrix and 
the S. aureus cells within biofilm which actually produces the matrix.  
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1.11 Objective of this research project 
The objective of this research were to test the hypothesis that mice vaccinated with 
bacterins from strong biofilm producing S. aureus will generate better immune 
response and confer protection against mastitis following challenge with a biofilm 
producing S. aureus than a vaccine which is composed of only bacterins from 
planktonic form of S. aureus. The ultimate goal of the project is to develop a rational 
effective vaccine formulation for the prevention of bovine mastitis in Australia. The 
aims under pinning the achievement of this goal are based on the potential 
mechanism/processes of pathogenesis followed by S. aureus to establish an infection 
in the mammary gland (udder) of ruminant species and produce mastitis. It is 
contended that the first step in the production of mastitis by S. aureus contributing to 
biofilm formation is colonisation via adhesins, accompanied by immune evasion via 
surface-associated protein and/or polysaccharide antigens. The second step is the 
damage caused to the mammary tissue by via exotoxins and/or production of 
proinflammatory cytokines. It is therefore essential to have knowledge on the 
potential virulence factors detected or produced by the Australian bovine mastitis 
isolates. Hence the aims of this investigation were as follows: 
 
1. Determination of biofilm forming potential and antibiograms of S. 
aureus isolated from cases of bovine mastitis in Australia. 
2. Distribution of virulence factors in S. aureus isolated from clinical 
and subclinical cases of bovine mastitis in Australia. 
3. Production of capsule-specific antisera for use as reagents for typing 
of S. aureus of Australian origin and determination of the prevalence 
of capsular polysaccharide (CPS) types of S. aureus isolated from 
clinical and subclinical cases of bovine mastitis in Australia. 
4. Standardise the mouse mastitis model system for use in the 
assessment of the immunogenic potential of different vaccine 
candidates developed in this project. 
5. Evaluation of immunogenicity and protective potential of S. aureus 
planktonic and biofilm- based vaccines using the mouse mastitis 
model system. 
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6. Evaluation of the immunogenicity and protective potential of the 2nd 
major immune evasion antigen, Protein A using the mouse mastitis 
model system. 
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Chapter 2: Methods 
Every chapter in the thesis (chapters 3 to 9) contains “Materials and Methods” 
section as applicable to the research question embodied in different chapters. This 
chapter only includes those general methods which have been used during 
investigations described in this thesis but have not been presented elsewhere in the 
thesis. 
 
2.1 Bacterial strains and culture conditions 
One hundred and fifty four (154) fully characterised S. aureus strains of Australian 
origin isolated from clinical cases of mastitis in cows in Victoria and Queensland 
were generously donated by Professor Margaret Deighton, (RMIT University), Dr. 
Sharon de Wet (Queensland Biosecurity laboratory) and Dr. Justine Gibson 
(University of Queensland). Reference strains representing CP types 1 (strain M), 2 
(strain Smith diffuse), 5 (strain Newman), 8 (USA 400 MW2) and a non-capsulated 
strain (LAC, USA 300) were donated by Professor Gerald Pier (Harvard Medical 
School, Boston, USA). S. aureus ATCC® 29213™, ATCC® 49775™, ATCC® 
8096™ and ATCC® 55804™ were purchased from ATCC, USA. Hu S. aureus 11 
strain from human origin was characterised and established in Associate Professor 
T.K. Mukkur’s laboratory. 
 
All the bacterial strains were grown on Mueller Hinton (MH) agar and subcultured in 
nutrient broth supplemented with 1% glucose and stored on cryobeads (Blackaby 
Diagnostics) or as glycerol (15%) broth stocks at -80°C. For preservation of the 
strains seven colonies were emulsified in cryo-preservative fluid and mixed 
thoroughly by inverting the vial and finally removing the cryo-preservative fluid. 
This was followed by storage at -80°C. 
 
2.2 Antimicrobial susceptibility test (CDS method) 
Sensitest plates (PathWest Laboratory Medicine, Western Australia) were used to 
perform antimicrobial susceptibility test. Overnight culture of S. aureus grown on 
MH agar plate was used for the study. Using a straight wire single colony of S. 
aureus was stabbed and inoculated in 0.9% saline. Using a Pasteur pipette saline was 
mixed up and down for 10 times. Sensitest plates were flooded with saline 
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suspension followed by rocking the plates for evenly distribution. Excess suspension 
was removed by using a Pasteur pipette and lid of the plates were removed and agar 
was allowed to dry for 10-15 min in room temperature. Plates were loaded with 
antibiotic disc limited to 6 discs in one plate. Plates were incubated at 35ºC for 18 h. 
The measurement for zone of inhibition was taken from the edge of the disc to the 
start zone of bacterial growth. Zone of inhibition 6 mm or greater in diameter were 
interpreted as sensitive except for vancomycin (VA5) and teicoplanin (TEC 15), for 
which, a 2 mm diameter was considered as the cut-off.  
 
2.3 Extraction of genomic DNA 
Extraction of genomic DNA was performed by using a kit (MO BIO Laboratories, 
Inc Carlsbad, CA). S. aureus strain was grown in brain heart infusion broth at 37ºC 
overnight. Briefly 1.8 ml of overnight grown culture was centrifuged at 10,000 x g 
for 30 sec at room temperature and pellet was retained. Pellet was suspended in 300 
µl of microbead solution, vortexed gently and transferred to micro bead tube. Fifty 
microliter of MD 1 solution was added, vortexed for 10 min and centrifuged at 
10,000 x g for 30 sec at room temperature. Supernatant was collected and 300 µl of 
MD 2 solution was added, vortexed for 5 sec and incubated at 4 ºC for 5 min. This 
was followed by centrifugation at 10,000 x g for 1 min. The supernatant was 
transferred to a new tube and 900 µl of MD 3 solution was added. The suspension 
was transferred to spin filter and centrifuged at 10,000 x g for 30 sec and supernatant 
was discarded. The pellet was suspended in 300 µl of MD 4 solution and centrifuged 
at 10,000 x g for 30 sec. The flow through was discarded and the spin filter was 
placed in a new 1.5 ml collection tube and 50 µl of MD 5 solution was added to the 
centre of the filter which was followed by centrifugation at 10,000 x g for 30 sec. 
The spin filter was discarded and DNA was stores at -20°C until use. 
 
2.4 Detection of mecA and pvl gene by using Genotype-MRSA kit 
Detection of mecA and pvl gene was performed by using Genotype-MRSA kit (Hain 
Lifescience). The test is based on DNA strip technology. Briefly, 45 µl of 
amplification mix was prepared by mixing 35 µl PNM, 5 µl 10x polymerase 
incubation buffer, 3 µl MgCl2 solution, 1.6 µl nuclease free water and 0.4 µl DNA 
polymerase. To the mixture 5 µl of genomic DNA was added to make a total volume 
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of 50 µl. The amplification conditions were 95°C for 5 min, 22 cycles each of 95°C 
for 20 sec and 60°C for 30 sec. The amplified product was stored at -20°C until the 
next step. The final step was hybridization biotin-labelled amplicons to membrane-
bound probes. This was achieved by Dispensing 20 µl of denaturation Solution to 
each well of the tray provided with the kit and adding 5-20 µl of amplified product. 
This was followed by incubation for 5 minutes at room temperature. One ml of 
hybridization buffer was added to each well and mix properly with gentle shaking. 
To each well a strip (provided with the kit) was placed and incubated at 45°C in 
shaking water bath for 30 min. After incubation hybridization buffer was aspirated 
and 1 ml of stringent wash solution was added to each strip and was further 
incubated at 45°C in shaking water bath for 15 min. Wash solution was poured out 
and each strip was washed with 1 ml of Rinse Solution for 1 minute and 1ml of 
conjugate was added and incubated for 30 min at the same temperature and 
condition. The strips were washed twice for 1min using 1ml each of rinse solution 
and distilled water. Finally water was poured out from the wells and 1 ml of substrate 
was added to each well and incubated the wells at 45°C for 20 min. The reaction was 
stopped by using distilled water and dried the strips by using absorbent paper. 
Evaluation and interpretation of results is done as per the bands developed in the 
strip. The strip has 6 reaction zones which are shown below in a diagram. 
 
 
 
 
 
 
 
 
 
 
 
           Figure 2.1: Reaction zones in the strip of Genotype MRSA kit 
Conjugate control 
Universal control 
S. aureus 
S. epidermidis 
mecA 
pvl 
Coloured marker 
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2.5 Preparation of splenocytes for estimation of IFN-γ levels post-
stimulation with experimental or control antigens 
Mice were euthanized by using cervical cordotomy in anaesthetised state and spleens 
were collected in ice-cold 2 ml of Dulbecco’s modified Eagle’s medium (CDMEM, 
Gibco) without adding fetal bovine serum (FBS). Spleens were ground on a 70µm 
cell strainer (BD) using a 10ml syringe piston and cells were collected in a 50ml 
falcon tube with a final rinse of 3ml of CDMEM without FBS. Splenocytes were 
pelleted at 1000 x g (Beckman Coulter Avanti® J-E) for 10 min which was followed 
by re-suspension of pellet in 3 ml of CDMEM without FBS and 500 µl of 
ammonium chloride was added to the splenocyte suspension for lysis of RBC. The 
suspension was incubated at room temperature for 2 min and centrifuged at 1000 x g 
for 10 min. Cells were washed twice using 3 ml of CDMEM without FBS at 1000 x 
g for 10 min. The pellet was resuspended in 10 ml of complete DMEM media with 
10% FBS, 100 µg/ml streptomycin/ml and 100 U penicillin/ml and centrifuged at 
1000 x g for 10 min. The viability of splenocytes were checked by aliquoting out 10 
µl of suspension and counting using a haemocytometer where staining of the cells 
was done with trypan blue. Haemocytometer (Neubauer) with a depth of 0.1 mm 
with conversion factor 10,000 was used to perform viable cell count. Ten ml of 
splenocytes was diluted 1: 10 with CDMEM. Trypan blue (Invitrogen) in equal 
proportion was added to get a dilution factor of 1:20. The chambers of 
haemocytometer were filled with the suspension by capillary action and average 
counting was performed for all the four large outer squares. The average number of 
cells/ml was multiplied by dilution as well as conversion factors to get the total 
number of viable cells per ml of splenocytes. The concentration of cell was adjusted 
to 1x10
7 
splenocytes/ml. One ml of CDMEM with 10% FBS was taken in each well 
of 24 well tissue culture plate and 1ml of splenocyte suspension was added to get a 
final cell concentration of 5 x 10
6 
splenocytes/well.  
 
Selected S. aureus antigens (killed biofilm S. aureus, killed planktonic S. aureus, 
ProteinA) were added in duplicate wells and cells were incubated at 37ºC with 5% 
CO2 for 72 h. The wells were checked every 24 h for cloudiness which indicates 
contamination and contaminated wells if any were discarded. After completion of 72 
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h supernatant from each well was collected for measurement of IFN-γ production. 
The splenocyte supernatants were stored at -80ºC for further study. 
 
2.6 Preparation of antigens for stimulation of splenocytes 
For both planktonic and biofilm vaccines, single colony of overnight grown 
BOAISRF S. aureus 51 strain was inoculated into each well of 24 well flat bottoms 
with lid tissue culture plates (Sarstedt Australia Pty Ltd, SA) which were filled with 
1.5 ml of 1% glucose enriched nutrient broth. Plates were incubated at 37º C for 24 h 
with gentle shaking at 80 rpm. Planktonic form of antigen was obtained by collecting 
the supernatant using a pipette and centrifuged at 10,000 x g for 10 min. The biofilm 
was collected by scooping out with sterile spatula and washed using 1ml of sterile 
PBS. Both the planktonic and biofilm forming cells were washed for five times at 
10,000 x g for 10 min by using PBS. Cells were suspended in 5 ml of PBS to which 2 
ml of 3% formalinized PBS was added and allowed to remain at room temperature 
for a period of 24 h. This was followed by centrifugation at 10,000 x g for 20 min 
and washing with PBS five times and resuspending in 5ml of sterile PBS. Based on 
the growth curve the desired colony forming units of BOAISRF S. aureus 51 in both 
planktonic and biofilm form were adjusted to 1 x 10
8
 cfu/ml. For ProteinA vaccine, 
2.5 µg of purified protein A was prepared for addition to each well of splenocyte 
suspension. 
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Chapter 3: Analysis of biofilm forming potential, antibiotic 
resistance and related genes of Australian bovine mastitis-
associated Staphylococcus aureus isolates 
 
Prologue 
One of the prerequisites for establishment of infection with most pathogens is 
colonisation of the target site, followed by formation of biofilms. Biofilm formation 
in the mammary gland of cows infected with S. aureus should be no exception. 
Biofilm formation by pathogens has been reported to bestow the property of 
enhanced resistance to antibiotics and phagocytosis (Matz et al., 2005; Bjarnsholt, 
2013). Biofilm formation creates a major obstacle in the treatment and prevention of 
bovine mastitis caused by S. aureus. 
 
3.1 Introduction 
Biofilm is the aggregation of bacterial colonies attached to biotic or abiotic surface 
and being enclosed by self-produced extracellular matrix. It is mainly composed of 
two components- micro colonies of S. aureus cells (≥15% by volume) and 
extracellular matrix (≥85%) [Kokare et al., 2009]. Formation of biofilm by S. aureus 
helps the bacterium to acquire nutrition (Decho, 1990) and new genetic traits (Brady 
et al., 2007). Besides, it protects the pathogen from host immune defence mechanism 
and antimicrobial agents (Monzon et al., 2002). Acute mastitis is usually caused by 
planktonic S. aureus which is easy to treat with antibiotics depending on the 
accuracy and promptness of diagnosis (Bjarnsholt, 2013). However, S. aureus 
succeedes in forming a biofilm does not respond to antibiotic treatment and develops 
into chronic form of mastitis (Bjarnsholt, 2013). 
 
Formation of S. aureus biofilm can be described in three steps: attachment, 
maturation and detachment (Otto, 2013). Attachment of S. aureus cells to mammary 
tissue occurs due to interaction of surface anchored bacterial factors, particularly the 
microbial surface component recognizing adhesive matrix molecules (MSCRAMMs) 
including fibronectin binding proteins (FnBPA, FnBPB), fibrinogen binding proteins 
(ClfA, ClfB), collagen binding protein (CNA) and bone sialo binding protein (BBP) 
(Patti et al., 1992; Mc Devitt et al., 1994; Tung et al., 2000 and O’Neill et al., 2008). 
The second step of biofilm development is the formation of polysaccharide 
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intercellular adhesion (PIA), alternatively referred to as PNAG (Poly-β-1, 6-linked 
N-acetylglucosamine) which is activated by four proteins including IcaA, IcaD, IcaB 
and IcaC produced by single icaADBC operon, IcaA and IcaD being the most 
important proteins for the production of PNAG (Otto, 2009). The role played by 
PNAG to form biofilm in S. aureus infections has been demonstrated (Maira- Litran 
et al., 2004). However, few recent studies have demonstrated the production of 
biofilm by even PNAG- negative strains with the help of other adhesion proteins of 
S. aureus including proteinA (Merino et al., 2009) and biofilm-associated protein 
[bap] (Lasa and Penades, 2006). The third step in biofilm formation is the 
detachment of biofilm which facilitates dissemination of S. aureus from the original 
site of infection to other tissues or surfaces (Gil et al., 2014). An accessory gene 
regulator (agr) can negatively influence biofilm production contributing to the 
detachment of biofilm and dispersion (Boles and Horswill 2011).  Among the four 
agr types (Goerke et al., 2003), specific types appear to be associated with certain 
phenotypes, including antibiotic resistance and biofilm production (Manago et al., 
2006). It has been demonstrated that specific agr type is associated with particular 
infections caused by S. aureus. Agr type 1-IV is associated with enterotoxigenic 
infections and endocarditis, endocarditis, toxic shock syndrome toxin and exfoliative 
disease, respectively (Jarraud et al., 2002). 
 
Different phenotypic and genotypic methods have been used to determine the ability 
to produce biofilm by S. aureus. The common phenotypic methods used are Congo 
red agar (CRA) method, Tissue culture plate (TCP) method, Tube method (TM) and 
the Transmission and Scanning Electron microscope method. The genotypic method 
includes the detection of intercellular adhesion genes (icaA, icaD, icaB and icaC), 
bap gene by using conventional polymerase chain reaction (PCR). Different 
investigators have reported different results regarding the effectiveness of biofilm 
production detection methods. Dhanawade et al (2010) reported the CRA method to 
be superior to the TCP and TM methods as TCP method identified 48.03% of biofilm 
producers, followed by 36.27% by TM method and 19.60-24.91% by TCP method. 
Similarly Vasudevan et al (2003) confirmed the superiority of the CRA methods over 
the other methods and reported the identification of 91.4% S. aureus strains as 
biofilm producers using the CRA method. In contrast, the TCP method was found to 
be superior detecting 57.8% of the strains as biofilm producer (Mathur et al., 2006). 
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These authors could not differentiate negative biofilm or weak biofilm producers 
using the TM method. Besides the CRA method did not show any correlation 
between TCP and TM methods in regards to biofilm formation. 
 
The antimicrobial tolerance of S. aureus biofilms may be due to factors like (a) 
presence of extracellular matrix (Kolpen et al., 2010) (b) decreased growth rate 
leading to smaller size of cells which are less susceptible to antibiotics (Thein and 
O’Toole, 2001) (c) presence of antibiotic degrading enzymes in biofilms causing 
inactivation of antibiotic molecules trying to enter into biofilm (Raza et al., 2013) 
and (d) change in the protein structure of cell wall of S. aureus in biofilms than the 
planktonic mode of growth (Potera, 1999). Ability to evade host defence mechanism 
and resist antibiotics and antimicrobial agents make S. aureus biofilm-associated 
infections untreatable and transforms the infection to chronic state (Cucarella et al., 
2004). There are no studies to the best of our knowledge; on either the development 
of persistence of biofilm-associated antibiotic resistance of S. aureus or the 
emergence of resistance to different antibiotics. The major aim of this study is to 
investigate: (a) the antimicrobial susceptibility pattern of S. aureus isolates from 
clinical cases of bovine mastitis (b) the biofilm forming potential of these isolates 
and the impact on emergence of persistent antibiotic resistance developed by selected 
clinical isolates of S. aureus or (c) inter-relationship between production of biofilm 
by these isolates and presence of ica, bap, blaZ or agr genes in these isolates. 
 
3.2 Material and Methods 
3.2.1 S. aureus isolates 
One hundred and fifty four (154) fully characterised S. aureus strains of Australian 
origin isolated from clinical cases of mastitis in cows in Victoria and Queensland 
were used for the study. Reference strains representing CP types 1 (strain M), 2 
(strain Smith diffuse), 5 (strain Newman and USA 100 NRS 648), 8 (USA 400 
MW2) and non-capsulated strains (LAC, USA 300 and USA 300 NRS 648) and a 
strong biofilm former ATCC 29213 were used as positive controls. BOAISRF S. 
aureus 15, 25, 114, 131 1nd 146 were characterised and established in our laboratory 
were used as positive control for bap and agr types (Table 3.1). These isolates were 
grown on Mueller Hinton (MH) agar and subcultured in nutrient broth supplemented 
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with 1% glucose and stored on cryobeads (Blackaby Diagnostics) or as glycerol 
(15%) broth stocks at -80°C. 
 
3.2.2 Screening of S. aureus isolates for antibiotic resistance 
One hundred and fifty four (154) strains of S. aureus were screened for their 
antibiogram by using CDS method (Bell et al., 2009). The antibiotics used in the 
experiment were benzylpenicillin (P 0.5), 0.5g, cefoxitin (FOX 10), 10g, 
cephalexin (CL 100), 100g, ciprofloxacin (CIP 2.5), 2.5g, co-trimoxazole (SXT 
25), 25g, erythromycin (E 5), 5g, linezolid (LZD 10), 10g, mupirocin (MUP 
200), 200ug, rifampicin (RD 1), 1g, teicoplanin (TEC 15), 15g, tetracycline (TE 
10), 10g and vancomycin (VA 5), 5g (Oxoid). Sensitest plates (PathWest) were 
used to subculture S. aureus and plates were incubated at 37°C for 18 h after which 
the antibiotic sensitivity or resistance was recorded as described elsewhere, with the 
measurement taken from the edge of the disc to the start zone of bacterial growth 
(Bell et al., 2009). Zones of inhibition of 6 mm or greater in diameter were 
interpreted as sensitive. Exceptions to this rule were for vancomycin (VA5) and 
teicoplanin (TEC 15), for which, a 2 mm diameter was used as the cut-off.  
 
To determine the persistence or emergence of antibiotic resistance, 28 biofilm 
forming (weak, intermediate and strong) S. aureus strains were selected and 
following the same protocol antibiotic resistance study was performed for both 
planktonic and biofilm forms of these S. aureus against the above mentioned 12 
antibiotic agents. These strains were all tested as sensitive against all the 12 
antibiotics in planktonic form. 
 
3.2.2.1 Screening of S. aureus isolates for methicillin resistance 
Detection of methicillin resistance of the 154 strains was detected by 3 different 
methods: Chromogenic MRSA ID plates, Use of MRSA kit and PCR analysis of 
mecA gene.  
 
3.2.2.1.1 Use of chromogenic culture media plates 
All isolates were streaked on Chromogenic MRSA ID plates to check for bacterial 
ability to grow in the presence of cefoxitin (Biomerieux, 2011). Chrom ID MRSA 
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plates [Biomerieux] use cefoxitin to assess resistance to methicillin, in combination 
with an antibacterial compound, which inhibits growth of MSSA and other bacteria. 
Colonies showing green blue pigment are classified as MRSA positive whereas 
MSSA strains do not grow on these plates. 
 
3.2.2.1.2 Detection of mecA gene by using Genotype-MRSA kit  
 As per the standard protocol provided with the Genotype-MRSA kit (Hain 
Lifescience) detection of mecA gene was accomplished as described in Chapter 2 
Section 2.4. The positive control used for mecA was Strain Newman (CP5). 
 
3.2.2.1.3 Detection of mecA gene  
To reconfirm the results acquired by the above two methods, identification of mecA 
gene was done using conventional PCR (Murakami et al., 1991). The positive control 
used for mecA was Strain Newman (CP5). The PCR conditions for mecA was 95°C 
for 5 min, 35 cycles of 95°C for 30 sec, Tm for 30 sec and 72°C for 45 sec with a 
final extension of 72°C for 10min. The PCR product was analysed by agarose gel 
(1.5%) electrophoresis, staining with 0.8uL/100mL of Midori Green DNA Stain 
(Nippon Genetics) using 1x SB Buffer. An O'RangeRuler DNA Ladder (100-1500 
bp, Fermentas) was used for comparing the approximate band sizes after visualising 
on UV transilluminator. 
 
3.2.3 Detection of biofilm production 
3.2.3.1 Congo red agar (CRA) method 
Detection of biofilm production on CRA plates was determined by a method 
described elsewhere (Freeman et al., 1989) with slight modification in the incubation 
time by increasing to 96h to ensure maximal biofilm formation. Briefly, Isolates 
were inoculated on CRA plates and incubated for 96 h at 37
o
C. Black, rough 
crystalline colonies were considered positive for biofilm production, and red/pink, 
rough crystalline or smooth colonies were considered as non-biofilm former. 
 
3.2.3.2 Tissue culture plate (TCP) method  
Aliquots (200uL) of nutrient broth, supplemented with 1% glucose, were inoculated 
with S. aureus strains and placed in a 96-well sterile microtitre plate (Kogan et al., 
2005).  The plates were left overnight in a 37°C incubator to ensure adequate biofilm 
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production. This was followed by assessment of their biofilm-forming property using 
the following methods:  
 
3.2.3.2.1 Treatment with sodium metaperiodate 
Sodium metaperiodate was used for treatment of the biofilms as it is known to 
disrupt PNAG-dependent biofilm formulation (Pozzi et al., 2012). This method was 
carried out as described by Kogan et al (2005). Briefly, inoculated TCP wells in the 
micro titre plate were washed with 200uL of 0.9% NaCl and then filled with 100uL 
of 10mM sodium metaperiodate in 50mM sodium acetate buffer. The microtitre plate 
was then incubated at 37°C for 2 hrs after which the wells were washed again with 
200uL of 0.9% NaCl. The plate was dried for 45 min at 55°C and then stained for 5 
mins with 5% safranin.  The plate was once again washed with 0.9% NaCl and the 
results viewed for optical density on a micro titre plate reader at 492 nm. The assay 
was repeated three times and the data was averaged. 
 
3.2.3.2.2 Crystal violet staining 
 This method, which measures the amount of biofilm attached to the polystyrene 
plate, was an adaptation of the procedures described elsewhere (Christensen et al., 
1985; Mathur et al., 2006). S. aureus strains were grown to produce biofilm in a 96-
well micro titre plate. The plates were washed with PBS (pH 7.2) to remove 
planktonic or free-floating bacteria (Mathur et al., 2006). The biofilm was fixed at 
55°C for 10 mins and stained with 2% crystal violet.  Biofilms were destained with 
alcohol and viewed on a microplate reader at 570 nm. The assay was repeated three 
times and the data was averaged.  The cut-off point used for non-biofilm producing 
strains was 0.120 as suggested by Christensen et al (1985). An arbitrary classification 
system for quantification of biofilm formation (Stepanovic et al., 2000) rendered 
more stringent was adopted. The arbitrary cut-off points for weak, intermediate and 
strong biofilm formers were 0.130-4.00 x 0.120 A570nm, 4.10-5.90 x 0.120 A570nm and 
6 x 1.20 A570nm, respectively. 
 
3.2.4 Detection of icaA, icaD, bap, agr types, and blaZ genes using conventional 
PCR 
3.2.4.1 Extraction of genomic DNA  
Genomic DNA was extracted from 154 S. aureus isolates using a kit (MO BIO  
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Laboratories, Inc Carlsbad, CA) as described in Chapter 2 Section 2.3. The extracted 
genomic DNA was stored at -20°C until use. 
 
Table 3.1: Amplification of biofilm related genes of S. aureus isolates from 
bovine mastitis in Australia using conventional PCR 
Target 
gene 
Positive 
control 
Primer Forward  
(5’-3’) 
Primer Reverse (5’-3’) Tm Expec
ted 
band 
size 
(bp) 
Reference 
icaA 
 
USA 400 
strain 
CCT AAC TAA CGA 
AAG GTA G 
AAG ATA TAG CGA 
TAA GTG C 
48°C 1315  Vasudevan et 
al. 2003 
icaD 
 
USA 400 
strain 
AAA CGT AAG 
AGA GGT GG 
GGC AAT ATG ATC 
AAG ATA C 
47°C 381  Vasudevan et 
al. 2003 
bap BOAISRF S. 
aureus 146 
CCC TAT ATC GAA 
GGT GTA GAA TTG 
CAC 
GCT GTT GAA GTT 
AAT ACT GTA CCT 
GC 
42°C  
 
971 Cucarella et 
al., 2001 
agrI BOAISRF S. 
aureus 131 
ATG CAC ATG GTG 
CAC ATG 
GTC ACA AGT ACT 
ATA AGC TGC GAT 
60oC 441 Gilot et al., 
2002 
agrII BOAISRF S. 
aureus 114 
ATG CAC ATG GTG 
CAC ATG 
TAT TAC TAA TTG 
AAA AGT GGC CAT 
AGC 
60oC 575 Gilot et al., 
2002 
agrIII BOAISRF S. 
aureus 131 
ATG CAC ATG GTG 
CAC ATG 
GTA ATG TAA TAG 
CTT GTA TAA TAA 
TAC CCA G 
60oC 323 Gilot et al., 
2002 
agrIV S. aureus 15 ATG CAC ATG GTG 
CAC ATG 
CGA TAA TGC CGT 
AAT ACC CG 
60oC 657 Gilot et al., 
2002 
blaZ BOAISRF S. 
aureus 25 
ACT TCA ACA CCT 
GCT GCT TTC 
TGA CCA CTT TTA 
TCA GCA ACC 
60oC 173 Melchior et 
al., 2000 
 
3.2.4.2 Detection of genes encoding icaA, icaD, bap, agr types, and blaZ genes 
PCR was conducted to detect icaA, icaD, bap, agr type I-IV, and blaZ genes of S. 
aureus in 154 S. aureus isolates from clinical mastitis cases in cows. The primers, 
Tms, band size for all the genes are provided in Table 3.1 with respective references. 
Following are the conditions used for detection of different genes: 
 
The PCR amplification conditions for icaA and icaD were 95°C for 5mins, 95°C for 
45secs, Tm for 45secs, 72°C for 5mins with 30 cycles and final extension at 72°C for 
5 mins. The cycling conditions for bap, blaz and agrI-IV types were 94
o
C for 5 min, 
30 cycles of 94
o
C for 30 sec, Tm for 30 sec and 72
o
C for 60 sec with a final 
extension of 72
o
C for 10 min. All PCR products were analysed by agarose gel (1.5%) 
electrophoresis, staining with 0.8uL/100mL of Midori Green DNA Stain (Nippon 
Genetics) using 1x SB Buffer. An O'RangeRuler DNA Ladder (100-1500 bp, 
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Fermentas) was used for comparing the approximate band sizes after visualising on 
UV transilluminator. 
 
3.2.5 Statistical analysis 
Two-way analysis of variance (ANOVA) using Windows 2007 was performed to 
assess the significance of association of each of the genotypes with biofilm positive 
isolates. 
 
3.3 Results 
3.3.1 Screening of S. aureus isolates for antibiotic resistance 
Antibiotic resistance study of 154 S. aureus strains against 12 different antimicrobial 
agents revealed all (100%) strains to be sensitive to cefoxitin and co-trimoxazole. 
Only 1 (0.65%) strain each was found resistant against cephalexin, tetracycline, 
vancomycin, rifampicin and linezolid, respectively. The resistant pattern against 
ciprofloxacin, erythromycin, Teicoplanin and mupirocin was 3.25%, 2.6%, 1.3%, 
1.3%, respectively. The maximum resistance was shown against penicillin which was 
recorded to be 18.83%. The detail result of antibiotic resistance study against 12 
different antibiotics is presented in Table 3.2 and figure 3.2.  
 
3.3.2 Screening of S. aureus isolates for methicillin resistance 
All the strains of S. aureus were found to be sensitive to methicillin in all the three 
tests performed viz, use of chromogenic culture media plates, Genotype-MRSA kit 
and PCR method. 
 
3.3.3 Detection of biofilm production 
Only 48 (31.17%) strains of S. aureus out of 154 were found to be positive for 
biofilm formation in CRA method. However, all the 154 (100%) strains were found 
be positive for biofilm formation which were graded as weak (74.68%), moderate 
(13.64%) and strong (11.69%) biofilm producer in TCP method. Detail results are 
presented in Table 3.3 and figure 3.1. This indicated the superiority of TCP method 
over CRA method for detection of biofilm formation by S. aureus isolates. 
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Table 3.2: Detection of antibiotic sensitivity of planktonic S. aureus (n=154) 
isolates from cases of bovine mastitis in Australia 
 
Sl. No Antibiotic (abbreviation, 
amount) 
No. of isolates 
resistant 
Percentage of 
isolates resistant 
1 Cephalexin (CL 100 g) 1 0.65% 
2 Cefoxitin (FOX 100 g) 0 0% 
3 Ciprofloxacin (CIP 2.5 g) 5 3.25% 
4 Erythromycin (ES g) 4 2.6% 
5 Teicoplanin (TEC 15 g) 2 1.3% 
6 Tetracycline (TE 10 g) 1 0.65% 
7 Penicillin G (P 0.5 g) 29 18.83% 
8 Mupirocin (MUP 200 g) 2 1.3% 
9 Vancomycin (VA 5 g ) 1 0.65% 
10 Rifampicin (RD 1 g) 1 0.65% 
11 Linezolid (LZD 10 g) 1 0.65% 
12 Co-trimoxazole (SXT 25 g) 0 0% 
 
 
Table 3.3: Detection of biofilm formation by S. aureus isolates by using CRA 
and TCP methods 
 
Method of detection 
of biofilm 
Total number of 
isolates tested 
Total number of 
isolates positive 
Percent of isolate 
positive (%) 
Congo Red Agar   154 48 31.17 
Tissue Culture Plate 154 SB
*
=18 (11.69%) 
IB
*
=21 (13.64%) 
WB
*
=115 
(74.68%) 
100 
*
SB= Strong biofilm, IB= Intermediate biofilm, WB= weak biofilm 
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3.3.4 Detection of icaA, icaD, bap, agr types, and blaZ genes 
To determine the genetic markers of biofilm formation all the 154 strains were 
subjected to PCR study. The results of PCR study are compiled in Table 3.4 and 3.5. 
A high percentage of isolates were positive for icaA (70.78%) and icaD (83.12%). 
However, only 2 (1.3%) strains were positive for Bap. The prevalence blaZ, agrI, 
agrII, agrIII and agrIV in 154 S. aureus isolates was 20.2%, 51.3%, 1.3%, 29.9% 
and o%, respectively.  
 
Table 3.4: Distribution of biofilm formation related genes in S. aureus isolates of 
bovine mastitis origin in Australia 
 
Target gene Total number of S. 
aureus strains positive 
Percent from total 
samples (%) 
icaA 109 70.78 
icaD 128 83.12 
Bap 2 1.3 
blaZ 31 20.2 
agrI 79 51.3 
agrII 2 1.3 
agrIII 46 29.9 
agrIV 0 0 
 
3.3.5 Comparison of Antibiotic susceptibility for biofilm and planktonic S. 
aureus  
Antimicrobial susceptibility studies conducted on biofilms of 28 selected S. aureus 
isolates revealed multiple antibiotic resistances when grown as biofilms. All these 
strains were tested as sensitive to all the 12 antibiotics in planktonic form. However, 
once biofilm is formed 3 (10.71%) strains of S. aureus (BOAISRF S.aur 32, 
BOAISRF S.aur 40, BOAISRF S.aur 41) developed multiple antibiotic resistances 
including cefoxitin, erythromycin, tetracycline, vancomycin, ciprofloxacin, co-
trimoxazole and teicoplanin (Table 3.6). To determine whether the developed 
resistance was transient or persistent, S. aureus cells were taken out from biofilm of 
these 3 strains and stored at 4ºC and re-tested for antibiotic susceptibility against the 
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same antibiotics on 7, 14, 21 and 30 days. The antibiotic resistance was found to be 
persistent upto 3 to 4 weeks and revert back to susceptibility mode after 4 weeks. 
 
Table 3.5: Comparison (%) of the shared pairs of genotypes among S. aureus 
isolates (n=154) 
 
Criterion TCP icaA icaD bap agrI agrII agrIII blaZ 
TCP 100        
icaA 70.78 100       
icaD 83.12 64.94 100      
bap 1.3 0.65 1.3 100     
agrI 51.3 33.12 48.70 0.65 100    
agrII 1.3 0.65 0.65 0 0 100   
agrIII 29.9 24.03 33.77 0 0.65 0 100  
blaZ 20.2 13.64 17.53 0 9.74 0 6.49 100 
 
 
 
Table 3.6: Emergence/persistence of antibiotic resistance by S. aureus isolates in 
biofilm 
 
Antibiotic BOAISRF 
S.aur 32 
BOAISRF 
S.aur 40 
BOAISRF 
S.aur 41 
BOAISRF 
S.aur 50 
Cefoxitin (Fox 10)  S to R
* S S S 
Cephalexin (CL 100) S
* 
S S S 
Ciprofloxacin (CIP 2.5) S S S to R S 
Erythromycin (E 5)  S to R S S S 
Teicoplanin (TEC 15)  S S S to R S 
Tetracycline (TE 10)  S to R S to R S to R S 
Penicillin G (P 0. 5)  S S S S 
Mupirocin (Mup 200)  S S S S 
Vancomycin (VA5)  S S to R S to R S 
Rifampicin (RD 1)  S S S S 
Linezolid (LZD 10)  S S S S 
Co-trimoxazole (SXT 25)  S S S to R S 
*
 S= Sensitive,   R= Resistant 
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3.3.6 Statistical analysis 
There was no correlation detected between biofilm formation and presence of ica 
loci, bap gene and agr types.  
 
3.4 Discussion 
In the present study 154 strains of S. aureus isolated from clinical cases of mastitis 
were evaluated for their ability to produce biofilm and also studied the role of five 
different genes such as icaA, icaD, bap, agr types and blaZ in formation of biofilm. 
Comparative study of CRA and TCP method for detection of biofilm formation by 
using 154 strains of S. aureus revealed that TCP method could determine biofilm 
forming ability of 100% of the strains. Whereas CRA method could only detect only 
48 (31.17%) biofilm producing strains proving superiority of TCP method over CRA 
method. Various researchers have reported the effectiveness of TCP method ranging 
from 30-68.57% (Vasudevan et al., 2003; Dhanawade et al., 2010).  
 
Most of the S. aureus strains used in this study were sensitive to the 12 different 
antibiotics used to perform antimicrobial susceptibility test. A total of 29 (18.83%) S. 
aureus strains were found to be resistant against penicillin which is followed by 
3.25% and 2.6% resistance against ciprofloxacin and erythromycin. All the S. aureus 
strains were found to be methicillin sensitive. However, interesting results of 
antibiotic resistance pattern could be seen in the S. aureus cells grown in biofilm. In 
the present study out of 28 selected S. aureus strains which were initially susceptible 
to 12 different antibiotics after formation of biofilm and the resistance persisted as 
long as 4 weeks. Various investigators have reported about development of antibiotic 
resistance in biofilms (Monzon et al., 2002; Melchior et al., 2006; Kwon et al., 
2008). However, this study has demonstrated that antibiotic resistance persist up to 4 
weeks and then revert back to antibiotic susceptible state. Transformation of 
antibiotic sensitivity to antibiotic resistant trait is a serious concern in the area of 
prevention and control of Staphylococcal infections including bovine mastitis. Based 
on this study it can be suggested that while performing antibiotic susceptibility test 
for treatment of bovine mastitis both planktonic and biofilm states of growth should 
be tested. 
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There are various reports on formation of biofilm by S. aureus which correlates with 
the presence of ica locus (Cafiso et al., 2004; Melchior et al., 2009). In the present 
study, >70% isolates producing biofilm were found to carry both icaA and icaD 
genes. However, statistical analysis of data showed that the presence of ica locus was 
not statistically different between biofilm formation by the isolates.  This finding is 
supported by several studies which have reported weak/no correlation between the 
presence of ica locus and biofilm formation (Yazdani et al., 2006; Dhanwade et al., 
2010; Szweda et al., 2012). Only 2 (1.3%) isolates were found to be carrying bap 
gene which is similar with previous researchers (Cucarella et al., 2004; Nemati et al., 
2009; Tang et al., 2013) who also reported rare prevalence of this gene in S. aureus 
isolated from bovine mastitis and poultry-associated infections. Presence of agr gene 
in S. aureus is associated with biofilm formation and antibiotic resistance, 
particularly against penicillin. Of the 4 agr types agrI and agrII are the most 
important types. agrI is associated with penicillin resistance and persistence of 
resistance, agrII is associated with antimicrobial susceptibility and biofilm formation 
(Manago et al., 2006; Mirani et al., 2013). agrIII is associated with non-invasive 
infections (Ben Ayed et al., 2006) and most of the exfoliatin producing S. aureus 
strain come from agrIV (Jarraud et al., 2000). In the present study, majority of the S. 
aureus strains produced agr type I (51.3%) and III (29.9%) and only 2 strains (1.3%) 
produced agr type II. None of the strains produced agr type IV. This finding is in 
accordance with Bibalan et al (2014) who has reported incidence of 43.3% and 
28.87% of agrI and agrIII, respectively from S. aureus isolates. Resistance to 
penicillin is reported to be mediated by blaZ gene (Melchior et al., 2009). In the 
present investigation a total of 31 (20.2%) strains of S. aureus were found to carry 
blaZ gene and 29 (18.83%) strains of S. aureus showed resistance against penicillin. 
There appears to be a possible correlation between blaZ gene and penicillin 
resistance according to the data generated by this investigation. However, blaZ 
cannot be the single reason for dividing bovine mastitis-associated S. aureus into 
penicillin resistant and susceptible strains (Melchior et al., 2009). The present study 
could not find co-relation between biofilm formation and presence of ica loci, bap 
gene and agr types. However, the study emphasizes the need for further research on 
genetic makeup of S. aureus isolates related to biofilm formation and antibiotic 
susceptibility phenotypes. This information could assist in delineating the 
mechanism or regulation of antibiotic resistance which would impact the persistence 
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and therapeutic measures to be adopted to control the pathogen in an individual 
animal as well as at the herd level. 
 
 
Figure 3.1A: Detection of biofilm by Tissue culture plate method 
                                                                                                               
                                                                                                                  
 
                                                                                                                 
                                                                                                                                                                                                           
                                                                                                               
 
 
 
 
Figure 3.1B: Growth of biofilm on micro titre plate  
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Figure 3.1 C: Detection of biofilm formation in CRA plates  
 
        Biofilm negative S. aureus                                    Biofilm positive S. aureus  
                               
 
Figure 3.2: Comparison of antimicrobial resistance against different antibiotics 
by planktonic S. aureus isolates 
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Chapter 4: Detection of virulence factors in Staphylococcus 
aureus isolated from clinical and subclinical cases of bovine 
mastitis in Australia 
 
4.1 Introduction 
Staphylococcus aureus is a well-known commensal of nares and skin of both human 
and animals (Wertheim et al., 2004). It can cause variety of infections when it 
crosses the epithelial barrier affecting almost all the organs of body. There have been 
numerous advances in the area of prevention and control of bovine mastitis. 
However, S. aureus is still the major contagious agent of bovine mastitis worldwide 
(Athar, 2007; Im et al., 2014). It causes contagious clinical or subclinical mastitis 
with an increase in the somatic cell count (SCC) in milk comprising macrophages, 
lymphocytes and neutrophils. It has been reported to cause more than 80% of 
subclinical mastitis cases in bovines causing a loss of US $300 per animal per year 
(Wilson et al., 1997; Karahan et al., 2011).  
 
S. aureus enters the mammary gland via teat orifice through chapped or injured teats. 
Once the organism enters into the mammary gland, it adheres to epithelial lining and 
invades the host immune system by variety of antiphagocytic factors including 
capsule, proteinA, and fibronectin binding proteins (Patti et al., 1992; Nanra et al., 
2013). Once an intra-mammary infection is established, damage to the mammary 
gland epithelial lining is initiated by ulceration and occlusion of lactiferous ducts and 
alveoli, infiltration of inflammatory cells in the parenchyma (Paape et al., 2002). 
Mammary tissue damage is further complicated by various toxins produced by S. 
aureus which act as super-antigens (Ikawaty et al., 2010). 
 
S. aureus produces a variety of virulence factors by which it causes damage to host 
leading to signs and symptoms of disease. These virulence factors evade host 
immune mechanism by adhering to eukaryotic membrane, resisting phagocytosis and 
killing eukaryotic cells. Broadly, the virulence factors of S. aureus can be classified 
into two groups-(a) Virulence factors involve in establishment of infection and (b) 
Virulence factors involve in maintenance of infection. The first step in establishing 
infection is the initial attachment of S. aureus to eukaryotic membrane followed by 
colonization and subsequent infection (Brouillette et al, 2003). Colonization is 
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commonly associated with a variety of adherence factors or adhesins which are 
known as microbial surface component recognizing adhesive matrix molecules 
(MSCRAMMs). These surface molecules attach to components of host tissue or 
plasma (Gordon and Lowy, 2008; Bien et al., 2011; Babra et al., 2013). There are 
over 20 different MSCRAMMs identified which can be expressed in S. aureus 
(Walsh et al., 2008) and they mediate attachment to surface proteins of host cells 
including collagen, elastin, fibrinogen, thrombospondin, fibronectin, bone 
sialoprotein and laminin ( Foster and Hook, 1998).  A number of MSCRAMMS take 
part in the formation of biofilm. Major adhesins in this group that mediate the initial 
attachment of bacteria to the bovine mammary gland, providing the first critical step 
for establishing infection (Foster and Hook, 1998)  include FnBPA, FnBPB, ClfA, 
ClfB, CNA and BBP ([Cucarella, et al., 2001, Gordon & Lowy, 2008, Plata, et al., 
2009). On the other hand, the virulence factors/ antigens particularly in biofilm 
formation include PNAG, Bap, Protein A, Agr, SasC and SasG, eDNA etc. (Lasa and 
Penades, 2006; Corrigan et al., 2007; Merino et al., 2009; Schroeder et al., 2009; 
Boles and Horswill 2011; Archer et al., 2011).  
 
Protein A is a crucial virulence factor of S. aureus which suppresses the host immune 
response because of its anti-opsonic and antiphagocytic property preventing 
clearance of around 99% of bacteria (Forsgren, 1970). Besides, Protein A contributes 
to the lack of immunity in host to succeeding S. aureus infections by exhibiting B-
cell associated super antigenic property (Kim et al., 2012). FnBPs mediate 
interactions of S. aureus with fibrinogen and fibronectin leading to formation of 
biofilm (Greene et al., 1995). It also helps in invasion S. aureus into mammary 
epithelial cells. ClfA and ClfB mediate S. aureus-induced platelet aggregation 
through their fibrinogen binding function (O’Brien et al., 2002). 
 
S. aureus produces a variety of virulence factors which permit the pathogen to evade 
the tissue and host immune system and thereby assisting in the maintenance of 
infection. These virulence factors include capsular polysaccharides, super antigenic 
exotoxins and cytotoxins. A large number of cytotoxins are produced by S. aureus 
which form pores in the cell membrane causing osmotic swelling leading to cell 
death. These cytotoxins include leukocidins, phenol soluble modulins (PSMs) and 
cytolysins. The cytolysins of S. aureus are α-, β-, γ-, and δ-toxins, of which α-toxin is 
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well characterised and most potent toxin (Wadstrom 1983). β-toxin is a 
sphingomyelinaseC which has been reported to be produced by 95% of the bovine 
mastitis isolates (Tollersrud, 2001). This toxin causes damage to epithelial lining of 
mammary gland. Gamma toxin is produced by coagulase positive S. aureus causes 
tissue damage by stimulating degranulation of neutrophils. Delta toxin is responsible 
for lysis of cells in different species (Hirsh et al., 2004). Leukocidins target the 
phagocytic cells and cause pore in the membrane of PMNs and interfere with the 
function of neutrophis (Rainard et al., 2003). Members of Leukocidin family are 
Panton Valentine Leukocidin (PVL), LukR-PV, LukM/FPV, LukE/D, γ-haemolysin 
and Leukocidin. Phenol soluble modulins (PSMs) are the peptides produced by S. 
aureus which are cytotoxic and proinflammatory. Recently PSMs have been reported 
to play a role in the formation of biofilm by S. aureus (Periasamy et al., 2012). S. 
aureus also produces a number of superantigens including enterotoxins (SEs), Toxic 
Shock Syndrome toxin (TSST) and exfoliative toxins (ETA and ETB). Enterotoxins 
of S. aureus include the classical enterotoxins A to E and the recently identified and 
characterised ones (SEG-SEU) [Dinges et al., 2000; Smyth et al., 2005]. These 
antigens are considered superantigens due to their ability to release cytokines in from 
both T cells and macrophages by binding to outer surface of MHC class II proteins 
and T cell receptors (Marrack and Kappler, 1990; Balaban and  Rasooly, 2000; 
Ulrich, 2000; Schlievert, 2008). Variability in the prevalence of virulence factors in 
S. aureus may result in various levels of severity and forms of mastitis in cows 
(Ikawaty et al., 2010). No studies have been done to investigate about the virulence 
factors of S. aureus from bovine mastitis origin in Australia. The aim of this study 
was to screen the bovine mastitis-associated S. aureus isolates for the distribution of 
different virulent factors including MSCRAMMS, cytotoxins and superantigens by 
using conventional polymerase chain reaction (PCR) and the available serological 
methods.  
 
4.2 Materials and methods 
4.2.1 S. aureus isolates 
One hundred and fifty four (154) fully characterised S. aureus strains of Australian 
origin isolated from clinical cases of mastitis in cows in Victoria and Queensland 
were used for the study. ATCC® 29213™, ATCC® 49775™, and ATCC® 8096™ 
65 
 
were used as positive controls in the study. S. aureus strains representing CP types 1 
(strain M), 2 (strain Smith diffuse), 5 (strain Newman), 8 (USA 400 MW2) and a 
non-capsulated strain (LAC, USA 300) were donated by Professor Gerald Pier 
(Harvard Medical School, Boston, USA) were used as positive controls. Besides 
BOAISRF S. aureus 25, 125 and human S. aureus 11 which were characterised in 
our laboratory were also used as positive controls in the study. These isolates were 
grown on Mueller Hinton (MH) agar and subcultured in nutrient broth supplemented 
with 1% glucose and stored on cryobeads (Blackaby Diagnostics) or as glycerol 
(15%) broth stocks at -80°C. 
 
4.2.2 Detection of enterotoxins in S. aureus isolates 
Detection of the SEA, SEB, SEC1, SEC2, SEC3, SED and SEE toxins in the 154 
strains of S. aureus was carried out using 3M™ Tecra™ Staph Enterotoxins Visual 
Immunoassay or 3M™ Tecra™ SET VIA kits (3M Australia Pty Ltd). The test was 
performed according to the instructions of the manufacturer. Briefly, wash solution 
provided with the kit was used to soak S. aureus cells and incubated at room 
temperature. 200L sample was added to the SE pre-coated wells and read optical 
density at 405 nm. Samples showing OD 0.2 were considered positive.  Two sets of 
positive and negative controls provided with the kit were run along.  
 
SET-RPLA Toxin Detection kit (Themo-Fisher Scientific, Australia) was used to 
confirm presence or absence of enterotoxin A-D in 154 S. aureus strains of bovine 
origin. Briefly, bacterial suspension prepared as per the protocol provided with the 
kit and latex particles linked to anti-enterotoxin A-D antibodies was added to 
bacterial suspension. The antigen-antibody suspensions were incubated at room 
temperature for 24 h and observed for agglutination to confirm the presence of 
enterotoxins. 
 
4.2.3 Detection of pvl and mecA gene in S.aureus isolates 
Detection of mecA and pvl genes was accomplished using the GenoType® MRSA 
assay (Hain-Lifesciences). The test is based on the DNA strip technology involving 
three steps viz. isolation of DNA from cultured material, multiplex PCR 
amplification with biotinylated primers and reverse hybridization.  
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4.2.4 Extraction of genomic DNA  
Genomic DNA was extracted from 154 S. aureus isolates using a kit (MO BIO 
Laboratories, Inc Carlsbad, CA). The extracted genomic DNA was stored at -20°C 
until use. 
 
4.2.5 PCR amplifications of different virulent genes of S. aureus 
Conventional PCR was carried out to detect 32 different virulent genes of S. aureus 
isolated from clinical bovine mastitis cases in Australia. The primers, Tms, band size 
for all the genes are provided in Table 4.1. Following were the conditions used for 
detection of different virulence factors: 
 
The amplification conditions for tsst-1, clfA, clfB, cna and spa are 95°C for 5 min, 30 
cycles of 95°C for 30 sec, Tm for 30 sec and 72°C for 45 sec with a final extension 
of 72°C for 10min.  The PCR conditions for fnbpA, fnbpB, hlb, mecA, sdrE, bbp, 
isdA and sdrD are 95°C for 5 min, 35 cycles of 95°C for 30 sec, Tm for 30 sec and 
72°C for 45 sec with a final extension of 72°C for 10min. isdB primers were 
developed in our lab (Babra et al., 2014) with the amplification conditions at 35 
cycles of 95°C for 30 sec, Tm for 1min and 72°C for 2 min with a final extension of 
72°C for 10min. Amplication of hla worked better at 95°C for 5 min, 38 cycles of 
95°C for 30 sec, Tm for 30 sec and 72°C for 45 sec with a final extension of 72°C for 
10min. The amplification conditions for sea, seb, sec, sed, see, seg, seh, sei and sej 
were 95°C for 5 min, 30 cycles of 95°C for 2 min, Tm for 1 min and 72°C for 1 min 
with a final extension of 72°C for 5min. eta and etb were amplified at 95°C for 5 
min, 30 cycles of 95°C for 1 min, 58°C for 1 min and 72°C for 1 min with a final 
extension of 72°C for 10min.  
 
All PCR products were analysed by agarose gel (1.5%) electrophoresis, staining with 
0.8uL/100mL of Midori Green DNA Stain (Nippon Genetics) using 1x SB Buffer.   
An O'RangeRuler DNA Ladder (100-1500 bp, Fermentas) was used for comparing 
the approximate band sizes after visualising on UV transilluminator. 
 
 
 
67 
 
Table 4.1: PCR amplification of virulence factor genes of S. aureus isolates from 
bovine mastitis 
 
Virulence 
factor 
 gene 
Positive 
control 
Primer Forward  (5’-
3’) 
Primer Reverse 
(5’-3’) 
Tm Expected 
band 
size (bp) 
Reference 
cna 
 
Strain M 
(CP1) 
AAA GCG TTG CCT 
AGT GGA GA 
AGT GCC TTC CCA 
AAC CTT TT 
50°C 192 Smith et al., 2010 
clfa 
 
Strain M 
(CP1) 
CGC CGG TAA CTG 
GTG AAG CT 
TGC TCT CAT TCT 
AGG CGC ACT T 
55°C 314 Stutz et al., 2011 
clfb 
 
Strain M 
(CP1) 
ATG ATC TTG CTT 
GCG TT 
CCG ATT CAA GAG 
TTA CAC C 
47°C 215  Stutz et al., 2011  
spa 
 
ATCC 
29213 
TCA AGC ACC AAA 
AGA GGA AGA 
GTT TAA CGA CAT 
GTA CTC CGT TG 
51°C Variable Montesinos et al., 
2002 
fnbpA 
 
LAC USA 
300 (CP 
neg) 
GCG GAG ATC AAA 
GAC AA 
CCA TCT ATA GCT 
GTG TGG 
48°C 1279 Booth et al., 2001 
fnbpB 
 
LAC USA 
300 (CP 
neg) 
GGA GAA GGA ATT 
AAG GCG 
GCC GTC GCC TTG 
AGC GT 
56°C 820 Booth et al., 2001 
bbp 
 
Strain M 
(CP1) 
AAC TAC ATC TAG 
TAC TCA ACA ACA G 
ATG TGC TTG AAT 
AAC ACC ATC ATC 
T 
53°C 575 Tristan et al., 
2003 
isdA 
 
ATCC 
29213 
CTG CGT CAG CTA 
ATG TAG GA 
TGG CTC TTC AGA 
GAA GTC AC 
52°C 332 Verkaik et al., 
2010 
isdB 
 
BOAISRF 
S. aureus 
25 
ACG AGA GTT TGG 
TGC GCT AT 
GTT GAG GCC CCT 
ACT TCT GA 
55°C 192 Babra et al., 2014 
sdrD 
 
Strain 
Newman 
(CP5)  
CGG AGC TGG TCA 
AGA AGT AT 
TGC CAT CTG CGT 
CTG TTG TA 
52.3°
C 
500 Verkaik et al., 
2010 
sdrE 
 
Strain 
Newman 
(CP5)  
AGA AAG TAT ACT 
GTA GGA ACT G 
GAT GGT TTT GTA 
GTT ACA TCG T 
50°C 433 Sabat et al., 2006 
tsst-1 
 
LAC USA 
300 (CP 
neg) 
ACC CCT GTT CCC 
TTA TCA TC 
TTT TCA GTA TTT 
GTA ACG CC 
53°C 326 Nada et al., 2012 
eta 
 
Hu S. 
aureus 11 
GCA GGT GTT GAT 
TTA GCA TT 
AGA TGT CCC TAT 
TTT TGC TG 
58°C 93 Sauer et al., 2008 
etb 
 
Hu S. 
aureus 11 
ACA AGC AAA AGA 
ATA CAG CG 
GTT TTT GGC TGC 
TTC TCT TG 
58°C 226 Sauer et al., 2008 
hla 
 
USA 400 
MW2 
(CP8) 
GTA CTA CAG ATA 
TTG GAA GC 
GTA ATC AGA TAT 
TTG AGC TAC 
47°C 274 Ramakrishna et 
al., 2013 
hlb 
 
USA 400 
MW2 
(CP8) 
GCC AAA GCC GAA 
TCT AAG 
CGC ATA TAC ATC 
CCA TGG C 
51°C 840 Booth et al., 2001 
sea 
 
Smith 
Diffuse 
(CP2) 
TTG GAA ACG GTT 
AAA ACG AA 
GAA CCT TCC CAT 
CAA AAA CA 
50°C 120 Rall et al., 2008 
seb 
 
Smith 
Diffuse 
(CP2) 
TCG CAT CAA ACT 
GAC AAA CG 
GCA GGT ACT CTA 
TAA GTG CC 
50°C 478 Rall et al., 2008 
sec 
 
Smith 
Diffuse 
(CP2) 
GAC ATA AAA GCT 
AGG AAT TT  
AAA TCG GAT TAA 
CAT TATA CC  
50°C 257 Rall et al., 2008 
sed 
 
ATCC 
8096 
CTA GTT TGG TAA 
TAT CTC CT 
TAA TGC TAT ATC 
TTA TAG GG 
50°C 317 Rall et al., 2008 
see 
 
ATCC 
8096 
AGG TTT TTT CAC 
AGG TCA TCC 
CTT TTT TTT CTT 
CGG TCA ATC 
50°C 209 Rall et al., 2008 
seg 
 
Smith 
Diffuse 
(CP2) 
AAG TAG ACA TTT 
TTG GCG TTC C 
AGA ACC ATC 
AAA CTC GTA TAG 
C 
55°C 287 Rall et al., 2008 
seh 
 
Smith 
Diffuse 
(CP2) 
GTC TAT ATG GAG 
GTA CAA CAC T 
GAC CTT TAC TTA 
TTT CGC TGT C 
48.4°
C 
213 Rall et al., 2008 
sei 
 
Smith 
Diffuse 
(CP2) 
GGT GAT ATT GGT 
GTA GGT AAC 
ATC CAT ATT CTT 
TGC CTT TAC CAG 
50°C 454 Rall et al., 2008 
sej 
 
BOAISRF 
S. aureus 
125 
CAT CAG AAC TGT 
TGT TCC GCT AG 
TGA ATT TTA CCA 
TCA AAG GTA C 
50°C 142 Rall et al., 2008 
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4.3 Results  
Both the conventional PCR and serological methods of detection, used in this study 
revealed  that α-toxin (94.16%) and β-toxin (83.12%) are the predominant cytotoxins 
detected in S.aureus isolated from clinical bovine mastitis cases in Australia. Among 
the superantigens seh (32.5%), sec (23.4%), seg (17.5%) and sei (13%) were the 
more prevalent enterotoxins in bovine S.aureus isolates. Details of prevalence and/or 
distribution of cytotoxins and superantigenic toxins among the bovine S. aureus 
strains are presented in Table 4.2 and Figure 4.1. 
 
The study revealed that clfA (91.56%), clfB (92.86%), spa (87.7%), fnbpA (54.5%), 
isdA (98.1%), isdB (100%), sdrD (98.1%) and sdrE (95.5%) are the predominant 
MSCRAMMS present in the S. aureus isolates. None of the strains are found to be 
positive for mecA.The detail finding of MSCRAMMS in bovine S. aureus isolates is 
presented in table 4.3 and Figure 4.2. 
 
Table 4.2: Distribution of toxin genes in S. aureus isolates of bovine mastitis 
origin in Australia 
S. aureus 
isolates  
hla hlb tsst-
1 
eta etb pvl sea seb sec sed see seg seh sei sej 
154 145 128 13 0 0 4 4 1 36 2 1 27 50 20 2 
percentage 94.16 83.12 8.44 0 0 2.6 2.6 0.65 23.4 1.3 0.65 17.5 32.5 13 1.3 
 
Figure 4.1: Comparison of distribution of the genes encoding toxins in S. aureus 
isolated from bovine mastitis cases in Australia  
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Table 4.3: Distribution of MSCRAMMS genes in S. aureus isolates of bovine 
mastitis origin in Australia  
S. aureus 
isolates  
cna clfA clfB spa fnbpA fnbpB bbp isdA 
 
isdB 
 
sdrD sdrE 
154 48 141 143 135 84 2 14 151 154 151 147 
Percent 
positive 
31.2 91.56 92.86 87.7 54.5 1.3 9.09 98.1 100 98.1 95.5 
  
Figure 4.2: Comparison of distribution of MSCRAMMS genes among S. aureus 
isolates of bovine mastitis origin 
             
           
Figure 4.3: Amplification of clfA, clfB, spa, fnbpA and fnbpB using conventional 
PCR 
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Figure 4.4: Amplification of cna, isdA, isdB, sdrD and sdrE in PCR 
 
 
 
Figure 4.5: Amplification of tsst-1, hla and hlb in PCR 
 
 
 
 
 
 
Lane 1 – 50 bp DNA ladder 
Lane 2 – cna, 192 bp 
Lane 4 – isdA, 332 bp 
Lane 5 – isdB, 192 bp 
Lane 6 – sdrD, 500 bp 
Lane 7 – sdrE, 433 bp  
Lane 8 – Negative control 
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Figure 4.6: Detection of PVL gene by using GenoType® MRSA kit 
                            
      
                         
               
       
            
    
 
 
 
 
Conjugate control: documenting the efficiency of conjugate binding and Substrate 
reaction, Universal control: It indicates the presence of bacterial DNA and the 
correct implementation of DNA isolation and amplification, S. aureus: 85 bp S. 
aureus-specific gene, PVL: 77 bp PVL fragment 
 
4.4 Discussion 
This study was conducted to determine the distribution of virulence factors produced 
by S. aureus isolated from clinical bovine mastitis cases in Australia. Due to 
emergence of resistance against antibiotics, virulence factors of S. aureus including 
MSCRAMMS and exoproteins have been potential targets to develop a suitable 
vaccine against bovine mastitis. Various investigators have suggested incorporation 
of predominant virulence factors as potential vaccine candidates while formulating a 
multicomponent vaccine as they have ability to trigger immune response (Verkaik et 
al., 2010). The current study has highlighted that clfA (91.56%), clfB (92.86%), spa 
(87.7%), fnbpA (54.5%), isdA (98.1%), isdB (100%), sdrD (98.1%), sdrE (95.5%) 
are the predominant MSCRAMMS detected and/or produced by S. aureus of clinical 
bovine mastitis origin. This finding is in accordance with the findings in other 
countries (Karahan et al., 2011; Zhao et al., 2011; Sorum et al., 2013). The 
predominant toxins in the S. aureus isolates in the present study are α-toxin 
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(94.16%), β-toxin (83.12%) which is in accordance with the finding of Ikawaty et al 
(2011) in Netherlands.  
 
Among the superantigens, the predominant toxins, in descending order were seh 
(32.5%), sec (23.4%), seg (17.5%) and sei (13%), respectively, with the sea, seb, sed, 
see, sej present in a low numbers ranging from 0.65-2.6%. All the previous 
investigations for detection of pvl gene in S. aureus isolates from bovine mastitis 
origin have pointed towards the results being negative (Prashanth et al., 2011; 
Gindonis et al., 2013; Pu et al., 2014) except one finding by Yamada et al (2005) 
who reported presence of pvl gene in 62.5% of S. aureus isolates from cases of 
bovine mastitis in Japan. In our study, 4 strains (2.6%) of S. aureus were found to be 
positive for pvl gene. The PVL toxin is responsible for destruction of leukocytes and 
necrosis of mammary tissue in bovine mastitis.  
 
None of the experimental vaccines or the available commercial vaccines has been 
demonstrated to prevent new intra-mammary infection (IMI), although some have 
been reported to reduce the clinical severity of the mastitis. MSCRAMMS including 
ClfA, ClfB, IsdB, FnBP, SdrD, SdrE (Stranger-Jones et al., 2006; Maira Litran et al., 
2005; Middleton, 2008) and toxins including TSST-1, SEC, β toxin and α toxin 
(Spaulding et al., 2012) have demonstrated partial protection against S. aureus 
infections in mice when used as single component vaccines. Perhaps the answer to 
the difficulty being faced in the development of an effective vaccine may lie in the 
identification of the MSCRAMMs expressed, not just detected, in vivo in the 
mammary gland following infection, which studies warrant urgent attention. 
 
Despite the potential of the exotoxins and cytotoxins to inflict damage to the 
mammary gland epithelial cell lining (Ikawaty et al., 2010 and the variability in the 
distribution of clinical S. aureus isolates, it may be merit worthy to confine the 
development of vaccines against S. aureus infections to the predominant 
MSCRAMMS such as ClfA, ClfB, ProteinA, isdA, isdB, SdrD and SdrE and toxins 
such as α toxin and β toxin as potential vaccine candidates against bovine mastitis 
caused by S. aureus. 
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Chapter 5: Serological versus molecular typing of 
Staphylococcus aureus isolated from clinical and subclinical 
cases of bovine mastitis in Australia  
 
5.1 Introduction 
One of the important virulence factors in variety of staphylococcal infections is the 
capsule, which constitutes an integral part of cell wall (Thakker et al., 1998). 
Capsular polysaccharide (CP) protects the bacterial cell from phagocytosis (Verdier 
et al., 2007) and has been reported to promote prolonged persistence of the bacteria 
in blood of host thus enhancing microbial virulence (O’Riordan and Lee, 2004).  
 
Karakawa and Vann in 1982 reported for the first time that most S. aureus isolates 
are encapsulated and identified 8 different capsular serotypes. Guidry et al (1998) 
reported that S. aureus isolated from human infections consisted of 12 
polysaccharide serotypes, 11 different capsular serotypes and one non-capsular 
surface polysaccharide 336. The majority of clinical isolates were reported to express 
a surface polysaccharide of either serotype 5 or 8, representing 70-80% of the 
isolates from all sources (Arbeit et al., 1984; Hochkeppel et al., 1987; Poutrel et al., 
1988). However, the percentage distribution of these capsular types appears to vary 
in different countries (Arbeit et al., 1984; Hochkeppel et al., 1987; Poutrel et al., 
1988; Roghmann et al., 2005; Han et al., 2000; Sompolinsky et al., 1985). Lee (2002) 
suggested that there were only four types of capsular polysaccharides, all other 
reported types representing mutated versions which still need elucidation. The rest 
were designated non-typeable S. aureus. Majority of these strains were reported to 
possess a unique surface polysaccharide antigen 336 (Guidry et al., 1998), which 
contained polyribitol-phosphate-N-acetylglucosamine, a component of cell wall 
teichoic acid (Verdier et al., 2007). 
  
Several studies have shown that purified capsular polysaccharides are poor 
immunogens, when used alone (O’Riordan and Lee, 2004; Jones, 2005), in eliciting 
protective immune responses, potentially because of T-cell independence and homo-
polymeric structure. However, upon cross-linking to high molecular weight carrier 
proteins, immunogenicity is improved due to the induction of T-cell-dependent 
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immune responses. For the designing CP-based vaccines, knowledge of the 
prevalence and type of CP is essential (Ma et al., 2004). Since the prevalence of CPs 
may be different in different countries (Arbeit et al., 1984; Sompolinsky et al., 1985; 
Poutrel et al., 1988; Han et al., 2000; Roghman et al., 2005), either specific 
formulations may be needed to control mastitis caused by S. aureus in different 
regions of the world or a conjugate vaccine formulation containing all the capsular 
types prevalent in different countries that is capable of producing antibodies against 
CP antigen also is needed. Capsular polysaccharide of S. aureus being the important 
immune evasion molecule (Nanra et al., 2013) has been used in the development of 
conjugate vaccine candidates. Since numerous capsular types of S. aureus exist 
around the world, it is important to know their prevalence in Australia in order to 
rationally select suitable conjugate vaccines in Australia for the prevention of bovine 
mastitis. However, there are no reports on the prevalence of different CP types of S. 
aureus causing bovine mastitis in Australia. Hence the objective of this study was to 
determine the distribution of different capsular phenotypes among the Australian S. 
aureus strains isolated from clinical bovine mastitis cases.  
 
Detection of capsule has been done by using a variety of methods such as 
characterisation of colony morphology in serum-soft agar, absence of clumping 
factor, negative staining by using nigrosin. These methods are considered crude and 
few S. aureus strains can be detected for capsule (O’Riordan and Lee, 2004). The 
present study was undertaken to investigate the prevalence of capsular types among 
the bovine mastitis-associated S. aureus isolates in Australia by using both 
serological and genotyping methods with one of the traditional methods that is 
negative staining.  
 
The main objectives of the study were to (a) produce CP-specific and surface 
polysaccharide-336 specific sera in mice that would not cross react with the other 
serotypes (b) identify the antibody isotypes produced in the sera (c) detection of 
presence or absence of capsule by using specific capsular stain (d) genotyping of the 
Australian S. aureus isolates using PCR (e) serologically type the S. aureus isolates 
of Australian origin by using CP-specific antisera. 
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5.2 Material and Methods 
5.2.1 Animal ethics approval 
A total of 180 six week-old specific pathogen-free Quackenbush Swiss line 5 mice 
(30 mice per capsular type including control) were obtained from the Animal 
Resources Centre, Perth, Western Australia and used for production of CP and 
antigen 336-specific antisera. All animal experiments were carried out with the 
approval of Curtin University’s Animal Ethics Committee (Approval No: 
AEC_2011_65) ensuring compliance with the Western Australian Animal Welfare 
Act, 2002.  
 
5.2.2 Capsular and surface polysaccharide specific S. aureus strains used in the 
study 
One hundred and fifty four (154) fully characterised S. aureus strains of Australian 
origin isolated from clinical cases of mastitis in cows in Victoria and Queensland 
were used for the study. Reference strains representing CP types 1 (strain M), 2 
(strain Smith diffuse), 5 (strain Newman), 8 (USA 400 MW2) and a non-capsulated 
strain (LAC, USA 300) were donated by Professor Gerald Pier (Harvard Medical 
School, Boston, USA). S. aureus ATCC-55804 designated as serotype 336 was 
purchased from ATCC, USA. These isolates were grown on Mueller Hinton (MH) 
agar and subcultured in nutrient broth supplemented with 1% glucose and stored on 
cryobeads (Blackaby Diagnostics) or as glycerol (15%) broth stocks at -80°C. 
 
5.2.3 Production of antisera for serological typing 
Preparation of the different anti-CP type 1, 2, 5, 8 and SP-336 antisera was carried 
out according to Fournier et al. (1984). Briefly, S. aureus CP types-1, 2, 5, 8 and SP-
336 were grown on MH agar at 37
o
C for 18 h. Plates containing colonies were 
washed with 20 ml of 3% formalinised PBS. The formalin-killed bacterial 
suspension was allowed to remain at room temperature for a period of 24 h followed 
by centrifugation at 10,000 x g for 20 min and washing with PBS five times. The 
pellet was resuspended in sterile PBS, sterility confirmed by absence of growth on 
MH agar and then stored at 4
o
C. Mice were immunized every week for 5 weeks with 
formalin-killed S. aureus. The first three doses contained the equivalent to 5x10
7
, 
1x10
8
 and 5x10
8
 CFU, respectively, and were administered intraperitoneally in 0.2 
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mL volume. For the fourth and fifth doses, the bacterin was mixed with equal 
proportion with Imject Alum (Thermo Scientific) and 0.2 mL containing an 
equivalent of 1x10
9
 and 5x10
9
 CFU, respectively, were administered subcutaneously 
one week apart. The control mice were vaccinated with PBS by using the same 
routes. Mice were bled and sera were obtained. The CP-/SP-specific antisera were 
cross-absorbed with non-capsulated S. aureus strain LAC, USA 300, followed by 
cross-absorption with the heterologous CP types CP1, CP2, CP5, and CP8 depending 
upon the desired CP specificity. For SP-336 serum, the same method was followed, 
initially cross absorbed with non-capsulated LAC USA 300 followed by cross 
absorption with CP 1, 2 5 and 8. 
 
5.2.3.1 Detection of antigen specific antibody isotypes in sera samples 
Antigen-specific antibody isotypes determination was carried out on both immunised 
and control sera samples. The levels of anti- S. aureus IgA, IgM, IgG, IgG1, IgG2a 
and IgG2b were determined by using an indirect ELISA (Fry, 2006). Formalinised 
killed S. aureus suspended in PBS representing different CP types was used as 
coating antigens. Conjugated antibodies used were affinity-purified anti-mouse 
heavy chain goat IgA, IgM, IgG, IgG1, IgG2a and IgG2b conjugated with alkaline 
phosphatase. The enzyme substrate was p-nitrophenyl-phosphate and absorbance at 
405 nm was measured with a micro-plate reader. Briefly, Nunc-Immuno
™
 
MicroWell
™
 96 well solid plates (Sigma Aldrich Pty Ltd, Australia) were coated 
with 100µl of CP8 positive, CP5 positive, CP2 positive, CP1 positive and SP-336 
positive S. aureus (OD adjusted to 0.3 at 630 nm) and incubated overnight at 4ºC. 
Wells were washed using wash buffer (Tris gelatine-0.05% Tween 20, pH 7.4) and 
blocked with blocking buffer (Tris/gelatin/BSA, pH 7.4) at 37 ºC for 2 h followed by 
washing of the wells thrice and adding 100µl of 2-fold serial dilutions of test and 
negative control sera in triplicates. Plates were then incubated at 37ºC for 2 h 
followed by rewashing of the wells using wash buffer. An aliquot of 100µl of 1: 
10,000 dilution of alkaline phosphatase labelled goat antimouse IgA, IgM, IgG, IgG1, 
IgG2a or IgG2b were added to the wells and incubated at 4ºC overnight. After washing 
for three times, substrate was added and the plates were read at 405 nm using ELISA 
plate reader (Model 550, Borad). Specific absorbance versus serum dilutions were 
plotted to calculate antibody titres.  
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5.2.4 CP serotyping of S. aureus isolates 
Slide agglutination test was performed to determine the serotype of the strains as 
described elsewhere (Verdier et al., 2007). Briefly each strain was grown overnight 
on MH agar and a single colony was resuspended in a drop of 0.9% normal saline in 
a clean glass slide. A drop of serum was added and mixed with the culture using a 
tooth pick and observed for agglutination in less than 20 sec. The strains, which 
showed no agglutination against any of the CP-specific antisera, were further tested 
for agglutination using anti-SP336 serum. Strains found negative with all the five 
specific sera were considered as non-typeable. 
 
5.2.5 CP genotyping of S. aureus isolates  
Genomic DNA was extracted from S. aureus using a kit (MO-Bio or Real Biotech). 
Detection of the presence of cap1, cap2, cap5 and cap8 loci in all the strains was 
carried out by Polymerase Chain Reaction (PCR). The primers used for typing cap1 
are 5’-AGG TCT GCT AAT TAG TGC AA-3’ (forward) and 5’-GAA CCC AGT 
ACA GGT ATC ACC A-3’ (reverse) with an expected product size of 550 bp and for 
cap2 are 5’-AGC AAT CTT CGG TTA TTG CCG GTG-3’ (forward) and 5’-ATG 
ACG GTA AGG CAT CAA GGT CG-3’ (reverse) with an expected amplicon size 
(non-specific). The PCR cycling parameters for both cap1 and cap2 were: 
denaturation at 94
o
C for 5 min followed by 94
o
C for 30 sec, Tm at 57
o
C (cap1) or 
60
o
C (cap2) for 30 sec, 72
o
C for 60 sec with 25-30 cycles and final extension at 72
o
C 
for 5 min.  
 
The primers used for typing cap5 and cap8 were 5’- ATG ACG ATG AGG ATA 
GCG-3’ (forward) and 5’- CTC GGA TAA CAC CTG TTG C-3’ (reverse) for cap5 
and 5’- ATG ACG ATG AGG ATA GCG-3’ (forward) and 5’- CAC CTA ACA 
TAA GGC AAG-3’ (reverse) for cap8, respectively (Moore et al., 2001). The 
expected band sizes were 881 bp and 1148 bp for cap5 and cap8, respectively.  
Thermal cycling conditions were denaturation at 95
o
C for 5 min, 95
o
C for 30 sec, Tm 
of 55
o
C (cap5) or 52
o
C (cap8) for 30 sec, 72
o
C for 5 min with 25-30 cycles and the 
final extension at 72
o
C for 5 min.  
 
The PCR products were analysed by agarose gel (1.5%) electrophoresis, Midori 
Green staining and UV trans-illumination. The positive controls included strains M, 
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Smith Diffuse, Newman and USA 400 for cap1, cap2, cap5 and cap8, respectively, 
and LAC, USA 300 was used as negative control. 
 
5.2.6 Microscopic detection of capsule by using negative staining 
Negative staining using nigrosin was performed on all the six strains of S. aureus. 
One drop of nigrosin was placed on a clean grease free slide; to which a few colonies 
of S. aureus were mixed avoiding the spread of the drop. Using another clean glass 
slide a thin smear was prepared and the film was allowed to air dry. The slide was 
saturated with crystal violet for one minute followed by rinsing with tap water. The 
slide was allowed to air dry before observing the smear under oil immersion. S. 
aureus stained purple with dark background and the capsule appeared clear (Figure 
5.5A, B).  
 
5.2.7 Statistical analysis 
Correlation coefficients, represented as Pearson r values, between the serological 
with the genotyping method, for CP1, CP5, CP8 positive and non-typeable S. aureus 
strains, were determined using Microsoft Excel, Windows 10. 
 
5.3 Results 
5.3.1 Serotyping of capsular or antigen 336 in bovine S. aureus isolates  
Serotyping of 154 S. aureus isolates using CP-specific sera (Table 5.1) confirmed the 
genotyping results; 36 (23.38%) and 49 (31.82%) of the isolates revealed the 
presence of CP5 and CP8, respectively, whereas none was positive for CP1. 
However, 14 (9.09%) strains were positive for CP2. The strains that were not 
agglutinated by any of the CP-specific sera were subjected to slide agglutination 
using anti- SP336 antiserum. Nine (5.84%) isolates were positive for SP-336 and the 
remaining 46 (29.87%) were declared as non-typeable (Table 5.1, Figure 5.3A).  
 
5.3.2 Genotyping of capsular or antigen 336 in bovine S. aureus isolates  
Genotyping of 154 S. aureus isolates revealed that 41 (26.62%) and 50 (32.47%) 
strains were positive for cap5 and cap8 (Table 5.1). None of the isolates were 
positive for the cap1 locus. The primers for the cap2 locus exhibited cross-reactivity 
with all the other three CP types producing amplicons of 700-800 bp (data not 
79 
 
shown). A total of 63 (40.91%) S. aureus strains, which carried none of the three loci 
(cap5, cap8 or cap1), were declared as negative by PCR (Table 5.1, Figure 5.3B). 
 
5.3.3 Detection of capsule in S. aureus isolates by using negative staining 
The negative staining using nigrosin corroborated the serological result. All the 99 S. 
aureus strains found positive in serology demonstrated capsule in negative staining 
method. The S. aureus with SP-336 though express surface polysaccharide but do not 
express any capsule (Verdier et al., 2007). The diagram of capsulated and non-
capsulated S. aureus is presented in Figure 5.5 (A, B). However, an interesting result 
could be observed in detection of capsule by negative staining. Out of the 55 non-
typeable strains confirmed by serological method, 13 S. aureus strains showed 
capsule while negative staining was performed. So, a total of 112 (72.72%) S. aureus 
strains demonstrated capsule using capsular staining method and 42 (27.27%) strains 
showed absence of capsule. 
 
5.3.4 Analysis of antibody isotypes of pooled CP-specific antisera  
The antibody isotypes in the 5 different sera revealed a diverse distribution of 
antibody activity. However, the predominant antibody isotypes in CP-8, 5, 2, 1 and 
SP-336 specific antisera were IgA, IgG2a and IgG, IgG2b being present in only CP5-
specific antisera. The detailed results are presented in Figure 5.1 and 5.2. 
 
5.3.5 Statistical analysis 
The correlation coefficient (r) between the serological and genotyping methods for 
detection of CP types 1, 5 and 8, and the non-typeable S. aureus isolates, was 
determined to be 0.97. 
 
5.4 Discussion  
Given the role of surface-associated polysaccharides in the virulence of S. aureus, 
epidemiological investigations on the distribution of capsular and surface 
polysaccharide types among S. aureus isolates is important for rational design of a 
vaccine formulation against infection with S. aureus regardless of their antibiotic 
susceptibility profiles. Numerous studies on human S. aureus capsular types have 
reported that 75-80% of all the isolates produce either CP5 or CP8 (Karakawa and 
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Van, 1982; Lee et al., 1990; Roghman et al., 2005).
 
However, the prevalence of the 
CP serotypes (CP5 and 8) among the S. aureus strains isolated from cow’s milk vary 
as low as 14% to as high as 95% (Poutrel et al., 1988; Guidry et al., 1998; Sordelli et 
al., 2000; Tollersrud et al., 2000). Paul-Satyaseela et al (2004) reported that CP 
typing was superior to bacteriophage typing whereas Schlichting et al (1993) had 
reported the capsular typing was less sensitive than genome typing yielding 26 
different S. aureus types. However, neither serotyping for the capsular types 1 and 2 
nor the localization of the potential antigens encoded by 26 types was determined. 
This study revealed that 64.29% of Australian bovine mastitis-associated S. aureus 
strains expressed capsule, of which, CP8 was predominant (31.82%), followed 
closely by CP5 (23.38%). In addition, 5.84% (nine of 154) of the isolates were 
positive for SP-336 and 30% of the isolates were non-typeable. Detection of 13 non-
typeable but capsulated S. aureus strains using negative staining method is an 
important discovery of this study which indicated that there may be more than the 5 
recognised types of CP and SP (4 CP types and 1 SP type) in S. aureus as proposed 
originally by Karakawa and Vann (1982). However, further studies for confirmation 
of this result are warranted. 
 
Very few studies have compared the performance of genotyping versus serology in 
the typing of S. aureus isolates. Most of the studies reported low proportion of 
phenotypic expression in comparison to genotypic expression of capsular 
polysaccharide types (Tollersrud et al., 2000; Camussone et al., 2012). In contrast, 
one study with human isolates, there was 100% correlation between capsular 
genotypes and phenotypes for CP5 and CP8 (Sutter et al., 2011). In this study, five 
(3.25%) bovine mastitis-associated strains carrying cap5 and one strain (0.65%) 
carrying cap8 were negative by agglutination. The discordance between genotyping 
and phenotyping may be attributable to non-expression of respective capsule-
encoding genes, possibly due to mutations (Cocchiaro et al., 2006) or due to the 
difference in culture conditions in vivo and in vitro (Poutrel et al., 1995; Poutrel et 
al., 1997).
 
 
It is thus clear from this study that any surface-associated polysaccharide antigens-
based vaccine formulation should not only include CP5 and CP8 types but also other 
capsular types with or without antigen 336 or poly-N-acetyl glucosamine (PNAG) 
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reported to be present in all S. aureus isolates (Gening et al., 2010) for prevention of 
clinical bovine mastitis caused by S. aureus. The prevalence of 29.87% of non-
typeable S. aureus strains in Australia also highlights the need to explore the 
existence of other surface-associated polysaccharides including additional capsular 
phenotypes as proposed originally by Karakawa and Vann (1982). 
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Figure 5.1: Relative distribution of antibody isotype titres of CP and SP-336 specific antisera 
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 Figure 5.2: Comparative distribution of antibody isotype titres of CP and SP-336 specific antisera 
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Table 5.1: Prevalence of capsular/surface polysaccharide genotypes and phenotypes in S. aureus isolates from cases of bovine mastitis in 
Australia 
 
          
      
SAT
a
= Slide agglutination test NT
1
= Non typeable, PDW2= Primer did not work,
 
PNA= Primer not available 
Correlation coefficient (r) between SAT and PCR method for detection of CP1, CP5, CP8 and non-typeable S. aureus strains is 0.97.  
 
 
 
 
 
 
 
 
 
 
 
 
No (%) of S aureus isolates 
Total 
no. of 
isolates 
Detection of capsular type by slide agglutination 
test (SAT
a
) 
Detection of capsular type by PCR Detection of capsule 
by staining 
CP1 CP2 CP5 CP8 SP-336 NT
1 
CP1 CP2 CP5 CP8 SP-
336 
NT Capsule 
+ve 
Capsule  
-ve 
154 0 14 
(9.09) 
36 
(23.38) 
49 
(31.82) 
9 
(5.84) 
46 
(29.87) 
0 PDW
2 
41 
(26.62) 
50 
(32.47) 
PNA
3 
63 
(40.91) 
112 
(72.73) 
42 
(27.27) 
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Figure 5.3: Comparison of detection of CP/SP types in S. aureus by genotyping and serotyping methods 
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Figure 5.4: Amplification of cap5 and cap8 loci in PCR 
 
                  
     
 
Lane 1 – Fermentas DNA Ladder, O’Range Ruler 50bp 
Lane 2 – cap5, 880bp (Moore and Lindsay et al., 2001) 
Lane 3 – cap8, 173bp (Verdier et al., 2007) 
Lane 4/5 – Negative controls 
Lane 6 – Fermentas DNA Ladder, O’Range Ruler 50bp  
 
 
Figure 5.5: Demonstration of encapsulated and non-capsulated S. aureus by negative 
staining 
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Chapter 6: Standardisation of a non-invasive mouse 
mastitis model by using different phenotypes of 
Staphylococcus aureus  
 
6.1 Introduction 
Mastitis is one of the major infectious diseases of dairy cows causing huge economic 
loss to the dairy industry worldwide (Halasa et al., 2007). Worldwide implementation 
of mastitis control programme though initially reduced the incidence of mastitis, it 
still remains an uncontrollable contagious disease worldwide mainly due to failure of 
mastitis control (Bradley, 2002), development of antibiotic resistance by some 
pathogens (Hillerton and Berry, 2005), increase international pressure to limit the use 
antibiotics due to its associated hazard to human health (Notebaert and Meyer, 2006). 
The pathogenesis of mastitis has been extensively studied in the last few decades 
with ultimate aim of prevention and control of bovine mastitis. However, more 
research is needed on mechanisms of damage to the mammary glands and 
mechanisms of immunity against infection of the mammary gland to study the mode 
of action of mastitis-associated pathogens, immune mechanism in host and efficacy 
of vaccine trials.  
 
The use of large animal models including cow, goat and sheep, to study bovine 
mastitis has its associated problems such as cost and management, even using 
minimal number of animals.  Besides, only limited number of hypotheses can be 
studied in large animals (Brouillette and Malouin, 2005). An alternative laboratory 
animal model which is cost effective and can easily be maintained in laboratory 
would contribute immensely to mastitis research. Experimental mouse mastitis 
model was first described and characterised by Chandler in 1969 (Chandler, 1969, 
1970). Mouse is still considered a suitable animal model for bovine mastitis research 
due to cost effectiveness, minimum management and similarity between mouse and 
cow’s mammary glands in respect to neutrophil infiltration and tissue damage 
(Brouillette and Malouin, 2005). Both the species have two pairs of anatomically and 
functionally independent mammary glands in inguinal region (Notebaert and Meyer, 
2006). In addition to these two pairs, mouse has three additional pairs of mammary 
gland in the thoracic region which can be used to study additional parameters in 
mastitis research (Notebaert and Meyer, 2006). Availability of large number of 
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laboratory animals at affordable cost is necessary for studying various parameters 
and prospective of mastitis, which also helps to secure valid statistics. Use of mouse 
mastitis model is useful when limited quantities of promising agents including 
vaccines, antimicrobials and immunomodulators are to be tested for their efficacy 
against bovine mastitis (Notebaert and Meyer, 2006). This model is particularly 
useful because of the potential of S. aureus to form biofilm on medical devices such 
as indwelling catheters and prostheses (Fitzpatrick et al., 2005). Biofilm formation 
by S. aureus in the bovine mammary gland may also assist in the establishment of 
bovine mastitis by promoting colonisation, persistence of the pathogen (Heilmann et 
al., 1996) and inducing antibiotic resistance (Babra et al., 2013). The properties of 
resistance to antibiotics and evasion of phagocytosis by biofilms may contribute to 
the occurrence of chronic mammary gland infection (Cucarella et al., 2004). 
 
Bovine mastitis is an inflammatory disease of mammary gland (Bannerman, 2009) in 
which bacterial invasion leads to the migration of neutrophils and possibly 
macrophages to the site of inflammation (Persson et al., 1993). S. aureus strains 
carrying superantigens including enterotoxins and toxic shock syndrome toxin are 
important virulent factors in S. aureus pathogenicity. These toxins are responsible to 
activate T-lymphocytes and mononuclear cells leading to production of cytokines 
(Ferens et al., 1998).The important inflammatory mediators in lactating cow’s udder 
are Interleukin (IL)-1, IL-2, IL-4, IL-10, IL-12, interferon gamma (IFN-γ) and 
Tumour Necrosis Factor (TNF)-α. IL-1 and TNF-α help in accumulation of 
neutrophils at the site of infection. Many investigators have reported higher 
concentrations of IL-1 (Riollet et al., 2000; Bannerman et al., 2004) and TNF- α 
(Kauf et al., 2007) in milk during mastitis as part of the mediation of local and 
systemic inflammatory responses. The inflammatory cytokine, TNF-α, was not 
detected in quadrant assessment of the udders in healthy cows, however, high 
concentrations were detected both in blood and milk from cows suffering from 
bovine mastitis (Bannerman, 2009). TNF-α has been reported to facilitate endothelial 
activation leading to migration of neutrophils to the site of infection (Brouckaert and 
Fiers, 1996). 
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Various intra-mammary inoculation techniques have been used to produce mastitis 
involving experimental animals. One technique involves inoculation of bacterial 
suspension by dropping it on the tip of mammary teat and allowing absorption 
(Anderson, 1979). Another technique inoculates bacterial pathogen by passing a 
micropipette of less than 75µm diameter through teat canal (Lee et al., 2003). A 
commonly used method is the injection of inoculum by using a 30 gauge needle after 
incising the near end of teat ((Brouillette and Malouin, 2005). The fourth technique 
of inoculation involves surgical exposure of mammary gland followed by injection of 
bacterial suspension into primary duct by using a 30 gauge needle (Nguyen et al., 
2000). However, this method is not suitable for lactating and pregnant mice as streak 
canal can hardly be located due to mammary tissue proliferation. 
 
The objective of this research was to (a) investigate the association of biofilm 
formation of S. aureus in the pathogenesis of bovine mastitis using the mouse 
mastitis model  (b) determine level of cytokines primarily of IL-1β, IL-6 and TNF-α, 
using serum samples of infected mice, other cytokines including IL-10, IL-12, IL-
17A and IFN-γ were also measured  (c) standardise a mammary gland inoculation 
technique in which, the mammary glands (L5 and R5) are inoculated without 
traumatising the teat with the intention of mimicking the natural mode of infection, 
and (d) semi-quantitatively measure the histological changes in host animals to 
estimate the level of infection and inflammatory response. CP8-positive S. aureus 
strains were selected for the experiment due to their predominance in both clinical 
and subclinical cases of bovine mastitis in Australia (Gogoi-Tiwari et al., 2014). 
 
6.2. Materials and methods 
6.2.1 Bovine S. aureus phenotypes  
A total of four encapsulated (CP8) S. aureus strains, isolated from mastitic milk of 
cows, with strong or weak biofilm forming potential, were used in this investigation 
(Table 6.1). These strains were selected from a collection of 154 strains, obtained 
from Victoria and Queensland, Australia. 
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                 Table 6.1: Properties of S. aureus strains used in the study 
 
 
 
 
 
 
 
Group S aureus 
strain  
Capsular 
polysaccharide 
type 
Biofilm 
formation 
(TCP/CRA 
method) 
 
Presence of ica 
genes 
icaA     icaD 
Detection of 
genes 
encoding 
enterotoxins 
A to J genes 
or 
production 
Presence 
of Alpha 
(hla) and 
beta (hlb) 
toxin 
genes 
Exfoliative 
toxins 
 
 
ETA     ETB 
PVL TSST-1 
1 BOAISRF 
S. aureus 
51 
CP8 Strong 
biofilm 
+ve     +ve SEH (seh)  hla, hlb -ve     -ve -ve      -ve      
2 BOAISRF 
S. aureus 
117 
CP8 Strong 
Biofilm 
+ve     +ve SEG (seg), 
SHE (she), 
SEI (sei) 
hla, hlb -ve     -ve -ve -ve 
3 BOAISRF 
S aureus 
48 
CP8 Strong 
biofilm 
+ve     +ve None  hla, hlb -ve     -ve -ve -ve 
4 BOAISRF 
S. aureus 
104 
CP8 Weak 
biofilm 
-ve     -ve None  hla, hlb -ve     -ve -ve -ve 
7 Control Normal saline - - - - - - - 
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6.2.2 Capsular typing of S. aureus isolates 
CP typing of the S. aureus strains isolated from bovine mastitis was carried out using 
molecular as well as serological methods as already described in Chapter 5, Section 
5.2.4 and 5.2.5 of this thesis.  
 
6.2.3 Determination of biofilm forming potential of S. aureus isolates 
6.2.3.1 Biofilm assay  
Determination of biofilm forming characteristics of the strains were determined 
using the Congo red agar (CRA) method (Freeman et al., 1989) and the Tissue 
Culture plate as described in Chapter 3, Section 3.2.3 of this thesis. 
 
6.2.4 ica typing of S. aureus isolates  
ica typing of the two S. aureus isolates was performed as per the protocol described 
in chapter 3. 
 
6.2.5 Determination of toxin production potential of S. aureus isolates 
Determination of different toxin forming potential of the strains by using PCR was 
discussed in Chapter 4, Section 4.25 of this thesis. 
 
6.2.6 Infection of mammary gland  
6.2.6.1 Preparation of bacterial inocula   
The S. aureus phenotypes were grown on MH agar plates at 37°C for 18h. The 
organisms were washed from the plates using 20 ml of isotonic saline and suspended 
in isotonic saline to give a final viable bacterial count of 4 x 10
11 
ml
-1
 (Anderson and 
Chandler, 1975). 
 
6.2.6.2 Animal ethics approval 
All animal work described in this investigation was approved by the Animal Ethics 
Committee of Curtin University (Approval number: AEC_2011_65) prior to 
commencement of the experiment. The mice were used for the study ensuring 
compliance with the Western Australian Animal Welfare Act 2002. 
 
6.2.6.3 Animals 
A total of 20 Balb/c first-pregnancy mice, in five groups of 4 mice each were used 
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 for the experiment. Pups were removed from the lactating mice when they were 
between 5-15 days old, approximately 1h prior to the experiment. The pups were 
euthanized and not allowed to suckle after inoculation of the mammary gland with 
the S. aureus strains or normal saline in case of the control group of mice. 
 
6.2.6.4 Method of infection of the mammary gland 
Inoculation of the different S. aureus phenotypes into mammary glands was carried 
out using a modification to the procedure described previously (Brouillette et al., 
2004) by eliminating the incision of the proximal end of the teat was made to expose 
the teat canal, and inoculating the S. aureus strains directly into the mammary duct. 
Briefly, mice were anaesthetised using 100 mg kg
-1 
ketamine and 10 mg kg
-1 
xylazine 
administered by the intraperitoneal route and laid in the supine position. The area 
surrounding the 5
th
 pair of mammary glands (L5 and R5) was disinfected with 70% 
ethanol. A binocular dissecting microscope was used to locate the duct orifice of the 
teat. While controlling the teats with sterile forceps, 0.05 ml of bacterial suspension 
equivalent to 2x 10
10 
CFU S. aureus was injected using a blunt smooth 31-gauge 
hypodermic needle to a depth of not more than 4mm. The infection was allowed to 
progress for 48 h and the mice were observed at six-hour intervals to assess 
development of macroscopic clinical signs of infection. All animals were 
administered one dose of Buprenorphine hydrochloride (0.05-0.1 mg kg
-1
) 
subcutaneously pre-operation so that anticipated pain relief was available for up to 
12 h post bacterial inoculation. A control group of mice was injected with normal 
saline using the same procedure. 
6.2.7 Post inoculation examination 
6.2.7.1 Macroscopic examination 
The mammary glands of mice were observed for clinical signs of mastitis including 
redness, swelling and discolouration of mammary gland and extrusion of exudate 
with or without squeezing of the mammary gland. Monitoring of mice for morbidity 
and mortality were carried out at 6 hourly intervals up to 48h. The level of clinical 
signs was graded as 0 (no macroscopic changes), + (low) grade, ++ (medium grade) 
and +++ (severe grade) based on the observed clinical features including redness, 
swelling, and discolouration of mammary gland, exudate, morbidity and  
mortality. 
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Mice were euthanized 48h after inoculation, and investigated for level of infection by 
determining the bacterial load (Anderson and Chandler, 1975) as described below 
and the mammary gland tissue collected for estimating the level of inflammation and 
histological changes (Anderson and Chandler, 1975).  
 
6.2.7.2 Bacteriological procedure 
6.2.7.2.1 Mammary gland 
At post-mortem examination, the L5 mammary glands from control and test mice 
were collected and individually ground in sterile Griffith’s tubes containing 2 ml of 
sterile normal saline. The homogenates from the mammary glands were subjected to 
serial tenfold dilutions and inoculated on Baird Parker (BP) agar plates (Pathwest, 
Laboratory Medicine, WA) by the spread plate method and incubated at 37°C for 
48h, followed by determination of colony counts of S. aureus per mammary gland 
(Fig 6.2).  
 
6.2.7.2.2 Blood, liver, lung and spleen 
Blood samples obtained by cardiac puncture and organs including liver, lung and 
spleen were inoculated on BP agar plates by streaking for isolated colonies and 
incubated at 37°C for 48 h.  
 
 6.2.7.3 Histological procedure 
6.2.7.3.1 Mammary gland 
After aseptically shaving the hair around the gland the R5 mammary glands were 
collected for histological examination. The R5 glands were fixed in 10% neutral 
buffered formalin for 24 h, processed on an automatic tissue processor and embedded 
in paraffin wax. Sections were cut at 4 µm thickness at three levels and stained by 
the Haematoxylin and Eosin stain (Bancroft and Gamble, 2008). An additional 
section was stained for bacteria using Gram Twort Method (Twort, 1924; Ollet, 
1947). 
 
6.2.7.3.2 Blood  
Blood smears were prepared following standard procedure and stained by the Diff 
Quik method (Skipper and Destephano, 1989). 
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6.2.8 Grading of histological changes observed in mammary glands 
The histopathological changes observed in mammary glands of mice, injected with 
 different strains of S. aureus, were graded as follows: 
Level 0: No reaction (Fig 6.1a). 
Level 1: Organisms identified with minimal inflammatory response in mammary 
tissue (Fig 6.1b). 
Level 2: Moderate inflammation in peri mammary and intra mammary tissue with 
intra luminal organisms observed (Fig 6.1c). 
Level 3: Marked inflammatory cell infiltration into mammary tissue in the presence 
of organisms with evidence of tissue degeneration including necrosis (Fig 6.1d). 
 
6.2.9 Quantification of inflammatory cytokines  
6.2.9.1 Procedure 
Quantification of inflammatory cytokines, IL-1β, IL-10, IL-12, IL-17A, IFN-γ and 
TNF-α was performed by using BD cytometric Bead Array (CBA) Mouse/Rat 
soluble protein Master Buffer Kit (BD Biosciences), USA. Preparation of Mouse/ 
Rat soluble protein flex set standards, capture beads and detection reagents were 
performed as per the standard protocol provided with the reagent kit. Briefly, 50µL 
of Mouse/Rat soluble protein flex set standard dilutions ranging from 1:2 to 1:256 
and one negative control containing only assay diluent was prepared. To 10µL of 
each unknown serum sample, 10µL of each capture bead and mixed PE detection 
reagent was added. Tubes were incubated at 4°C for one hour each after addition of 
capture beads and PE detection reagent protected from light. Following incubation, 
200µL of wash buffer was added to each tube and centrifuged at 200g for 5min. The 
supernatant was aspirated carefully and discarded. The remaining pellet was 
reconstituted using 200µL of wash buffer and analysed using Attune Acoustic 
Focussing Flow Cytometer using the FlowJo software. 
 
 6.2.10 Statistical analysis 
Statistical analysis was carried out using STATA v11 (StataCorp. 2009. Stata 
Statistical Software: Release 11. College Station, TX: StataCorp LP) for comparing 
total viable counts of S. aureus recovered from mammary glands 48 h post-harvest 
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and the grade of histopathological changes with the biofilm formation of the S. 
aureus strains.  
To compare the TNF- levels between groups of mice injected with strong biofilm 
and weak biofilm forming S. aureus phenotypes student’s t-test was performed. 
Statistical significance was set at p < 0.05.  
 
6.3 Results 
6.3.1 Macroscopic examination of mammary glands 
The control group showed no macroscopic changes in the inoculated glands. All of 
the test mice showed varying degrees of change in the gross appearance of mammary 
glands (Table 6.2).     
 
Table 6.2:  Clinical signs observed in different groups of inoculated mice 
(Observations up to 48 hours post inoculum) 
 
 
Level of clinical signs* observed in test mice injected with different S. aureus 
phenotypes** 
 
Time post inoculation       S. aureus 51     S. aureus117     S. aureus 48           S. aureus 104       
 
6h                               0                     0                  0                         0                              
12h                             +                     +                  +                        +                              
18h                           ++                   ++                 ++                       +                               
24h                          ++                    ++                 ++                       +                               
30h                         +++                 +++                +++                    ++                             
36h                         +++                  +++               +++                    ++                             
42h                        +++                   +++               +++                    ++                                                       
48h                     +++                +++              +++                  ++                                                   
*Clinical features include redness, swelling, and discolouration of mammary gland, 
exudate,    morbidity and mortality. Grade scores compare observed features to the 
most severe changes: 0 - no macroscopic changes, + low grade, ++ medium grade, 
+++ severe grade. 
** Column representing mice injected with normal saline by the intramammary route 
is not presented because of the absence of histopathological changes. 
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 6.3.2 Bacterial load and histopathological changes of mammary gland 
The bacterial loads in the mammary glands as a measure of proliferation of S. aureus 
at the injection site and the associated histopathological grade observed in the 
mammary tissue are shown in Table 6.3 and Figures 6.1 and 6.2. The bacteriological 
load study demonstrated that mice injected with CP8 S. aureus strains  with strong 
biofilm forming ability (S. aureus 51, 117 and 48) had higher bacterial count than the 
CP8 weak biofilm producing strain (S. aureus 104).  A one-way ANOVA between 
the mice groups injected with the four S. aureus strains showed statistically 
significant differences in bacterial load between the groups (P < 0.001). A Bartlett’s 
test for equal variances showed that the variances of the four groups were not 
unequal (P > 0.05). A pairwise comparison analysis between each group adjusted for 
multiple-comparison using the Bonferroni correction showed that the mice group 
injected with the S. aureus 51 strains had the highest load (P < 0.001).  
Histopathological studies showed that mice injected with CP8 S. aureus with strong 
biofilm forming characteristics (S. aureus 51, 117 and 48) produced severe mastitis 
lesions characterised by level 3 histopathological lesions, showing a profuse 
inflammatory infiltrate with severe tissue damage including necrosis in mammary 
tissue. On the other hand, S. aureus strain 104 with weak biofilm forming ability 
demonstrated only level 2 histopathological changes (Table 6.3).  
 
6.3.3 Bacteriology of blood and and histopathology of liver, lung and spleen 
The culture of blood and organs (liver, lung and spleen) in BP agar plates was 
negative for S. aureus consistent with no evidence of systemic infection. No overt 
microscopic evidence of inflammation was observed in tissue sections of lung, liver 
and spleen from any of the mice. 
 
6.3.4 Quantification of inflammatory cytokines 
Quantification data of inflammatory cytokines, IL-1β, IL-6, IL-10, IL-12, IL-17A, 
IFN-γ and TNF-α is presented in Table 6.4. The result showed that the levels of TNF-
α were significantly higher (p<0.05) in the sera of mice inoculated with CP8-
positive, strong biofilm forming S. aureus than those inoculated with weak biofilm 
forming CP8-positive S. aureus. 
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6.4 Discussion  
Various investigators have reported the importance of CP (Thakker et al., 1998; 
Tuchscherr et al., 2005) and biofilm (McKenney et al., 1999, Rupp et al., 1999) as 
virulence factors in the pathogenesis of S. aureus in different animal models 
including the mouse model. This study aimed to assess the importance of biofilm as 
virulence factor of S. aureus in bovine mastitis using a mouse mastitis model. Given 
the production greater mammary tissue damage (level/grade 3 histopathological 
changes by the strong biofilm-producing S. aureus strains versus level/grade 2 
lesions by the weak biofilm-producing strain, also verified by the lack of detection of 
the icaA and icaD), it is clear that strength of the biofilms produced by S. aureus 
appeared to contribute to the mammary tissue damage. This observation suggests the 
inclusion of antigens contributing significantly to biofilm formation in a cocktail 
vaccine formulation for prevention of bovine mastitis. 
 
The bacteriological load study demonstrated higher bacterial count in the mice 
injected with CP8 strong biofilm forming S. aureus than the mice injected with CP8 
weak biofilm former. However, the bacterial load values were significantly different 
from one another (Table 6.3); suggest a lack of correlation between S. aureus load in 
the mammary gland and associated tissue damage. However, it appears that 
mammary tissue damage may be associated with the biofilm forming ability of S. 
aureus as there was significantly different bacterial load between the biofilm former 
and non-biofilm former S. aureus injected mammary glands of mice.  
 
Elevated levels of TNF-α concentration both in serum and milk of cows suffering 
from natural infection of E. coli mastitis has been reported (Nakajima et al., 1997; 
Hisaeda et al., 2001) suggesting a potential role for this cytokine in development of 
inflammation in mammary gland. The level of TNF-α in serum is highly elevated in 
acute cases of clinical mastitis (Nakajima et al., 1997) that has been observed to 
result in activation and migration of neutrophils (Blum et al., 2000). A sharp increase 
in mRNA transcription of TNF-α at 24 h followed by a decrease at 32 h post 
infection with S. aureus (Alluwaimi et al., 2003) has been reported. In our study, the 
level of TNF-α was significantly higher (p<0.05) in mice inoculated with the strong 
biofilm forming S. aureus than the weak biofilm forming strain even 48 h post 
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infection. This finding suggests the possible role of TNF-α in the damage caused by 
S. aureus to the mammary glands positively supporting the need for further studies 
on the role of inflammatory cytokines in acute and chronic bovine mastitis. 
 
However, there was either no statistically significant difference between the levels of 
other cytokines except IL-10 and IL-12 produced by only one of the 3 strong biofilm 
forming strains (S. aureus 48) and the weak biofilm forming strain (S. aureus 104). 
Interestingly however the weak biofilm for ing strain (S. aureus strain 104) produces 
significantly more (p<0.05) IL-10 and IL-12 than the 2 other strong biofilm forming 
strains (S. aureus strains 51 and 117). Because of the inconsistency of this data, 
repeat studies are clearly warranted prior to hypothesizing their potential roles in the 
induction of mouse mastitis.  
 
This study has demonstrated that mastitis can be reliably produced in a mouse model 
by direct inoculation of S. aureus into the mammary gland via the mammary duct 
without traumatising the mammary gland surface epithelium or glands. This 
approach was applied to mimic the most likely natural route of infection. The 
bacteriological and histopathological study revealed proliferation of the bacteria as 
well as inflammatory infiltrates in mammary glands. Use of a direct delivery 
inoculum in a mouse mastitis model may minimise the chance of secondary bacterial 
infection, which can occur in the case of invasive mouse mastitis model where the tip 
of the mammary gland is incised (Brouillette and Malouin, 2005; Brouillette et al., 
2005). The secondary bacterial infection may be caused by different microorganisms 
including S. aureus and those in the environment, cage litter or from the hands of 
animal handlers while picking up the animals to observe the mammary glands for 
clinical symptoms. Establishment of this mouse mastitis model provides an 
opportunity to determine the identity of S. aureus antigens responsible for induction 
of inflammatory cytokines with a view to formulation of a cocktail vaccine capable 
of reducing the levels of the inflammatory cytokines and potentially preventing or 
significantly reducing damage to the mammary gland. 
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Table 6.3: Total viable counts of S. aureus recovered from mammary glands 48 h post-harvest and the grade of histopathological changes  
Group S. aureus 
phenotype 
Total number of mammary 
glands investigated 
 
Log average number of bacteria (CFU) 
recovered from mammary glands ± SE 
 
Grades for histopathological  
changes 
M
*
1         M2         M3        M4 
1 S. aureus 51 4 8.08 ± 0.002 3 3 3 3 
2 S. aureus 117 4 7.72 ± 0.003 3 3 3 3 
3 S. aureus 48 4 7.92 ± 0.001 3 3 IF
** 
2 
4 S. aureus 104 4 7.52 ± 0.009 2 2 2 2 
5 Control (NS
***
) 4 0 0 0 0 0 
      M*= Mammary gland, IF**= Inoculation failed, NS***= Normal saline 
In one-way ANOVA between the mice groups (P < 0.001),   Bartlett’s test for equal variances for four groups was unequal (P > 0.05),  pairwise 
comparison analysis between each group adjusted for multiple-comparison using the Bonferroni correction showed that the mice group injected 
with the S. aureus 51 strains had the highest load (P < 0.001). 
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 Table 6.4: Detection of levels of various inflammatory markers in sera samples of mice 48 h post-infection 
 
 
Group S. aureus 
phenotype 
IL-1β 
Pg/mL± SE 
IL-6 
Pg/mL± 
SE 
IL-10 
Pg/mL± SE 
IL-12 
Pg/mL± SE 
IL-17A 
Pg/mL± 
SE 
IFN-γ 
Pg/mL± SE 
TNF-α 
Pg/mL± SE 
Histopathology 
grade 
 
 
1 S. aureus 51 
 
3.6405±0.35 
 
1.9±1.1 5.50±0.89 
 
2.18±0.57 0.10±0.02 
 
9.85±1.19 
 
13.0045±0.50 
 
3 
2 S. aureus 117 
 
3.62025±0.25 
 
5.1±1.9 4.36±0.28 1.43±0.35 1.16±0.02 7.76±0.27 20.6285±4.57 
 
3 
 
3 S. aureus 48 
 
4.04175±0.79 
 
16.9±14 12.70±0.72 12.24±1.25 2.64±0.13 7.08±0.1 33.874±14.3 
 
 2.7 
 
4 S. aureus 104 
 
3.19175±0.59 
 
33.4±9 7.28±0.84 8.75±0.76 1.67±0.26 11.03±1.67 8.85475±2.04 
 
2 
 
5 Control (NS) 
 
0 
 
0 0 0 0 0 0  
 
0 
 
 
In student’s t-test for TNF- levels between groups of mice injected with strong biofilm ( S. aureus 51, 117, 48) and weak biofilm forming S. 
aureus phenotypes (S. aureus 104)  showed high TNF- (p < 0.05) level in mice injected with strong biofilm forming S. aureus. 
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                  Figure 6.1: Histopathological changes observed in mammary tissue 
                
                               
                               Figure 6.1(a): Mouse mammary tissue.  Control animal. No evidence of inflammatory 
  response in mammary  tissue (A) to sterile injection. H&E x100mag 
                                                                                         
                                                                                     
                                                     
                                                                                                                        
Figure 6.1(b): Level 1 inflammation. Mouse teat and mammary tissue. Inflammatory 
response induced by injection of S.aureus via the mammary duct. Note exudate in duct 
(A) , acute response in mammaryglands (B) including necrosis (C). H&E x40mag 
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       Figure 6.1(c): Mouse mammary tissue. Level 2 inflammation.Mammary glands       
   (A)Infiltration of  acute inflammatory cells in supporting connective tissue and    
   intraluminal space (B). H&E x200mag 
  
  
                                                                                  
                                    Figure 6.1(d): Mouse mammary tissue.  Level 3 inflammation. Marked acute  
       inflammatory cell infiltration (A) with tissue necrosis (B). H&E x200mag, 
 
 
103 
 
                            
 
                         Figure 6.1(e): Mouse mammary tissue.  Infiltrate detail. Gram positive bacteria and    
               associated inflammatory cell exudate.  Gram Twort x400mag. 
 
 
            
 
         Figure 6.2: Standard plate count of S. aureus colonies in Baird Parker agar medium 
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Chapter 7: Mammary tissue damage caused by a non-
typeable Staphylococcus aureus strain using the mouse 
mastitis model and assessment of the potential of anti-
inflammatory cytokine or cytokine receptor antibodies in 
the prevention of mortality  
 
7.1 Introduction 
The predominant capsular types in S. aureus from human source are reported to be 
CP5 and CP8, with non typeable strains representing less than 25% (Lee and Lee, 
2000). In contrast, S. aureus isolates from bovine mastitis cases have been either 
encapsulated are 14-40% of isolates  (Sompolinsky et al., 1985; Poutrel et al., 1988; 
Han et al., 2000; Sordelli et al., 2000). While investigating the prevalence of S. 
aureus CP types associated with bovine mastitis cases in Australia, 30% of the 
isolates were detected serologically to be nontypeable (Gogoi-Tiwari et al., 2014). 
Essentially no attempts have been made to develop vaccines against non-typeable 
(NT) isolates. However, given that NT strains can persist in the mammary gland for 
longer duration than the encapsulated strains and can invade mammary epithelial 
cells in higher numbers than the encapsulated ones (Tuchscherr et al., 2005), the only 
alternative left is treatment with antibiotics. 
 
While standardizing the non-invasive mouse mastitis model for bovine mastitis, it 
was discovered that damage caused to the mammary gland by infection with test 
encapsulated S. aureus was associated with the strength of biofilm formation with an 
increase in TNF-α level (Refer Chapter 6). It was therefore necessary to determine if 
the same held true for the NT S. aureus strains and whether administration of 
antibodies against the inflammatory cytokine produced and its receptor could prevent 
mortality in mice infected with strong biofilm forming strain. 
 
The aims of this experiment, therefore, were: 
(a) To determine the virulence of non-typeable strain with strong versus weak 
biofilm forming ability as measured by the level of tissue damage in the 
mammary glands of infected mice using a mouse mastitis model. 
(b) To determine the production of various inflammatory biomarkers in sera 
samples of infected mice 
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(c) To treat mice with antibodies against the predominant cytokine produced 
and its receptor to reduce mammary tissue damage and prevent mortality, if 
any. 
 
7.2 Material and Methods 
7.2.1 Bovine S. aureus phenotypes 
A total of two non-typeable S. aureus strains, isolated from mastitic milk of cows, 
with strong or weak biofilm forming potential, were used in this investigation (Table 
7.1).  
7.2.2 Capsular typing of S. aureus isolates 
Capsular typing of the two S. aureus strains used in this investigation was carried out 
using molecular as well as serological methods as described in Chapter 5 Section 
5.2.4 & 5.2.5. 
 
7.2.3 Determination of biofilm forming potential of S. aureus isolates 
Biofilm forming potential of the two nontypeable strains were determined by Congo 
red agar (CRA) method (Freeman et al., 1989) and the Tissue Culture plate method 
as described in Chapter 3 Section 3.2.3. 
 
7.2.4 ica typing of S. aureus isolates  
ica typing of the two S. aureus isolates was performed as per the protocol described 
in Chapter 3 Section 3.2.4.2. 
 
7.2.5 Determination of toxin production potential of S. aureus isolates 
Determination of different toxin forming potential of the strains by using PCR was 
discussed in Chapter 4, Section 4.2.5 of this thesis. 
 
7.2.6 Infection of mammary gland using non typeable S. aureus strains 
7.2.6.1 Preparation of bacterial inocula   
The S. aureus phenotypes were grown on MH agar plates at 37°C for 18h. The 
organisms were washed from the plates using 20 ml of isotonic saline and suspended 
in isotonic saline to give a final viable bacterial count of 4 x 10
11 
ml
-1
 (Anderson and 
Chandler, 1975). 
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               Table 7.1: Phenotypes of S. aureus strains used in the study 
 
 
 
 
               
 
 
 
 
               Table 7.2: Experimental design for treatment with anti-inflammatory cytokines      
Treatment group Number 
of mice 
Control 
group (PBS) 
Total number 
of mice 
Anti-IL-6 antibody 6 6 12 
Anti-IL-6β receptor antibody 6 6 12 
 
Group S aureus 
strain  
Capsular 
polysaccharide 
type 
Biofilm 
formation 
(TCP/CRA 
method) 
 
Presence of ica 
genes 
icaA     icaD 
Detection of 
genes 
encoding 
enterotoxins 
A to J genes 
or 
production 
Presence 
of Alpha 
(hla) and 
beta (hlb) 
toxin 
genes 
Exfoliative 
toxins 
 
 
ETA     ETB 
PVL TSST-1 
1 BOAISRF 
S. aureus 
83 
Non- 
capsulated 
Strong 
biofilm 
+ve     +ve SEC (sec), 
SED (sed), 
SEG (seg), 
SEI (sei) 
hla, hlb  -ve     -ve -ve -ve 
2 BOAISRF 
S. aureus 
87 
Non- 
capsulated 
Weak 
biofilm 
-ve     -ve none    hla, hlb -ve     -ve -ve -ve 
3 Control Normal saline - - - - - - - 
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7.2.6.2 Animal ethics approval 
All animal work described in this investigation was approved by the Animal Ethics 
Committee of Curtin University (Approval number: AEC_2011_65) prior to 
commencement of the experiment. The mice were used for the study ensuring 
compliance with the Western Australian Animal Welfare Act 2002. 
 
7.2.6.3 Animals 
A total of 12 Balb/c first-pregnancy mice, in three groups comprising 4 mice/group 
were used for the experiment. Pups were removed from the lactating mice when they 
were between 5-15 days old, approximately 1h prior to the experiment. The pups 
were euthanized and not allowed to suckle after inoculation of the mammary gland 
with the S. aureus strains or normal saline in case of the control group of mice. 
 
7.2.6.4 Method of infection of the mammary gland 
Inoculation of the different S. aureus phenotypes into mammary glands was carried 
out as per the method described in the Chapter 6, Section 6.2.4.4. 
 
7.2.6.5 Post inoculation examination 
All the postinoculation examinations including macroscopic examination, bacterial 
load study and histopathological study of mammary glands were carried out as per 
the methods described in Chapter 6, Section 6.2.5.1, 6.2.5.2.1, 6.2.5.3.1, respectively. 
 
7.2.7 Quantification of inflammatory cytokines  
Quantification of proinflammatory cytokines, IL-1β, IL-6, TNF-α, IFN-γ and other 
cytokines (IL-10, IL-12 and IL-17A) was performed by using BD cytometric Bead 
Array (CBA) Mouse/Rat soluble protein Master Buffer Kit (BD Biosciences), USA. 
The detail method is described in Chapter 6, Section 6.2.7.1. 
 
7.2.8 Experimental design for treatment of mice with anti-inflammatory 
cytokine, IL-6 and IL-6 receptor antibodies 
 
7.2.8.1 Animal ethics approval 
All animal work described in this investigation was approved by the Animal Ethics 
Committee of Curtin University (Approval number: AEC_2014_01) prior to 
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commencement of the experiment. The mice were used for the study ensuring 
compliance with the Western Australian Animal Welfare Act 2002. 
 
7.2.8.2 Animals 
A total of 24 lactating (7 days) were used in the study. Two different treatment 
groups comprising 6 lactating mice were used as treatment groups. Two control 
groups also comprised 6 lactating mice in each (Table 7.2).  
 
7.2.8.3 Treatment of animals with anti-inflammatory cytokine or anticytokine 
receptor antibody 
The mice were injected with 400µl (85 µg) of IL-6 and IL-6β receptor antibodies by 
intraperitoneal routes on 1st day. A booster injection comprising the same dose was 
injected on the next day by the same route. Mice were challenged in both L5 and R5 
mammary glands with 0.05 ml of bacterial suspension equivalent to 2x 10
10 
CFU S. 
aureus was injected using a blunt smooth 31-gauge hypodermic needle to a depth of 
not more than 4mm. The detail of the method is described in Chapter 6, Section 
6.2.4.4. The mice were observed at one-hour intervals to assess development of 
macroscopic clinical signs of infection and mortality. 
 
7.2.9 Statistical analysis 
Statistical analysis was carried out using student’s t-test to compare total viable 
counts of S. aureus recovered from mammary glands injected with non typeable 
strong biofilm forming S. aureus and weak biofilm forming S. aureus. t test was also 
performed to compare the IL-1β, IL-6, IL-12, IL-17, TNF-α and IFN-γ levels 
between groups of mice injected with S. aureus phenotypes. Statistical significance 
was set at p < 0.05.  
 
7.3 Results 
7.3.1 Infection of mammary gland using non-typeable S. aureus strains 
7.3.1.1 Observation of mammary gland for clinical symptoms  
The control group of mice injected with PBS did not show any clinical symptoms 
and the mammary glands appeared normal. Both the test groups of mice vaccinated 
with S. aureus 83 and 87 strains showed medium grades of clinical symptoms. 
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However mice injected with S. aureus 83 died 24 h of post inoculation and the group 
injected with S. aureus 87 died 30 h post inoculation (Table 7.3). 
 
 
Table 7.3: Clinical signs observed in different groups of mice post-infection 
(observations up to 30 h post inoculation) 
 
*Clinical features include redness, swelling, and discolouration of mammary gland, exudate, 
morbidity and mortality. Grade scores compare observed features to the most severe 
changes: 0 no macroscopic changes, + low grade, ++ medium grade, +++ severe grade. 
 
7.3.1.2 Bacterial load and histopathological changes of mammary gland 
The log average number of bacteria (CFU) isolated from the mammary glands of all 
the three groups of mice including control group and the associated histopathological 
changes in the mammary glands are presented in Table 7.4. The histopathological 
changes noted in mammary tissue are shown in Figure 7.1. 
 
Table 7.4: Total viable counts of S. aureus recovered from mammary glands 
after death of mice 
 
Group S. aureus 
phenotype 
Total number of 
mammary 
glands 
investigated 
 
Log average 
number of 
bacteria (CFU) 
recovered from 
mammary 
glands ± SE 
 
Histopathology 
grade 
 
1 S. aureus 83 4 8.23 ± 0.001 1 
2 S. aureus 87 4 7.91 ± 0.003 1 
3 Control (NS
*
) 4 0 0 
NS*= Normal saline 
 
Time post inoculation S. aureus 83 S. aureus 87 PBS (Control) 
6 h 0 0 0 
12 h + + 0 
18 h ++ + 0 
24 h ++/death ++ 0 
30 h  ++/death 0 
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7.3.1.3 Bacteriology of blood and histopathology of liver, lung and spleen 
The culture of blood and organs (liver, lung and spleen) in BP agar plates was 
negative for S. aureus indicating no evidence of systemic infection. There was no 
evidence of inflammation in tissue sections of lung, liver and spleen from any of the 
mice. 
 
7.3.1.4 Quantification of inflammatory cytokines in serum 
Quantification study of inflammatory cytokines, IL-1β, IL-6, TNF-α and other 
cytokines including  IL-10, IL-12, IL-17A and IFN-γ showed that the levels of IL-1β, 
IL-6, IL-12, IL-17 and IFN-γ were significantly higher (p<0.05) in the sera of mice 
inoculated with non-typeable strong biofilm forming S. aureus 83 than those 
inoculated with weak biofilm forming non typeable S. aureus 87 (Table 7.5).  
 
7.3.2 Treatment of mice using anti-inflammatory cytokine IL-6 and anti 
cytokine receptor antibodies IL-6Rβ 
The detailed results of studies of clinical signs, mortality, bacterial load and 
histopathological grades of mammary glands in anti-inflammatory cytokine treated 
mice are presented in Table 7.6. The histopathological changes observed in 
mammary tissue are presented in Figure 7.1-7.4. 
 
7.4 Discussion 
Studies carried out with CP8 positive strong versus weak biofilm forming S. aureus 
isolates revealed that the extent of mammary tissue damage was associated with the 
strength of biofilms formed by S. aureus strains (Refer Chapter 6). This study was 
undertaken to compare the pathogenicity of two non-typeable S. aureus strains with 
and without biofilm forming ability. The study also aimed to determine the potential 
of anti-inflammatory cytokine, IL-6 and IL-6 R β antibodies to prevent mortality in 
mice. Non-typeable strains of S. aureus can survive in the mammary gland for longer 
duration than the encapsulated strains (Tuchscherr et al., 2005). Higher degree of 
inflammation appeared to have been induced by encapsulated than the non typeable 
S. aureus strains, which leads to quick clearance of these cells by the host immune 
system. The non-typeable cells are quickly internalized by the mammary epithelial 
cells due to absence of capsule and thus they are protected from the action of 
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phagocytic cells (Tuchscherr et al., 2005). In the current study, both the strains 
produced identical clinical symptoms and mammary tissue damage. Both the strains 
produced moderate level of clinical symptoms of mastitis and level 1 
histopathological lesion in the mammary gland. However, the bacterial load in the 
mammary glands of mice injected with the non typeable S. aureus 83 strain with 
biofilm forming ability was significantly higher (≤0.05) than the non-biofilm forming 
S. aureus strain 87 strain. The period of observation in the study was 48 h. However, 
both the test groups of mice died before 48h, the mice injected with S. aureus 83 
strain survived only 24 h followed by the mice injected by S. aureus 87. Mice in the 
latter died at 30h post inoculation. 
 
The epithelial cells of mammary gland can produce cytokines (Bannerman, 2009). 
One of the effective alternative approaches to treat bovine mastitis caused by S. 
aureus can be the use of anticytokines as immunotherapeutic agents. Cytokines being 
the important soluble defence mechanism of mammary gland acts as mediators as 
well as regulators of inflammatory mediator cytokines by promoting recruitment of 
neutrophils to the site of infection. A variety of cytokines are reported to be present 
in healthy and infected mammary gland. They are interleukins (IL), colony 
stimulating factors (CSF), interferon gamma (IFN-γ) and tumour necrosis factor 
(TNF) [Alluwaimi, 2004]. The interleukins which are associated with bovine 
mammary gland infections are IL1, IL2, IL6 and IL8 (Alluwaimi, 2004). There are 
various reports of upregulation of level of IFN-γ (Bannerman et al., 2004), IL-1β 
(Riollet et al., 2001), IL-6 (Riollet et al., 2001), IL-12 (Lee et al., 2006) and TNF-α 
(Dernfalk et al., 2007) in milk and serum. Availability of a variety of recombinant 
cytokines and also due to their proven immune-modulatory properties (Bannerman, 
2009), these cytokines have opened new avenues in the area of therapy and 
prophylaxis of bovine mastitis. Various researchers have reported the prevention and 
clearance of infection from mammary gland and enhancement of efficacy of 
antibiotic treatment in bovine mastitis due to use of cytokine therapy (Sordillo and 
Babiuk, 1991; Erskine et al., 1998; Takahashi et al., 2005). It has been demonstrated 
in vitro that neutrophils exceeding  5x107 cells/mL of milk produce IL-1β, IL-12, 
IFN-γ and TNF-α (Sohn et al., 2007).  
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In the present study, the analysis of sera samples collected from mice immediately 
before death showed higher levels of IL-1β, IL-6, IL-10, IL-17A, IFN-γ and TNF-α 
(Table 7.5).  It has been speculated that quick internalization of non-typeable S. 
aureus cells by the mammary epithelial cells have prevented the clearance of S. 
aureus from the mammary gland which provided scope for production of cytokines 
of different types. The highly elevated of level of various cytokines can lead to 
cytokine storm, a fatal immune response which may result in sudden death 
(Osterholm, 2005).  It has been demonstrated that patients died due to cytokine storm 
had higher levels of anti-inflammatory cytokine, IL-10 and pro inflammatory 
cytokines, IL-1β, IL-6 and TNF-α in serum samples (Horst, 2002). In the present 
study, between both the groups of test mice, the mice injected with S. aureus 83 
produced significantly higher levels of IL-1β, IL-6, IL-12, IL-17 and IFN-γ (p < 
0.05) than the mice injected with S. aureus 87. The level of IL-6 in sera samples of 
mice injected with S. aureus 83 was extremely high (15479.9±532 Pg/mL) which 
could have been responsible for the death of the mice within mere 24 h post 
inoculation. The only phenotypic difference between both the strains was the biofilm 
forming ability. Though not conclusively, but it can be concluded that biofilm 
forming ability of non-typeable strain may play role in the virulence of the S. aureus 
strain in bovine mastitis.  
 
Based on results of the cytokine analysis, anti-IL-6 and IL-6R β antibodies were 
selected to use for the treatment of the mice in the second animal trial. We 
hypothesized that anti IL-6 and IL-6R β antibodies will down-regulate the 
proinflammatory cytokine IL-6 resulting delayed or absence of mortality in mice. An 
experiment studying the prophylactic effect of IL-2 and IFN-γ in healthy mammary 
gland showed promising results in cows (Alluwaimi, 2004). However, it failed to 
prevent S. aureus-associated intramammary infections. In the current study, though 
the mortality of the mice could not be prevented completely, but the duration of 
survival was increased by to 12 h 30 min and 13 h 15 min in mice treated with anti-
IL-6 and anti-IL-6R β antibodies, respectively. Severity of mastitis was also reduced 
in terms of clinical symptoms and bacterial load from the mammary glands. The 
clinical symptoms level has been reduced from medium to low grade and there was 
significant difference in the load of S. aureus in the mice treated with anti-IL6 and 
IL-6R β antibodies. However, the delayed mortality provides window for treatment 
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of mastitis given the administration of a suitable antibiotic with the extended 
timeframe. Clearly further research is needed to check the status of mortality if anti-
cytokines or anti-cytokine receptor antibodies are used in combination with 
antibiotics to treat bovine mastitis caused by S. aureus. 
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Table 7.5: Detection of levels of different cytokine biomarkers in sera samples of mice after death of mice 
 
 
Group S. aureus 
phenotype 
IL-1β 
Pg/mL 
±SE 
IL-6 
Pg/mL  
±SE 
IL-10 
Pg/mL  
±SE 
IL-12 
Pg/mL 
±SE 
IL-17A 
Pg/mL 
±SE 
IFN-γ 
Pg/mL 
±SE 
TNF-α 
Pg/mL 
±SE 
1 S. aureus 83 
 
321.7±23 15479.9±532 66.8±0.96 3.0±0.42 28.6±1.79 59.5±1.78 163.3±4.5 
2 S. aureus 87 
 
27.7±41 529±109 12.86±0.69 1.43±0.35 18.20±0.5 12.70±1.50 174.9±21 
3 Control (NS) 
 
0 
 
0 0 0 0 0 0  
 
 
In student’s t-test for IL-1β, IL-6, IL-12, IL-17 and IFN-γ levels between groups of mice injected with S. aureus 83 and S. aureus 87 showed 
high IL-1β, IL-6, IL-12, IL-17 and IFN-γ (p < 0.05) levels in mice injected with S. aureus 83.         
Table 7.6: Studies of clinical signs, mortality, bacterial load and histopathological grades of mammary glands in anti-inflammatory 
cytokine treated mice 
Treatment group Total number of 
mammary 
glands 
investigated 
 
Clinical 
symptoms 
grading 
Mortality 
(hour) 
Log average number of 
bacteria (CFU) 
recovered from mammary 
glands after death of mice 
 
 
Histopathology 
grade 
 
IL-6 6 ++ 36h 30 min                  7.64±.03 1 
IL-6R β 6 + 37 h 15 min 7.58 ±.04 1 
PBS control (IL6) 6 + 24h 8.29±0.02 1 
PBS control (IL-6 R β) 6 + 24h 8.24±0.05 1 
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Figure 7.1: Mammary tissue specimen from lactating mouse injected with PBS 
and challenged using non-typeable S. aureus 83. Small numbers of interlobular 
inflammatory infiltrates in mammary tissue (A). Level 1 category inflammation. 
H&E x 100mag.  
 
 
Figure 7.2: Mammary tissue specimen from lactating mouse injected with PBS 
and challenged using non-typeable S. aureus 83 (Figure 7.1). Gram positive 
bacteria (Arrow) within suppurative inflammatory material. Gram Twort 
x1000mag. 
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Figure 7.3: Mammary tissue specimen from lactating mouse immunized with 
anti IL6 antibody via intraperitoneal route and challenged using non typeable S. 
aureus 83. Mammary glands (A) Infiltration of acute inflammatory cells in 
perilobular connective tissue (B). Level 1 category inflammation. H&E x 
200mag. 
 
 
Figure 7.4: Mammary tissue specimen from lactating mouse immunized with 
anti IL6R β antibody via intraperitoneal route and challenged using non-
typeable S. aureus 83. Mild inflammatory cell infiltrate in periductal connective 
tissue (A). Level 1 category inflammation. H&E x 40mag. 
A 
B 
A 
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                        7.5(a)                                                      7.5 (b) 
Figure 7.5: Mammary tissue specimen from lactating mouse immunized with 
anti IL6R β antibody via intraperitoneal route and challenged using non-
typeable S. aureus 83 from sample 11 (Figure 7.4). 7.5(a) Small numbers of 
inflammatory cells in intralobular (A) and perilobular site (B). Level 1 category 
inflammation. H&E x 400 mag. 7.5(b) Gram positive bacteria (Arrow) in 
inflammatory material Gram Twort x1000mag. 
A 
B 
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Chapter 8: Evaluation of the immunogenicity and 
protective potential of planktonic versus biofilm-based 
whole cell vaccines against bovine mastitis using the mouse 
mastitis model 
 
8.1 Introduction   
Staphylococcus aureus is one of the prominent etiological agents of clinical, 
subclinical, persistent and chronic forms of mastitis in cows (Clutterbuck et al., 2007; 
Middleton, 2008; Pereira et al., 2011). It is normally present in almost all the external 
surfaces of cow (Roberson et al., 1998) and udder is the most preferred site for 
colonization of S. aureus in dairy cows (Jorgensen et al., 2005). Upon entry into the 
mammary gland S. aureus cells adhere to the epithelial lining of mammary gland. 
This is followed by formation of multilayered clusters of S. aureus cells which is 
enclosed by a slimy extracellular matrix known as biofilm (Melchior et al., 2006). 
Formation of biofilm in the mammary gland makes treatment of mastitis difficult as 
S. aureus in biofilm does not respond to antimicrobial therapy resulting in chronic 
mastitis (Cucarella et al., 2004). 
 
The current conservative therapy of mastitis includes the use of antimicrobial agents. 
Despite scheduling treatment regimens to prolong the availability of appropriate 
antibiotics for an extended period of time in the mammary gland (Erskine, 2001), the 
cure rates of mastitis particularly for S. aureus infections have not been very 
satisfactory (Timms, 2001). This has further been complicated by the biofilm 
forming ability of the pathogen as the pathogen in biofilm is protected from the 
effect of antimicrobial agents. S. aureus growing in a biofilm expresses different 
genes than the S. aureus growing in planktonic form (Beloin et al., 2004; Waite et 
al., 2005; Yao et al., 2005; Resch et al., 2006; Shemesh et al., 2007). Moreover, S. 
aureus carrying biofilm-associated genes such as ica types, bap, agr types have 
increased potential to induce (Baselga et al., 1993) and develop recurrent infections 
of mammary gland (Cucarella et al., 2004). As such, there is a serious need to 
develop a suitable vaccine to prevent S. aureus-associated bovine mastitis. While 
formulating an effective vaccine, it is important to consider the different antigens 
which are expressed in biofilm form of growth of S. aureus. 
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A wide variety of extracellular virulence antigens of S. aureus have been reported to 
be associated with biofilm formation. These mediators include poly-N acetyl 
glucosamine (PNAG) or polysaccharide intercellular adhesion (PIA) [Vuong et al., 
2004], surface associated proteins viz. FnBPA, FnBPB, ClfA, ClfB, CNA, bap, 
ProteinA, SasG and bone sialo binding protein (BBP) [Patti et al., 1992; Mc Devitt et 
al., 1994; Tung et al., 2000; Cucarella et al., 2001; Corrigan et al., 2007; O’Neill et 
al., 2008; Merino et al., 2009; Vergara-Iriqaray et al., 2009]. Extracellular DNA 
(eDNA) has also been found to be associated with biofilm formation of S. aureus 
(Rice et al., 2007; Izano et al., 2008).  
 
Various studies have been conducted to test the immunogenicity potential of some of 
these molecules. However, when tested for their protective potential as “single 
antigen” vaccines, only partial protection measured by passive transfer of antigen 
specific antibodies or as immunogens (Mamo et al, (1994; Maitran et al, 2004; Zhou 
et al, 2006) A study conducted by Cywes-Bentley et al (2013) demonstrated that 
mice immunized with antibodies against PNAG protected them from S. aureus 
associated localized and systemic infections. However, slime associated antigenic 
complex (SAAC) also known as PNAG, failed to prevent intramammary infection in 
cows, only reduced the multiplication of S. aureus in the mammary gland (Prenafeta 
et al., 2010). FnBpA and Protein A have been found to provide partial protection to 
mice infected with S. aureus systemic infection (Zhou et al., 2006; Kim et al., 2010; 
Kim et al., 2012). Similarly, vaccination of mice with the CNA-FnBP proteins 
reduced the post-challenge mortality (Zhou et al, 2006) whereas dairy heifers 
vaccinated with these proteins alone or in combination were not effective in 
countering challenge with the parent strain.  
 
Due to involvement of multiple mediators in the development of biofilm by S. 
aureus, a vaccine containing a single or two antigens as vaccine candidates can only 
provide partial protection against biofilm associated S. aureus infections. Literature 
indicates that gene expression of a bacterial pathogen residing in biofilm is different 
from the bacteria from its planktonic form (Prignent-Combaret et al., 1999). 
Moreover, a study has demonstrated that host immune response to planktonic form of 
S. aureus is different from its biofilm counterpart (Thurlow et al, 2011).  The authors 
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found that S. aureus in biofilm attenuate the traditional antibacterial host immune 
response and reduces the production of cytokine or chemokines and thus altering the 
host immune system. We hypothesize that a vaccine composed of resident S. aureus 
cells from biofilm will provide better immune response and protection against S. 
aureus-associated mastitis due to reduction in the strength of biofilm forming ability. 
Based on this hypothesis, the immunogenicity and protective potential of formalin 
killed S. aureus planktonic versus biofilm vaccines were carried out using mouse 
mastitis model. 
 
8.2 Material and Methods 
8.2.1 Immunogenicity and protective potential of planktonic versus biofilm S. 
aureus-based vaccines 
8.2.1.1 Bacterial strain 
BOAISRF S. aureus 51, a clinical CP 8 positive and a strong biofilm producer 
(genotype shown in Table 8.1) was used in this study.  This strain was the most 
virulent encapsulated strain as judged by extent of mammary tissue damage and the 
number of S. aureus isolated from mammary gland post-infection. The strain was 
selected from a collection of 154 bovine mastitis-associated S. aureus strains 
obtained from Victoria and Queensland, Australia. The details of the genotypic 
and/or phenotypic characteristic of this strain determined in this project embodying 
this PhD thesis are listed in Table 8.1. 
 
The parental strain (BOAISRF S. aureus 51) was used in the challenge experiment to 
determine the protective potential of the planktonic versus the biofilm S. aureus 
vaccines.  
 
8.2.1.2 Animal ethics approval 
A total of 96 numbers of 3days pregnant Balb/c mice were obtained from the Animal 
Resources Centre, Perth, Western Australia and used for this study. All animal 
experiments were carried out with the approval of Curtin University’s Animal Ethics 
Committee (Approval No: AEC_2013_24) ensuring compliance with the Western 
Australian Animal Welfare Act, 2002.  
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Table 8.1: Phenotypic/genotypic characteristics of BOAISRF S. aureus 51 strain 
used in development of planktonic and biofilm vaccines 
 
Phenotypic/ genotypic characteristics 
Biofilm formation Strong  
Capsular Polysaccharide type CP8 
Presence of Biofilm associated 
genes 
icaA, icaD, agr typeIII 
Presence of MSCRAMMS genes spa, can, clfA, clfB, α-isdA, α-isdB, sdrD, 
sdrE 
Presence of toxin genes hla, hlb, seh 
 
8.2.1.3 Preparation of vaccines 
24 well flat bottom with lid tissue culture plates (Sarstedt Australia Pty Ltd, SA) 
were filled with 1.5 ml of 1% glucose enriched nutrient broth. Single colony of 
overnight grown BOAISRF 51 strain was inoculated into each well. Plates were 
incubated at 37º C for 24 h with gentle shaking at 80 rpm. The supernatant 
(Planktonic vaccine) was collected carefully by using a pipette and centrifuged at 
10,000 x g for 10 min. The biofilm was collected by scooping out with sterile mini 
spatula (LEAP Biosciences) and washed using 1ml of sterile PBS. Both the 
planktonic and biofilm forming cells were washed for five times at 10,000 x g for 10 
min by using PBS. Finally the cells were suspended in 5 ml of PBS and stored at 4ºC 
to prevent growth. Tenfold dilutions up to 10
11 
was performed for both the planktonic 
and biofilm suspensions and 100 µl from each dilution was plated on Baird Parker 
agar media plates in triplicates by using spread plate method. The plates were 
incubated at 37ºC for 48 h followed by determination of colony counts of S. aureus. 
To each 3 ml of planktonic/biofilm suspensions, 2 ml of 3% formalinized PBS was 
added and allowed to remain at room temperature for a period of 24 h. The bacterial 
suspensions were then subjected centrifugation at 10,000 x g for 20 min and washing 
with PBS five times. Finally the pellet was suspended in 5ml of sterile PBS. Based 
on the growth curve, the desired colony forming units of BOAISRF S. aureus 51 in 
both planktonic and biofilm form were adjusted to 10
7 
CFU/0.05 ml, 10
8
 CFU/0.05 
ml and 10
9
 CFU/0.05 ml. 
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8.2.1.4 Preparation of bacterial inocula for challenge 
BOAISRF S. aureus 51 was grown on MH agar plates at 37°C for 18h. The pure 
colonies were washed from the plates using 20 ml of isotonic saline and suspended in 
isotonic saline to give a final viable bacterial count of 4 x 10
11 
ml
-1
 (Anderson and 
Chandler, 1975). 
 
 8.2.1.5 Immunization protocol 
A total of 96 mice were divided into 8 groups comprising 12 mice in each group. The 
details of the groups are presented in Table 8.2. All the four test groups of mice were 
vaccinated with 3 doses of 0.1 ml of killed whole cell vaccines. 0.05 ml of vaccine 
containing an equivalent of 10
7
, 10
8
 and 10
9
 CFUs/mL was mixed in equal 
proportion of alum-based adjuvant such as Imject Alum (Thermo Fisher Scientific) 
and injected to the mice on days 0, 7 and 14 day, respectively using s/c and i/mam 
routes. Mice in the control groups were vaccinated with 0.1 ml of sterile PBS on 0, 7 
and 14 days using the same routes as that used in test mice. For i/mam inoculation, 
mice were anaesthetised with intraperitoneal (i.p.) dose of 100 mg ketamine kg−1 
and 10 mg xylazine kg−1, put on their back under a binocular and the teats and the 
surrounding area were disinfected with 70% ethanol. The hind teat, numbered R5, 
was held with fine forceps and the duct orifice was located. A volume of 0.1 ml of 
killed vaccines was injected through the orifice using 31 gauge blunt needles. The 
needle was not inserted more than four millimetres deep into the canal. The control 
mice were inoculated with sterile PBS. The mice were monitored twice a day. Six 
mice from each group were euthanized on 28
th
 day of vaccination and blood and 
spleen were sampled for detection of antigen-specific antibodies in serum and level 
of Interferon gamma (IFN-γ) in splenocyte supernatants. Remaining 48 mice were 
used for challenge experiment. 
 
8.2.1.6 Detection of antigen-specific antibodies in serum 
Antigen-specific antibody isotype analysis of sera samples of mice immunised with 
the planktonic or biofilm vaccine was carried out prechallenge. The levels of anti-S. 
aureus IgG, IgG1 and IgG2a were determined using an indirect ELISA (Chapter 5, 
Section 5.2.3.1).  
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Table 8.2: Experimental design for determination of immunogenicity and 
protective potential of planktonic versus biofilm vaccines (n=96) 
 
Sl. No Group Route of administration Number of mice 
1 Planktonic test s/c 12 
2 Planktonic 
control 
s/c 12 
3 Planktonic test i/mam 12 
4 Planktonic 
control 
i/mam 12 
5 Biofilm test s/c 12 
6 Biofilm control s/c 12 
7 Biofilm test i/mam 12 
8 Biofilm control i/mam 12 
 
8.2.1.7 Estimation of Interferon gamma (IFN-γ) in antigen stimulated splenocyte 
supernatants 
Methods for the stimulation of splenocytes cultured in vitro and collection of 
splenocyte supernatants have been detailed in Chapter 2 Section 2.5.  Estimation of 
IFN-γ, as an indirect indicator of cell mediated immunity (CMI) was carried out for 
the vaccinated and control groups of mice. This was accomplished using ab46081 
IFN gamma Mouse ELISA kit (Abcam
®
) following manufacturer’s instructions. 
 
8.2.1.8 Challenge experiment 
A total of 48, three days pregnant Balb/c mice which were vaccinated on day 0, 7 
and 14 days (Described in Chapter 8, Section 8.2.1.5) were challenged on the 28
th
 
day of post vaccination. The lactating mice (5-15 days) from both test and control 
groups were challenged in both L5 and R5 mammary glands using 50 µl (CFU 
2x10
10
) of homologous strain of BOAISRF S. aureus. Mice were challenged via 
intra-mammary route using thirty one gauge needles (Chapter 6, Section 6.2.4.4). 
The mice were observed twice daily for morbidity and mortality until 5 days post-
challenge. Percent protection against mouse mastitis was recorded and surviving 
mice euthanized after sampling blood and mammary glands.  
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8.2.1.8.1 Clinical observation  
The mammary glands of mice were observed for clinical signs of mastitis including 
redness, swelling and discolouration of mammary gland and extrusion of exudate 
with or without squeezing of the mammary gland (Chapter 6, Section 6.2.5.1).  
 
8.2.1.8.2 Bacterial load study of mammary glands 
The L5 mammary glands from control and test mice were collected and subjected to 
bacterial load study (Chapter 6, Section 6.2.5.2.1) 
 
8.2.1.8.3 Histological observation 
R5 mammary glands were collected from both control and test mice for 
histopathological examination (Chapter 6, Section 6.2.5.3.1) 
 
8.2.1.9 Statistical analysis 
To compare the antigen specific antibody levels, Interferon gamma (IFN-γ) levels 
and Log average number of bacteria (CFU) recovered from mammary glands 
between groups of mice immunized with planktonic and biofilm S. aureus vaccines, 
student’s t-test was performed. Statistical significance was set at p < 0.05.  
 
8.3 Results 
8.3.1 Immunogenicity trial using planktonic versus biofilm based vaccines 
8.3.1.1 Detection of antigen-specific antibody classes/isotypes in sera samples of 
mice 
The serum IgG and IgG1 antibody titres of mice immunised with the planktonic S. 
aureus vaccine using subcutaneous route were significantly greater than the titres 
induced by vaccination using intramammary route (Figure 8.1A and 8.1B). 
 
The serum IgG2a and IgG antibody titres of mice immunised with the biofilm S. 
aureus vaccine using intramammary route were significantly higher than the mice 
vaccinated by biofilm S. aureus vaccine using subcutaneous route (Figure 8.2A and 
8.2B). 
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Figure 8.1A: Detection of antigen-specific antibody isotypes of mice vaccinated 
with planktonic killed S. aureus vaccine by s/c route 
 
 
 
Figure 8.1B: Detection of antigen-specific antibody isotypes of mice vaccinated 
with planktonic killed S. aureus vaccine by i/mam route 
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Figure 8.2A: Detection of antigen-specific antibody isotypes of mice vaccinated 
with biofilm killed S. aureus vaccine by s/c route 
 
 
 
 
 
Figure 8.2B: Detection of antigen-specific antibody isotypes of mice vaccinated 
with biofilm killed S. aureus vaccine by i/mam route 
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Figure 8.3: Comparison of levels of antigen-specific antibody isotypes of mice 
vaccinated with planktonic and biofilm killed S. aureus vaccine by using 
subcutaneous and intramammary routes 
 
 
 
8.3.1.2 Detection of Interferon gamma (IFN-γ) levels in splenocyte supernatants 
Mice vaccinated with S. aureus planktonic and biofilm vaccines using both s/c and 
i/mam routes produced variable levels of IFN-γ when splenocytes were stimulated 
with killed planktonic and biofilm BOAISRF S. aureus 51. Mice vaccinated with S. 
aureus planktonic vaccine via s/c and i/mam routes produced 48.2±15.61 pg/ml and 
19.06±12.06 pg/ml IFN-γ, respectively when the splenocytes were stimulated with 
killed planktonic S. aureus. However, splenocytes stimulated with ConA produced 
6220±34.16 pg/ml of IFN-γ (Figure 8.4).  
 
The splenocytes of mice vaccinated with S. aureus biofilm vaccine using s/c and 
i/mam routes produced 460.87±148.69 pg/ml and 4259.33±367.11 pg/ml of IFN-γ, 
respectively when the splenocytes were stimulated with killed biofilm S. aureus. The 
splenocytes stimulated with ConA produced 6166.67±47.73 pg/ml of IFN-γ (Figure 
8.5).  
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8.3.2 Protection study against planktonic and biofilm based vaccines 
8.3.2.1 Clinical observation of mammary glands of challenged mice for mastitis 
The control groups of mice showed prominent signs of mastitis in the infected 
glands. All the test mice showed varying degrees of changes including redness, 
swelling, and discolouration of mammary gland, exudate and morbidity (Table 8.3, 
Figure 8.6).     
 
Figure 8.4: Concentration of IFN-γ produced by killed planktonic S. aureus 
stimulated splenocytes of mice immunized with planktonic S. aureus vaccine 
using different routes 
 
 
 
 
Figure 8.5: Concentration of IFN-γ produced by killed biofilm S. aureus 
stimulated splenocytes of mice immunized with biofilm S. aureus vaccine using 
different routes 
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Table 8.3:  Clinical signs observed in different groups of mice immunized with 
planktonic and biofilm S. aureus vaccines (Observations up to 5 days post 
cahllenge) 
 
 
Level of clinical signs* observed in mice injected with Planktonic and biofilm 
vaccines 
 
Sl. 
no 
Vaccination group 24 h 48 h 72 h 96 h 120 h 
1 Planktonic vaccine (s/c route) + ++ ++ ++ ++ 
2 Planktonic vaccine (i/mam route) + ++ ++ ++ ++ 
3 PBS control for planktonic s/c 
route 
++ +++ +++ +++ +++ 
4 PBS control for planktonic i/mam 
route 
++ +++ +++ +++ +++ 
5 Biofilm vaccine (s/c route) + ++ ++ ++ ++ 
6 Biofilm vaccine (i/mam route) 0 + + + + 
7 PBS control for biofilm s/c route ++ +++ +++ +++ +++ 
8 PBS control for biofilm i/mam 
route 
++ +++ +++ +++ +++ 
*Clinical features include redness, swelling, and discolouration of mammary gland, 
exudate,    morbidity and mortality. Grade scores compare observed features to the 
most severe changes: 0 - no macroscopic changes, + low grade, ++ medium grade, 
+++ severe grade 
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Figure 8.6: Observation of clinical symptoms of mastitis in mammary glands of 
mice vaccinated with killed whole cell planktonic and biofilm vaccine 
 
 
Fig 8.6: Mammary glands of mice showing various levels of clinical symptoms 
including redness, swelling, discolouration and exudate in mammary gland, exudate.  
A: Mammary gland of mouse immunized by killed whole cell biofilm vaccine via 
i/mam route after 24 h of post challenge. No visible signs of mastitis. Mammary gland 
appears normal, Grade score o. B: Mammary gland of mouse immunized by killed 
whole cell biofilm vaccine via i/mam route after 120 h of post challenge. Grade score 
+ low grade. C: Mammary gland of mouse immunized by killed whole cell planktonic 
vaccine via s/c route after 120 h of post challenge. Grade score ++ medium grade. D: 
Mammary gland of mouse immunized by PBS after 120 h of post challenge. Grade 
score +++ severe grade. 
 
 
8.3.2.2 Bacterial load study of mammary glands of challenged mice 
The bacteriological load study demonstrated that mice vaccinated with planktonic S. 
aureus vaccine had a bacterial load of 6.58±0.24 versus 6.63±0.38 CFU S. aureus in 
the mammary glands immunized by s/c and i/mam routes, respectively. The control 
mice for planktonic S. aureus vaccine group showed 6.85±0.049 and 7.68±0.05 CFU 
of S. aureus in their mammary glands when mice were injected by s/c and i/mam 
routes, respectively. The mice vaccinated with biofilm S. aureus vaccine showed 
A 
D C 
B 
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5.64±0.05 and 5.57±0.01 CFU of S. aureus in the mammary glands when vaccinated 
by s/c and i/mam routes, respectively. The control mice in biofilm S. aureus vaccine 
group showed 6.80±0.48 and 7.63±0.08 CFU of S. aureus when vaccinated by s/c 
and i/mam routes, respectively. The details of the bacterial load study is presented in 
Table 8.4. 
 
8.3.2.3 Histopathological observation of mammary glands of mice challenged 
with S. aureus 51 strain 
Histopathological grade observed in the mammary tissue are shown in Table 8.4 and 
Figures 8.7- 8.14. All the mice from groups including control, planktonic vaccine 
(s/c and i/mam routes) and biofilm (s/c route) demonstrated level 3 histopathological 
changes in mammary glands. However, 6 mice vaccinated with biofilm (i/mam 
route) vaccine showed histopathological grading as 1, 2, 2, 2, 2, 1 in M1 to M6, 
respectively. 
 
 
 
 
Figure 8.7: Mammary tissue specimen from lactating mouse immunized with killed 
S. aureus Planktonic vaccine (s/c route) and challenged using strong biofilm forming 
S. aureus 51. Interlobular acute inflammatory infiltration with cellular necrosis (A). 
Level 3 category inflammation. H&E x 400mag. 
A 
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Table 8.4: Detection of bacterial load and histopathological changes in the mammary glands of mice vaccinated with S. aureus 
planktonic and biofilm vaccines 
 
Sl. No Vaccine group Total number of 
mammary 
glands 
investigated 
 
Log average number 
of bacteria (CFU) 
recovered from 
mammary glands 
 
Grades for histopathological  
changes 
 
M1            M2              M3             M4             M5         M6 
1 Planktonic s/c route 6 6.58±0.24 3 3 3 3 3 3 
2 Planktonic i/mam route 6 6.63±0.38 3 3 3 3 3 3 
3 PBS control for planktonic s/c route 6 7.68±0.05 
 
3 3 3 3 3 3 
4 PBS control for planktonic i/mam 
route 
6 6.85±0.049 3 3 3 3 3 3 
5 Biofilm vaccine (s/c route) 6 5.64±0.05 3 3 3 3 3 3 
6 Biofilm vaccine (i/mam route) 6 5.57±0.01 1 2 2 2 2 1 
7 PBS control for biofilm s/c route 6 6.80±0.48 3 3 3 3 3 3 
8 PBS control for biofilm i/mam route 6 7.63±0.08 3 3 3 3 3 3 
        M*= Mammary gland 
In paired t test between biofilm vaccine (s/c and i/mam routes) with planktonic vaccine (s/c and i/mam routes) demonstrated significant 
difference (< 0.05) in bacterial load and histopathological grades of mammary tissue lesions between biofilm vaccine (i/mam route) with both s/c 
and i/mam routes of planktonic vaccine. Biofilm vaccine (s/c) route although demonstrated significant difference in bacterial load compared to 
planktonic vaccine by either s/c or i/mam route, but no significant difference was detected in respect to tissue damage. 
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Figure 8.8: : Mammary tissue specimen from lactating mouse immunized with 
killed S. aureus Planktonic vaccine (i/mam route) and challenged using strong 
biofilm forming S. aureus 51. Inflammatory abscess shows inflammatory exudate in 
fibrinous capsule. Level 3 category inflammation. H&E x 40mag. 
 
 
Figure 8.9: Mammary tissue specimen from lactating mouse immunized with killed 
S. aureus Planktonic vaccine (i/mam route) and challenged using strong biofilm 
forming S. aureus 51. Gram positive bacteria within interlobular inflammatory 
infiltrate (Arrow). Gram Twort x1000mag. 
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Figure 8.10: Mammary tissue specimen from lactating mouse injected with PBS 
(i/mam route) and challenged using strong biofilm forming S. aureus 51. Gram 
positive bacteria (Arrow) and associated inflammatory cell exudate. Gram Twort 
x1000mag. 
 
Figure 8.11: Mammary tissue specimen from lactating mouse immunized with killed 
S. aureus biofilm vaccine (s/c route) and challenged using strong biofilm forming S. 
aureus 51. (A) Mammary teat (B) Intramammary abscess shows central liquefactive 
necrosis and fibrinous capsule. Level 3 category inflammatory lesion. H&E x 40mag. 
 
A 
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Figure 8.12: Mammary tissue specimen from lactating mouse immunized with killed 
S. aureus biofilm vaccine (s/c route) and challenged using strong biofilm forming S. 
aureus 51. Gram positive bacteria (Arrow) within suppurative inflammatory 
material. Gram Twort x1000mag. 
 
Figure 8.13: Mammary tissue specimen from lactating mouse immunized with killed 
S. aureus biofilm vaccine (i/mam route) and challenged using strong biofilm forming 
S. aureus 51. (A) Inflammatory lesion of mixed cellularity includes acute 
inflammatory macrophages and fibroblasts (B). Level 2 category inflammation. H&E 
x 40mag. 
A 
B 
136 
 
 
Figure 8.14: Mammary tissue specimen from lactating mouse injected with PBS and 
challenged using strong biofilm forming S. aureus 51. Level 3 category 
inflammation. Abscess in mammary tissue with tissue necrosis (A). H&E x 40mag. 
 
8.4 Discussion 
S. aureus is frequently associated with formation of biofilm in the mammary gland 
making antibiotic therapy of bovine mastitis difficult (Melchior et al., 2006). The S. 
aureus residing in biofilm do not respond as well to antimicrobial agents and resist 
host immune mechanism (Gil et al., 2014). Upon entry into the mammary gland S. 
aureus attaches to the epithelial lining of mammary gland using specific receptors 
and starts colonizing. At this stage, these planktonic S. aureus cells are either 
eliminated by immune system of host or the cells end up developing biofilm by 
attaching to the extracellular matrix proteins of host (Harro et al, 2010). Biofilm of S. 
aureus is composed of two major components: extracellular matrix and S. aureus 
cells within extracellular matrix. While formulating a vaccine development against S. 
aureus-associated infections, the growth form of the pathogen needs to be considered 
as there is difference in gene expression, cellular attachment, cellular regulatory 
circuits and virulence of planktonic and biofilm forms of growth of bacterial 
pathogens (Prignent-Combaret et al., 1999; Serra et al., 2008; Babra et al., 2014 
unpublished data). To the best of our knowledge the majority of the biofilm vaccine 
trials have included extracellular matrix itself or the associated protein of 
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extracellular matrix to formulate a vaccine and study its protective potential in mouse 
model (Maira Litran et al., 2005; Prenafeta et al., 2010; Skurnik et al., 2010; Gil et 
al., 2014). Use of slime-associated antigenic complex (SAAC) of S. aureus have 
been reported to protect S. aureus localized and systemic infections in mice (Cywes-
Bentley et al., 2013) but failed to protect intramammary infection in cows, only 
leading to a reduction in the multiplication of S. aureus in the mammary gland 
(Prenafeta et al., 2010). PNAG being immune evasion molecule of S. aureus and 
component of polysaccharide intercellular adhesion of biofilm has been targeted as a 
potential vaccine candidate (Mc Kenney et al., 1998; Maira Litran et al., 2005; Perez 
et al., 2009; Gening et al., 2010). Maira Litran et al (2005) demonstrated that 
deacetylated PNAG (dPNAG) is more efficient than the acetylated (90%) form of 
PNAG as the acetylated form gets released into the suspension while the dPNAG 
retains on cell surface of bacteria (Cerca et al., 2007). However, vaccine studies 
using PNAG as a potential vaccine candidate though reduced the number of S. 
aureus at the site of infection but failed to provide complete protection against S. 
aureus associated infections (Middleton, 2008). A recent study to detect the 
protective immune response of biofilm matrix exoproteome was carried out in CD1 
mice using mesh-associated biofilm infection model (Gil et al., 2014). The study 
demonstrated reduction in the colonization of S. aureus in kidney and liver of mice, 
but failed to protect infection in the mice. 
 
Our approach was to formulate a killed whole cell biofilm vaccine based on the 
presence of ica genes promoting biofilm formation. However, the fact that S. aureus 
without ica genes is also capable of producing biofilm, potentially due to the 
presence of various surface proteins of S. aureus (Cucarella et al., 2001). Moreover, 
to the best of our knowledge, an approach to formulate a killed while cell vaccine 
using the resident S. aureus cells from biofilm has not been studied using mouse 
mastitis model. It was decided to formulate a killed whole cell vaccine using S. 
aureus resident in the biofilm and evaluate its immunogenicity and protective 
potential using mouse mastitis model.  This study has revealed that the mice 
vaccinated with planktonic vaccine by using s/c route produced significantly higher 
(p<0.05) humoral immune response (IgG1 and IgG) than the biofilm vaccine 
delivered using both s/c and i/mam routes. However, no detectable level of IgG2a was 
found in mice vaccinated using both s/c and i/mam routes for the planktonic vaccine. 
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In contrast, the both the groups of mice vaccinated by s/c and i/mam routes produced 
detectable levels of IgG2a in sera samples. The detection of IFN-γ level in the 
spelnocyte supernatant revealed that mice vaccinated with biofilm vaccine using 
i/mam route produced significantly higher levels than the planktonic vaccine using 
both s/c and i/mam routes. Observation of clinical symptoms up to 5 days of post 
challenge showed interesting results. All the four groups of control mice vaccinated 
by PBS demonstrated grade score of +++ with all the signs of mastitis including 
redness, swelling, exudate and discolouration of mammary gland. Mice vaccinated 
by planktonic vaccine using s/c and i/mam routes and biofilm vaccine using s/c route 
showed grade score ++ clinical symptoms. However, the mice vaccinated with 
biofilm vaccine using i/mam did not show any visible signs of mastitis on the first 
day of postchallenge and a grade score of + clinical symptoms appeared on second 
day postchallenge which lasted till the 5
th
 day of observation. The bacterial load 
study of mammary glands collected from mice on the 5
th
 day of postchallenge 
showed that the mice vaccinated with the biofilm vaccine using both s/c and i/mam 
routes had significantly less number of log average of S. aureus CFU in the 
mammary glands (p<0.05) than the mammary glands of mice vaccinated with 
planktonic vaccine using both s/c and i/mam routes and the control groups of mice. 
However, mice vaccinated with planktonic vaccine using s/c route showed 
significant difference in the total S. aureus load in mammary gland than the control 
group of mice. But no significant difference could be observed between total S. 
aureus load in mammary gland in mice vaccinated by planktonic or biofilm vaccine 
regardless of the route of immunisation. Histopathology study of the mammary tissue 
supported the finding of bacterial load. The histopathological grading of the 
mammary tissue lesions in all the groups except biofilm (i/mam) group was observed 
to be 3. In these groups, well preserved mammary tissue showed the evidence of 
intramammary abscess with central liquefactive necrosis that was walled off by a 
fibrinous capsule (Figure 8.8). Numerous gram positive cocci within liquefactive 
necrosis and lumina of mammary gland were observed. However, mice vaccinated 
with biofilm i/mam route showed less than grade 2 (average of 1.67) 
histopathological changes in mammary tissue with minimal to moderate 
inflammatory response and sporadic or no presence of bacteria in mammary tissue. 
Though there was reduction in the severity of tissue damage in the mammary glands 
in mice immunised with the killed whole cell biofilm vaccine by i/mam route, 
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complete prevention of tissue damage could not be observed against a heavy 
challenge dose sufficient to induce clinical mastitis. 
 
In summary, it can be concluded that a vaccine comprising of killed whole cell of S. 
aureus residing in biofilm and delivered via i/mam route induces protective immune 
response potentially due to the induction of cell-mediated immunity against mastitis 
caused by S. aureus and reduced the colonization of S. aureus in mammary gland, 
severity of clinical symptoms and tissue damage in mammary gland was lessened. 
The planktonic vaccine despite producing significantly higher humoral immune 
response was not protective as judged by the level of tissue damage, clinical severity 
and colonization of S. aureus in mammary gland. If the challenge dose was lower as 
is observed in chronic mastitis, complete protection may have been observed. 
However, this study proved the concept underpinning the hypothesis that a biofilm 
vaccine will be more protective than the planktonic vaccine. 
 
 The above findings lay the foundation for future research on the identification of the 
novel antigens present in the extracellular matrix of biofilm and evaluation of their 
immunogenicity and protective potential using the mouse mastitis model. Regardless, 
it has become clear that immunisation by the intramammary route is the better route 
of immunisation than the subcutaneous route because of generation of both humoral 
and cell-mediated immune responses against S. aureus-associated bovine mastitis. 
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Chapter 9: Evaluation of immunogenicity and protective 
potential of Protein A against bovine mastitis caused by 
Staphylococcus aureus using mouse mastitis model 
9.1 Introduction  
The two most important immune evasion antigens of Staphylococcus aureus are 
Protein A encoded by the spa gene and capsular polysaccharide (Forsgren, 1970; 
O’Riordan and Lee, 2004). Capsular polysaccharides are poorly immunogenic and 
have been evaluated for their vaccine potential against S. aureus infections in 
humans as conjugate vaccines (Middleton, 2008). It has been reported to be an 
important MSCRAMM mediating formation of biofilm (Merino et al., 2009) 
although more recently it was reported that there was no association between 
capsular polysaccharide and biofilm formation (Babra et al., 2013). The N-terminal 
region of spa contains immunoglobulin binding domains (Sjodahl, 1977) which can 
bind to the Fcγ and Fab portions of IgG and IgM, respectively leading to suppression 
of immune response including both innate and adaptive immunity (Kim et al., 2010). 
Besides, spa is capable of inhibiting opsonisation of S. aureus hindering 
complement-binding sites of immunoglobulins resulting prevention of activation of 
available alternative complement pathway (Spika et al., 1981). In addition, the 
immunoglobulin binding domains of Protein A can further interact with the von 
Willebrande factor (vWF) assisting adherence of S. aureus cells onto vascular 
endothelial cells (Kim et al., 2012). Besides its intense effects on innate immune 
system, Protein A suppresses adaptive immune system by interacting with VH
3
- type 
of IgM which is expressed in around 30% of B lymphocytes of human origin (Kim et 
al., 2012). This interaction is responsible for down regulation of B cell receptors 
(Kim et al., 2012) resulting apoptosis of the B lymphocytes (Goodyear et al., 2004). 
Due to the immune evasion nature of Protein A, it is considered one of important 
virulence determinants of S. aureus. Various studies performed in murine model 
have demonstrated the importance of spa in the virulence of S. aureus associated 
infections (Kim et al., 2010; Kim et al., 2012).  
 
In one study, comparison between a S. aureus mutant strain devoid of spa gene and a 
wild type S. aureus was studied in murine bacteraemia model (Kim et al., 2010). 
Mice were infected via intravenous route and the rate of mortality recorded. There 
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was significant lower mortality in mice infected with the mutant strain of S. aureus 
than the wild type. This study has demonstrated the importance of Protein A as an 
important vaccine candidate to be considered while formulating a vaccine against S. 
aureus-associated infections. Mice immunised with a modified non-toxic form of 
protein A spAKKAA was shown to protect against renal infections with a reduction in 
bacterial load in renal tissue samples (Kim et al., 2010). spAKKAA was also found to 
boost humoral immune response by producing antibodies to neutralize Fcγ/Fab 
binding characteristics of spa (Kim et al., 2012). However, contrast to these studies, 
spa was not found to be a contributor of virulence of S. aureus when studied in 
mouse mastitis and rabbit keratitis models (Jonsson et al., 1985; Callegan et al., 
1994). 
 
In our previous study to investigate the prevalence of Protein A in 154 strains of S. 
aureus isolated from bovine mastitis cases in Australia, it was revealed that a total of 
135 (87.7%) of S. aureus strains were found to posess the spa gene (Refer Chapter 4 
Section 4.3). Based on this information, Protein A was chosen as one of the vaccine 
candidates to study its immunogenicity and protective potential against bovine 
mastitis using the mouse mastitis model.  
 
9.2 Material and Methods 
9.2.1 Detection of immune response generated by protein A using mouse 
mastitis model 
9.2.1.1. Animal ethics approval 
A total of 24 numbers of 3 days pregnant Balb/c mice (6 mice per group for four 
different groups including control) were obtained from the Animal Resources Centre, 
Perth, Western Australia and used for the study. All animal experiments were carried 
out with the approval of Curtin University’s Animal Ethics Committee (Approval 
No: AEC_2013_24) ensuring compliance with the Western Australian Animal 
Welfare Act, 2002.  
 
9.2.1.2 Immunization procedure 
The experimental mice (n=24) were divided into four groups, each group comprising 
6 mice (Table 9.1). One group of mice was immunised with Protein A by s/c route 
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whereas the second group was vaccinated by i/mam route. The remaining two groups 
were control mice for s/c or i/mam routes. 25µg of proteinA (Sigma Aldrich, 
Australia) was dissolved 50µl PBS. It was mixed with 50µl of Imject Alum (Thermo 
Fisher Scientific) and a total of 100 µl was administered to the mice on days 0, 7 and 
14 day, respectively using s/c and i/mam routes. For i/mam inoculation, mice were 
anaesthetised with intraperitoneal (i.p.) dose of 100 mg ketamine kg−1 and 10 mg 
xylazine kg−1, put on their back under a binocular and the teats and the surrounding 
area were disinfected with 70% ethanol. The hind teat, numbered R5, was held with 
fine forceps and the duct orifice was located. A volume of 0.1 ml of proteinA with 
adjuvant was injected through the orifice using 31 gauge blunt needles. The mice 
were monitored twice a day. Blood and spleen were sampled on 28
th
 day for 
collection of sera for antibody isotyping and cytokine analysis, respectively.  
 
9.2.1.3 Detection of antigen-specific antibody isotypes in serum 
Estimation of IgG, IgG1 and IgG2a anti-S.aureus specific antibody isotypes was 
carried out on both immunised and control mice sera samples. The antibody titres 
were determined by using an indirect ELISA (Chapter 5, Section 5.2.3.1). 
  
9.2.1.4 Estimation of interferon gamma (IFN-γ) in splenocyte supernatants 
Estimation of IFN-γ, as an indirect indicator of cell mediated immunity (CMI) was 
carried out for the vaccinated and control groups of mice using ab46081 IFN gamma 
Mouse ELISA kit (Abcam
®
) following manufacturer’s instructions. Methods for the 
stimulation of splenocytes cultured in vitro and collection of splenocyte supernatants 
have been detailed in Chapter 2 Section 2.5.   
 
9.2.2 Determination of protective potential of Protein A using the mouse mastitis 
model 
9.2.2.1 S. aureus strain 
A strong biofilm former BOAISRF S. aureus 51 with capsular polysaccharide type 8 
and carrying both icaA and icaD loci was chosen to be used in the challenge 
experiment (Details of phenotypic characteristics provided in chapter 8, Section 
8.2.1.1). This strain was selected from a collection of 154 bovine mastitis-associated 
S. aureus strains obtained from Victoria and Queensland, Australia. 
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9.2.2.2 Animal ethics approval 
A total of 24 numbers of 3 days pregnant Balb/c mice (6 mice per group for four 
different groups including control) were purchased from the Animal Resources 
Centre, Perth, Western Australia and used for the study. All animal experiments were 
carried out with the approval of Curtin University’s Animal Ethics Committee 
(Approval No: AEC_2013_24) ensuring compliance with the Western Australian 
Animal Welfare Act, 2002.  
 
9.2.2.3 Preparation of bacterial inocula for challenge 
BOAISRF S. aureus 51 was grown on MH agar plates at 37°C for 18h. The pure 
colonies were washed from the plates using 20 ml of isotonic saline and suspended in 
isotonic saline to give a final viable bacterial count of 4 x 10
11 
ml
-1
 (Anderson and 
Chandler, 1975). 
 
9.2.2.4 Challenge experiment 
A total of 24 mice vaccinated with 3 doses of Protein A were challenged on 3-5 days 
of lactation (Table 9.1). Both L5 and R5 mammary glands of 24 lactating mice from 
each treatment group were injected with 50 µl (CFU 2x10
10
) of CP8 positive, strong 
biofilm former strain, BOAISRF S. aureus 51 strain. Mice were challenged via intra-
mammary route using thirty one gauge needles. The mice were observed twice daily 
for morbidity and mortality until 5 days post-challenge. Percent protection against 
mouse mastitis was recorded and surviving mice euthanized after sampling blood and 
mammary glands.  
 
Table 9.1: Experimental groups of mice used in the immunogenicity and 
protective potential trials of Protein A vaccines (n=48) 
 
Sl. 
No 
Group Number of mice for 
immunogenicity trial 
Number of mice for 
protective potential trial 
1 Protein A s/c route 6 6 
2 Protein A i/mam route 6 6 
3 PBS control for s/c route  6 6 
4 PBS control for i/mam 
route 
6 6 
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9.2.2.5 Clinical observation  
The mammary glands of mice were observed for clinical signs of mastitis including 
redness, swelling and discolouration of mammary gland and extrusion of exudate 
with or without squeezing of the mammary gland (Chapter 6, Section 6.2.5.1).  
 
9.2.2.6 Bacterial load study of mammary glands 
The L5 mammary glands from control and test mice were collected and subjected to 
bacterial load study (Chapter 6, Section 6.2.5.2.1). 
 
9.2.2.7 Histological observation 
R5 mammary glands were collected from control and test mice were collected for 
histopathological examination (Chapter 6, Section 6.2.5.3.1). 
 
9.2.2.8 Statistical analysis 
To compare the antigen specific antibody levels, Interferon gamma (IFN-γ) levels 
and Log average number of bacteria (CFU) recovered from mammary glands 
between groups of mice immunized with planktonic and biofilm S. aureus vaccines, 
student’s t-test was performed. Statistical significance was set at p < 0.05.  
 
9.3 Results 
9.3.1 Detection of antigen-specific antibody in sera samples of mice vaccinated 
with ProteinA 
The titre of IgG, IgG1 and IgG2a was determined by using indirect ELISA. The 
overall titre of IgG, IgG1 and IgG2a in mice vaccinated by s/c route was 531.67 
±146.21, 306.67±58.35 and 116.67±17.45, respectively (Figure 9.1A) and 
242.5±9.29, 46.67±6.67 and 126.67±4.22, respectively for the mice vaccinated by 
i/mam route (Figure 9.1B). 
 
9.3.2 Interferon gamma (IFN-γ) levels in splenocyte supernatants 
Splenocytes of mice vaccinated with Protein A by both s/c and i/mam routes 
produced low levels of IFN-γ when stimulated with Protein A. However, splenocytes 
stimulated with ConA produced very how level of IFN-γ (5700 pg/ml). In s/c and 
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i/mam vaccination groups, IFN-γ levels in Splenocytes stimulated with Protein A 
produced 159±9.18 pg/ml and 186.34±20.09 pg/ml, respectively (Figure 9.2).  
 
 
Figure 9.1A: Antibody isotypes of mice vaccinated with Protein A by s/c route 
 
 
 
Figure 9.1B: Antibody isotypes of mice vaccinated with Protein A by i/mam 
route 
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Figure 9.2: Concentration of IFN-γ produced by splenocytes of Protein A 
stimulated mice immunized by Protein A using different routes.  
 
9.3.3 Clinical observation of mammary glands of challenged mice 
The control group showed signs of mastitis in the inoculated glands. All of the test 
mice showed varying degrees of changes in the gross clinical appearance of 
mammary glands (Table 9.2).     
 
Table 9.2:  Clinical signs observed in different groups of mice immunized with 
Protein A (Observations up to 5 days post challenge) 
 
Level of clinical signs* observed in test mice injected with Protein A 
 
Vaccination                     Day1            Day2           Day3           Day4            Day5 
 
ProteinA (s/c route)           ++              +++                 +++             +++              +++                                               
ProteinA (i/mam route)     ++              ++                    ++               +++              +++ 
PBS (s/c route)                  ++             +++                 +++              +++              +++                                
PBS (i/mam route)            ++             +++                 +++              +++              +++                                       
*Clinical features include redness, swelling, and discolouration of mammary gland, 
exudate,    morbidity and mortality. Grade scores compare observed features to the 
most severe changes: 0 - no macroscopic changes, + low grade, ++ medium grade, 
+++ severe grade. 
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9.3.4 Bacterial loads in the mammary glands of challenged mice 
The bacterial load of mammary gland of mice vaccinated with Protein A by i/mam 
route was 7.33±0.29 CFU compared to vaccination of mice by the s/c route with 
significantly higher (p<0.05) bacterial load of 8.18±0.14 CFU (Table 9.3). In paired t 
test between Protein A vaccine (s/c and i/mam routes) with control PBS immunized 
mice (s/c and i/mam routes) demonstrated significant difference (< 0.05) in bacterial 
load of mammary glands between Protien A (i/mam route) vaccinated and control 
mice. 
 
9.3.5 Histopathological observation of mammary glands of challenged mice 
Histopathological grade observed in the mammary tissue are shown in Table 9.2 and 
Figures 9.3-9.10. There was no significant difference (p>0.05) detected in 
histopathological grades of mammary tissue lesions between Protien A vaccinated 
and control mice. 
 
Table 9.3: Detection of bacterial load and histopathological changes in the 
mammary glands of mice immunized with Protein A 
 
Group Vaccine group Total number 
of mammary 
glands 
investigated 
 
Log average 
number of bacteria 
(CFU) 
recovered from 
mammary glands ± 
SE 
 
Grades for histopathological  
changes 
 
M1   M2       M3      M4       M5       M6 
1 ProteinA s/c 
route 
6 8.18±0.14 3 3 3 3 3 2 
2 ProteinA 
i/mam route 
6 7.33±0.29 3 3 3 3 2 3 
3 PBS control 
s/c route 
6 9.04±0.06 3 3 3 3 3 3 
4 PBS control 
i/mam route 
6 9.05±0.04 3 3 3 3 3 3 
      M*= Mammary gland 
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Figure 9.3: Mammary tissue specimen from lactating mouse immunized with 
Protein A vaccine (s/c route) and challenged using strong biofilm forming S. aureus 
51. Marked inflammatory cell infiltration within intralobular (A) and perilobular 
tissue (B). Level 3 category inflammation. H&E x 100mag. 
 
 
Figure 9.4: Mammary tissue specimen from lactating mouse immunized by Protein 
A vaccine (i/mam route) and challenged using strong biofilm forming S. aureus 51. 
Abscess in mammary tissue (A). Level 3 category inflammation. H&E x 100mag 
A 
B 
A 
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Figure 9.5: Mammary tissue specimen from lactating mouse immunized by Protein 
A vaccine (i/mam route) and challenged using strong biofilm forming S. aureus 51. 
Gram positive bacteria and associated inflammatory cell infiltrate (Arrow). Gram 
Twort x 400mag. 
 
Figure 9.6: Mammary tissue specimen from lactating mouse injected with PBS and 
challenged using strong biofilm forming S. aureus 51. Abscess in mammary tissue 
with tissue necrosis (A). Level 3 category inflammation. H&E x 40mag. 
A 
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Figure 9.7: Mammary tissue specimen from lactating mouse injected with PBS and 
challenged using strong biofilm forming S. aureus 51(from figure 9.6). 9.7(a) 
Inflammatory abscess shows inflammatory exudate in fibrinous capsule (A). ). 
Level 3 category inflammation.  H&E x 100mag. 9.7(b) Gram positive bacteria 
(Arrow) in inflammatory material Gram Twort x1000mag. 
 
9.4 Discussion  
The study of immune response generated by Protein A in the mouse mastitis model 
showed that mice vaccinated by subcutaneous and intra-mammary routes produced 
all the three antibody isotypes (IgG, IgG1 and IgG2a) in sera samples. However, the 
titre of all the three antibodies were significantly low, IgG2a being the lowest than 
those estimated for the killed whole cell biofilm vaccine (Refer Chapter 8 Section 
8.3.1.2). Intra-mammary route administration of protein A induced comparatively 
better IgG2a than the subcutaneous route. The detection of IFN-γ levels as indirect 
indicator of cell-mediated immunity in splenocyte supernatants in both subcutaneous 
and intra-mammary routes of vaccinated mice indicated production of lower levels of 
IFN-γ and intra-mammary route of vaccination producing slightly higher level of 
IFN-γ. 
 
Upon challenge by the CP8 positive, biofilm forming and S. aureus strain, the 
mortality rate and clinical symptoms developed in mice were recorded for up to 5 
days post-challenge. There was no mortality of mice up to 5 days post-challenge. 
However, varied levels of clinical symptoms were observed. There was no difference 
A 
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between the levels of clinical symptoms between PBS control and Protein A group of 
mice vaccinated by subcutaneous route. The group of mice which were vaccinated 
with Protein A by intra-mammary route showed medium level of clinical symptoms 
up to 3 days, though on 4
th
 day onwards there was no difference between the levels 
of clinical severity among all the groups of mice. 
 
The bacterial loads of the mammary glands of all the four groups of mice showed 
high bacterial load ranging from log average number (CFU) 7.33±0.29 to 9.05±0.04. 
However, the mammary glands of mice vaccinated by intra-mammary route had 
significantly lower numbers (p<0.05) of bacteria than the other groups. 
 
Histopathological analysis of the tissue sections did not project any difference 
between the mice immunized with Protein A using either subcutaneous or intra-
mammary routes or the control mice immunized using PBS. All the four groups of 
test and control mice showed almost identical picture of mammary tissue damage. 
 
It can be concluded that mice immunized with Protein A using subcutaneous or 
intramammary routes yielded antibody and cell-mediated immune responses that 
were significantly lower than those observed in mice vaccinated with the whole cell 
biofilm vaccine and failed to protect the mice which were challenged with CP8 
positive and strong biofilm producing S. aureus via i/mam route. Whether a 
conjugate vaccine (Protein A+CP8) will provide better immune responses and 
protection against challenge infection with S. aureus would be interesting to be 
determined.  
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Chapter 10: General discussion  
10.1 Summary 
Mastitis is the predominant intra-mammary infection in dairy cattle in Australia 
causing a huge economic loss to the dairy industry. Both clinical and subclinical 
bovine mastitis are responsible for reduction in milk production, deterioration of 
quality of milk and milk products, increased amount of health care expenditure, 
financial loss due to culling of sick animals and even mortality of cow. Despite 
application of various management practices and antibiotic therapy, mastitis is still 
an unresolved battle in dairy industry worldwide including Australia. 
 
S. aureus is the prominent causative contagious agent of bovine mastitis. During 
1960 to 1990, the predominant causative agent of bovine mastitis in Australia was S. 
aureus and S. agalactiae. However, in the past 20 years, the environmental pathogen 
such as S. uberis has become the predominant mastitis pathogen in Australia. While 
the incidence of mastitis due to environmental pathogens can be reduced by 
improvement in management practises such as cleaning of udder before and after 
milking, pre and post-milking teat dipping, adequate nutrition with selenium and 
vitamin E supplementation, use of teat sealant in dry cows, culling etc. The only 
effective treatment regimen against mastitis caused by S. aureus is the use of 
antimicrobial agents to combat intra-mammary infection. But ability of this pathogen 
to develop antibiotic resistance within a short span of time has made conservative 
treatment approach unsuccessful. Besides, those cases where treatment is successful 
to control mastitis, the somatic cell count remains higher or reduced and starts 
increasing after a short period (Melchior et al., 2006). Success of antibiotic therapy 
depends on various factors. These factors include serum protein binding, solubility of 
lipid, pKa value of used antimicrobial agent (Melchior et al., 2006), composition of 
antibiotic preparation (Du Preez, 2000), level of tissue damage in mammary gland 
(Shoshani et al., 2000). Due to these factors the cure rate of mastitis caused by 
bacterial pathogen ranges from 0-80% in general and only 0-52% for lactating 
animals (Melchior et al., 2006). 
 
Since 1990 there has been an increasing emphasis on another important aspect of S. 
aureus, the biofilm forming potential. Biofilm producing S. aureus can attach more 
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effectively to the epithelial lining of mammary gland to develop intra-mammary 
infection (Baselga et al., 1993). In fact, S. aureus isolated from mammary gland are 
more likely to form biofilm than S. aureus isolated from external sources including 
milking machine (Fox et al., 2005). Besides, bacteria growing in biofilm demonstrate 
10-1000 times increased resistance to antimicrobial therapy than its planktonic form 
of growth (Olson et al., 2002). This resistance to various antimicrobial agents may be 
due to delayed penetration of antimicrobial agents crossing the barrier of slimy 
biofilm matrix, modification in the growth rate of pathogen residing in biofilm and 
certain physiological and genotypic changes in pathogen residing in biofilm 
(Melchior et al., 2006). 
 
S. aureus produces a wide range of virulence factors ranging from capsular and 
surface polysaccharides, MSCRAMMS, toxins, superantigens, enzymes etc which 
make the S. aureus a versatile one among all the other bacterial pathogens associated 
with intramammary infection. Moreover, the mechanism of pathogenicity and 
protective immune mechanism against S. aureus are still not clear. In addition, S. 
aureus is capable of neutralizing the host immune response more effectively than any 
other bacterial pathogen (Lowy, 1998). All these factors have collectively 
contributed to the difficulty to develop a potential vaccine against S. aureus-
associated infections. Numerous clinical trials have been completed in both human 
and animals and different antigens have been targeted to stimulate immune responses 
which have all ended essentially in failure (Leitner et al, 2003b; Leitner et al., 2003c; 
Middleton, 2008).  
 
Various reasons can be hypothesized for the failure of developing an effective 
vaccine against S. aureus infections. These reasons include (a) failure to choose the 
right combination of antigens as vaccine candidates or (b) a reduction in opsonic 
killing capacity due to competitive inhibition of bacterial activity of antibodies 
directed against different antigens (Skurnik et al., 2010). Moreover, use of animal 
models although informative, cannot be equated to the actual host of the S. aureus 
associated-infection i.e the ruminant species.  
 
Taking into consideration the previous efforts of vaccine development and their 
failures, this project was undertaken using an entirely different approach. We decided 
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to evaluate the immunogenicity and protective potential of a vaccine candidate that 
should potentially present as many of the MSCRAMMS including the capsular 
polysaccharides and PNAG, hence to use killed whole cell of S. aureus residing in 
biofilm versus killed planktonic whole cell vaccine administered by s/c versus i/mam 
route. It was hypothesized that mice vaccinated with bacterins from strong biofilm 
producing S. aureus will generate better immune responses and confers better 
protection against mastitis following challenge with a biofilm producing S. aureus 
than a planktonic vaccine. The genes expressed by S. aureus in biofilm and host 
immune response against S. aureus in biofilm has been reported to be different from 
that induced by S. aureus cells in the planktonic form (Prignent-Combaret et al., 
1999). To arrive at our ultimate goal of formulating a suitable biofilm based vaccine 
against S. aureus-associated bovine mastitis in Australia, investigations on the 
biofilm forming potential of various clinical S. aureus isolates of bovine mastitis 
origin in Australia and prevalence of the detectable virulence factors in these isolates 
were carried out. Furthermore, a non-invasive method for production of mastitis in 
mice was developed to enable evaluation of the immunogenicity and protective 
potential of vaccine candidates. 
  
Virulence of Staphylococcus species in chronic and local infections like mastitis may 
be largely dependent on the bacterium’s ability to form biofilms (Mah and Toole, 
2001). Our study has evaluated the biofilm forming potential of 154 clinical isolates 
of S. aureus isolated from bovine mastitis in Australia using the Tissue Culture Plate 
(TCP) and the Congo Red Agar (CRA) methods. TCP method was found to be a 
better indicator test of biofilm-forming potential of S. aureus. A substantial number 
of biofilm-producing isolates was missed when the CRA method was used alone. 
TCP method could determine biofilm forming ability of 100% of the strains, whereas 
CRA method could detect only in 31.17% of the biofilm producing strains.  
 
Majority of the S. aureus strains used in this study were sensitive to the 12 different 
antibiotics used to perform antimicrobial susceptibility test. A total of 29 (18.83%) S. 
aureus strains were found to be resistant against penicillin which is followed by 
3.25% and 2.6% resistance against ciprofloxacin and erythromycin, respectively. 
Twenty eight S. aureus strains which were initially susceptible in planktonic form to 
12 different antibiotics were selected to confirm the development of resistance to 
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different antibiotics in the biofilm to many antibiotics developed but it also persisted 
for up to 4 weeks when grown as planktonic culture before reverting back to 
antibiotic susceptibility. The study suggests that (a) biofilm formation assays should 
be carried out using more than one method, and (b) antibiotic sensitivity tests on 
clinical samples should include both the planktonic and biofilm forming cultures, 
with a view to improving the therapeutic outcomes in the treatment of bovine 
mastitis caused by S aureus, and potentially other biofilm-producing pathogens.  
 
In the present study, >70% isolates producing biofilm were found to carry both icaA 
and icaD genes but the presence of ica locus was did not correlate with biofilm 
formation by the isolates. The present study also could not find a correlation between 
biofilm formation and presence of bap gene and agr types in S. aureus. The 
investigation also demonstrated lack of correlation between encapsulation and 
biofilm formation since non-encapsulated clinical S. aureus isolates were also found 
to form biofilms confirming results reported previously (Babra et al., 2013). 
 
Another study was conducted to determine the distribution of virulence factor-
encoding genes in the 154 clinical S. aureus isolates from bovine mastitis in 
Australia. By using serological methods and conventional PCR developed in this 
investigation, it was revealed that clfA (91.56%), clfB (92.86%), spa (87.7%), fnbpA 
(54.5%), isdA (98.1%), isdB (100%), sdrD (98.1%), sdrE (95.5%) genes were the 
predominant MSCRAMMS-encoding genes in S. aureus of clinical bovine mastitis 
origin. The predominant enterotoxin encoding genes were seh (32.5%), sec (23.4%), 
seg (17.5%) and sei (13%) in bovine S. aureus isolates, with sea, seb, sed, see, sej 
being detected in very low numbers ranging from 0.65-2.6%. However, detection of 
virulence factors in S. aureus isolates has been limited to the human origin in 
Australia. No information on the prevalence of virulence factors including 
MSCRAMMS, superantigens and cytotoxins associated with Australian bovine 
mastitis S. aureus isolates are available in the literature. This study suggests 
considering predominant MSCRAMMS such as ClfA, ClfB, ProteinA, isdA, isdB, 
SdrD, SdrE and FnBpA as potential vaccine candidates against bovine mastitis 
caused by S. aureus in Australia. Given the presence of the genes encoding α and β 
toxin in majority of the S. aureus isolates (94.16 % α toxin and 83.12 % β toxin) and 
their role in biofilm formation it is also important to consider these as important 
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potential vaccine candidates for the development of biofilm antigen based vaccine 
against bovine mastitis.  
 
S. aureus, a predominant contagious pathogen causing bovine mastitis, expresses 
capsular polysaccharides (CPs) which are important virulence determinant (Lee et 
al., 1987). CPs contribute to the virulence of S. aureus by resisting phagocytosis and 
thus allowing persistence of the pathogen in tissues of infected host and promoting 
formation of abscess (O’Riordan and Lee, 2004). Based on the recent classification 
suggested by Lee (2002), S. aureus CPs can be classified into four different types: 
CP1, CP2, CP5 and CP8. CP 1and CP2 and heavily capsulated and produces mucoid 
colonies on solid medium (Karakawa and Vann, 1982). However, CP 5 and CP8 S. 
aureus do not produce mucoid colonies and are the most prevalent CP types in 
clinical isolates from human as well as cows (Verdier et al, 2007; Gogoi-Tiwari et 
al., 2014 unpublished data). CP5 and CP8 S. aureus are referred as 
microencapsulated strains due to their ability to produce limited capsule in broth 
culture. The S. aureus isolates carrying none of the four CP types are classified as 
non typeable and majority of these strains were reported to possess a unique surface 
polysaccharide antigen 336 (Guidry et al., 1998), which are reported to be composed 
of polyribitol-phosphate-N-acetylglucosamine, a component of cell wall teichoic acid 
(Verdier et al., 2007).  
 
There is no data available in the literature on the prevalence of capsular 
polysaccharide types in S. aureus isolates of bovine mastitis origin in Australia. 
Gaining this knowledge is important for development and evaluation of vaccines as a 
strategy for prevention of bovine mastitis. Our study has determined the prevalence 
of the different capsular polysaccharide (CP) and the major surface-associated non-
CP antigen 336 (SP-336) types among 154 S. aureus isolated from bovine mastitis 
cases in Australia. Mouse antisera raised against CP types (CP1, CP2, CP5, and CP8) 
or SP-336 were used in slide agglutination tests and compared to detection of cap1, 
cap5 and cap8 gene fragments by PCR. Serological studies revealed the presence of 
CP2, CP5, CP8 and SP-336 in 9.09, 23.38, 31.82, and 5.84 percent of the Australian 
S. aureus isolates, respectively. By PCR, CP1, CP5 and CP8 accounted for 0, 26.62 
and 32.47 percent of the S. aureus isolates of mastitis origin in Australia. Both PCR 
and serological study have demonstrated that CP5 and CP8 were the predominant 
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capsular types in Australia. The study has also demonstrated a strong correlation 
between both the methods of typing used for CP1, CP5, CP8 and non-typeable S. 
aureus. Capsular staining method has confirmed the result of serological detection of 
capsule in S. aureus isolates. Besides, out of 55 non typeable strains detected in 
serological method, 13 S. aureus strains were found to be positive for capsules in 
negative staining method. This is an important finding of this study which suggests 
that there may be more than the 5 (4 CP types and 1 SP type) recognised types of CP 
and SP in S. aureus as proposed originally by Karakawa and Vann (1982). 
 
Variety of intra-mammary inoculation techniques have been used to produce mastitis 
in the mouse model system. However, However, these techniques have included 
inoculation of bacterial suspension by dropping it on the tip of mammary teat and 
allowing absorption (Anderson, 1979), inoculation of bacterial pathogen by passing a 
micropipette of less than 75µm diameter through teat canal (Lee et al., 2003), 
injection of inoculum by using a 30 gauge needle after incising the near end of teat 
(Brouillette and Malouin, 2005) and surgical exposure of mammary gland followed 
by injection of bacterial suspension into primary duct by using a 30 gauge needle 
(Nguyen et al., 2000). These methods have one or the other disadvantages such as 
trauma and rupture of the mammary teat leading to failure of the techniques or 
chance of secondary bacterial contamination at the inoculation site. While 
standardizing the mouse mastitis model, one of the objectives was to improvise the 
method of inoculating mammary gland without traumatising the teat lactiferous duct 
or the tissue encasing the gland with the intention of mimicking the natural mode of 
infection. Besides, the study was undertaken to determine the impact of the strength 
of biofilm formation on the extent of damage to the mammary tissue caused by 
encapsulated S. aureus isolates using the non-invasive mouse mastitis model system 
developed in this project. 
 
Four strains of S. aureus of the same capsular phenotype (CP8) but variable in the 
strength of biofilm formation were used in this study. The delivery of the infectious 
dose of S. aureus, performed without invasive scraping of the teat surface, was 
carried out directly through the teat lactiferous duct using a syringe fitted with a 
blunt ended 31-gauge hypodermic needle. Histopathological analysis showed that 
mice infected with encapsulated (CP8) strong biofilm forming S. aureus with icaA 
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and icaD genes produced marked acute mastitis lesions characterised by a profuse 
inflammatory infiltration with evidence of necrosis in the mammary glands (Chapter 
6 Figure 6.1d). The damage was significantly less severe in tissue sections from mice 
injected with the weak biofilm-forming S. aureus in absence of icaA and icaD genes 
(Chapter 7 Figure 7.1). A significant increase in the inflammatory cytokines IL-1 
and TNF- level determined by flow cytometry was found to correlate with the 
extent of the tissue damage suggesting a potential role of biofilm formation and 
inflammatory cytokines in the pathology of bovine mastitis. This study has 
demonstrated that mastitis can be successfully produced in the mouse model by 
direct inoculation of S. aureus into the mammary gland via the mammary duct 
without scrapping off the mammary gland surface epithelium or glands. The 
bacteriological and histopathological study revealed proliferation of the bacteria as 
well as inflammatory infiltrates in mammary glands and not in the blood or liver or 
spleen ruling out sepsis. Use of a direct delivery inoculum in a mouse mastitis model 
may minimise the chance of secondary bacterial infection with skin associated 
opportunistic pathogens such as Pasteurella pneumotropica, S. aureus and 
Corynebacterium bovis (Baker, 1998), which can occur in the case of invasive mouse 
mastitis model where the tip of the mammary gland is scrapped or incised 
(Brouillette and Malouin, 2005; Brouillette et al., 2005).  
 
Given the finding that strength of biofilm formation by encapsulated S. aureus 
correlated with extent of tissue damage to the mammary gland with no observed 
mortality. It was important to determine if the same would hold true for strong versus 
weak biofilm forming non-capsulated i.e non-typeable S. aureus. However, 
surprising and unexpected finding was made. Mice infected with two different non-
typeable strains strong biofilm forming BOAISRF S. aur 83 versus weak biofilm 
forming BOAISRF S. aur 87 showed surprising results. All the mice inoculated by 
BOAISRF S. aureus 83 and 87 died within 24 and 30 h of post infection, 
respectively. However, the histopathological analysis of mammary tissue damage 
revealed minimal inflammatory infiltrates in the mammary gland. This was 
unexpected because of the absence of one major immune evading capsular antigen. 
Flow cytometry analysis of sera samples collected from mice immediately before 
death showed higher levels of IL-1β, IL-6, IL-10, IL-17A, IFN-γ and TNF-α than the 
sera of control mice.  The highly elevated level of various cytokines can lead to 
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cytokine storm, a fatal immune response which may result in sudden death 
(Osterholm, 2005) as human patients died due to cytokine storm despite higher levels 
of anti-inflammatory cytokine, IL-10 but the presence of pro-inflammatory 
cytokines, IL-1β, IL-6 and TNF-α in serum samples (Horst, 2002). The pro-
inflammatory cytokines IL-1β, IL-6 and TNF-α produced by BOAIRSF S. aureus 83 
was significantly higher (p < 0.05) than those induced by and BOAIRF S. aureus 87 
infection. The level of IL-6 in serum sample of mice injected with the BOAISRF S. 
aureus 83 was as high as 15479.9±532 pg/mL. The reason for the observed quick 
mortality in mice infected with NT S. aureus strains used in this project was not 
investigated due to time constraints. However, our hypothesis is that the presence of 
capsular polysaccharides attenuates the release of the pore forming toxins such alpha 
and beta toxins and superantigenic exotoxins such the enterotoxins in vivo. Since the 
NT strains used in this project were non-encapsulated, significantly more toxins 
would have been released in vivo, hence the observed quick mortality. Validation of 
this hypothesis warrants further investigations.   
 
Based on this observation, anti-IL-6 and IL-6Rβ antibodies were selected for use in 
the immunotherapy experiment. The study revealed that mortality was delayed for 12 
h 30 min and 13 h 15 min in the mice treatment with anti-IL-6 and anti-IL-6R 
antibodies, respectively. Severity of mastitis was also reduced in terms of clinical 
symptoms as was the bacterial load of the mammary glands. The clinical 
menifestations were reduced from medium to low grade and there was significant 
difference in the load of S. aureus in the mammary glands of mice treated with anti-
IL-6 and IL-6Rβ antibodies versus the PBS control groups. Although not completely 
prevented, but delaying of mortality time provides a window for treatment with 
antibiotics to prevent mortality due to infection with S. aureus. Whether this delay is 
sufficient for antimicrobial therapy resulting in prevention of death needs to be 
determined. However, the time constraint associated with the submission of this 
thesis and the end date of IPRS scholarship prevented accomplishment of this 
objective. 
 
An important aim of this project was to compare the immunogenicity and protective 
potential of planktonic versus biofilm S. aureus vaccine for the prevention of mastitis 
using mouse as a model system. It was discovered that mice immunised with 
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planktonic vaccine by the s/c route induced high levels of the antibody IgG1 but 
lower levels of IgG2a, and the cytokine IFN-γ, indirect indicators of the induction of 
CMI. The immunogenicity and protective potential of the planktonic S. aureus 
vaccine delivered by the intra-mammary route, although yielded slightly lower 
immune responses, the protective potential was similar to that obtained with the s/c 
route of administration. On the other hand, high levels of IgG and IgG2a antibody 
isotypes and IFN-γ were induced when the biofilm vaccine was administered by 
i/mam route. Our approach was different from the previously reported data in that the 
protective potential of antibodies raised by active immunisation of mice with select 
biofilm antigens against systemic challenge as an indicator of protective potential 
(Maira Litran et al., 2005; Prenafeta et al., 2010; Skurnik et al., 2010; Gil et al., 
2014). In this study i/mam route was used for vaccination as well as challenge. This 
is the first time in the world that superiority of biofilm S. aureus vaccine given by 
i/mam route over the planktonic vaccine has been demonstrated. 
 
 
Protein A, a surface-associated molecule of S. aureus is an important member of 
MSCRAMMS, is not only an immune evasion molecule of S. aureus, is present in 
over 80% of the isolates and also mediates formation of biofilm in mammary gland, 
it was decided to study the immunogenicity and protective potential of this protein 
against bovine mastitis using the non-invasive mouse mastitis model developed in 
this project. It was hypothesized that if the immunogenicity and protective potential 
of this molecule was found to be significant, a vaccine composed of Protein A 
conjugated with the purified CP8, the predominant capsular polysaccharide in the 
Australian bovine S. aureus isolates could be formulated for testing as a prototype 
vaccine candidate. Mice immunized with Protein A by the s/c or i/mam routes and 
challenged with biofilm forming, CP8 positive S. aureus strain revealed no 
difference between the levels of clinical symptoms between PBS control and Protein 
A groups of mice. The mice group which was vaccinated by Protein A by intra-
mammary route showed medium level of clinical symptoms up to 3 days, though on 
4thday onwards there was no difference between the levels of clinical severity 
among all the groups of mice. Bacterial load study and histopathological analysis of 
tissue damage in mammary glands of vaccinated mice did not show any difference 
from the control group of mice.  
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Mice immunized with ProteinA by subcutaneous and intra-mammary routes 
produced all the three antibody isotypes (IgG, IgG1 and IgG2a) in sera samples. 
However, the titre of all the three antibodies were low and IgG2a being the lowest. 
Similarly, IFN-γ levels in splenocyte supernatants of mice immunized by intra-
mammary route produced slightly higher level of IFN-γ than the subcutaneous route, 
but overall the levels of IFN-γ in spelocyte supernatant was very low. Since Protein 
A failed to produce desired immune response to prevent intra-mammary infection in 
mice, the planned study involving development of a conjugate vaccine using CP8 
(Predominant capsular type in S. aureus of bovine mastitis origin in Australia) and 
Protein A was cancelled. 
 
This study was therefore concluded with the findings that a vaccine comprising of 
formalin killed whole cell of S. aureus residing in biofilm and delivered via i/mam 
route induced a significant cell mediated immune responses (IFN-γ) and protection 
against mastitis caused by S. aureus and significantly reduced the colonization of S. 
aureus in mammary gland, severity of clinical symptoms and tissue damage in 
mammary gland was lessened. The planktonic vaccine although produced 
significantly higher humoral immune response ((IgG1 and IgG), damage to the 
mammary tissue and clinical severity upon challenge could not be prevented. 
 
 10.2 Conclusion 
(a) Comparative study of CRA and TCP method for detection of biofilm formation 
by the154 strains of S. aureus revealed that TCP method could determine biofilm 
forming ability of 100% of the strains. Whereas CRA method could only detect only 
31.17% of the biofilm producing strains proving superiority of TCP method over 
CRA method. 
 
(b) A high percentage (over 70%) of isolates were positive for both icaA and icaD 
genes, with only 2 (1.3%) of the strains being positive for bap gene. The present 
study could not find any correlation between biofilm formation and presence of ica 
loci, bap gene or agr types. 
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(c) All the 154 S. aureus strains of bovine mastitis origin against 12 different 
antimicrobial agents revealed all (100%) strains to be sensitive to cefoxitin, an 
indirect indicator of methicillin sensitivity. This was confirmed using chromogenic 
culture media plates, Genotype-MRSA kit and conventional PCR. 
 
(d) Twenty eight selected S. aureus strains were subjected to persistence of antibiotic 
resistance study which were initially susceptible to 12 different antibiotics. All the 
strains developed resistance to more than one antibiotic after formation of biofilm 
and the resistance persisted as long as 4 weeks. 
   
(e) The current study highlighted that clfA (91.56%), clfB (92.86%), spa (87.7%), 
fnbpA (54.5%), isdA (98.1%), isdB (100%), sdrD (98.1%) and sdrE (95.5%) were the 
predominant microbial surface component recognizing adhesive matrix molecules 
(MSCRAMMS) in S. aureus of bovine mastitis origin. 
 
(f) The predominant cytotoxins produced by the S. aureus isolates were α-toxin 
(94.16%), β-toxin (83.12%). The potential super antigenic enetrotoxins produced 
were seh (32.5%), sec (23.4%), seg (17.5%) and sei (13%), respectively. The 
detection of 4 strains (2.6%) of S. aureus positive for pvl gene is an important finding 
as pvl genes are not common in bovine mastitis cases. 
 
(g) This study revealed that majority of the Australian bovine mastitis-associated S. 
aureus isolates (64.29%) expressed capsule, of which, CP8 was predominant 
(31.82%), followed closely by CP5 (23.38%). In addition, 5.84% (nine of 154) of the 
isolates were positive for SP-336 and 30% of the isolates were non-typeable. The 
study further demonstrated that there was strong correlation between the serological 
and genotyping methods for detection of CP types 1, 5 and 8, and the non-typeable S. 
aureus isolates.  
 
 (h) The strength of biofilms produced by S. aureus appears to contribute to the 
mammary tissue damage. Histopathological analysis showed that mice infected with 
encapsulated (CP8) strong biofilm forming S. aureus produced marked acute mastitis 
lesions showing a profuse inflammatory infiltration with evidence of necrosis in the 
mammary glands. The damage was significantly less severe in sections of tissue from 
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mice injected with the weak biofilm forming S. aureus CP8 strain and there appeared 
to be correlation between S. aureus load in the mammary gland and associated tissue 
damage. 
 
(i) This study has demonstrated that mastitis can be reliably produced in a mouse 
model by direct inoculation of S. aureus into the mammary gland via the mammary 
duct without traumatising the mammary gland surface epithelium or glands. 
Inflammatory cytokine, TNF-α was significantly higher (p<0.05) in sera sample of 
mice inoculated with the strong biofilm forming S. aureus than the weak biofilm 
forming strain even 48 h post infection. 
 
(j) The mammary glands of mice infected with non-typeable strain of S. aureus with 
strong biofilm forming potential had significantly higher (≤0.05) load of S. aureus in 
mammary glands than the mammary glands of mice infected with non-typeable non-
biofilm forming S. aureus strain. Although there was no significant difference 
observed in the level of tissue damage in mammary glands of mice infected with 
non-typeable biofilm producing and non-biofilm producing strains, a significantly 
high level of inflammatory cytokines particularly IL-6 was produced resulting in the 
death of animals within 48 h of post inoculation. 
 
(k) Treatment of mice with anti-IL6 and anti IL6-Rβ antibodies delayed that 
mortality of mice up to 13h 15 min. Severity of mastitis was also reduced in terms of 
clinical symptoms and bacterial load from the mammary glands of immunized mice. 
 
(l) This study demonstrated that mice immunized with Protein A using subcutaneous 
and intra-mammary routes failed to show enhanced cell-mediated or humoral 
immune response. The vaccine failed to protect the mice which were challenged with 
CP8 positive and strong biofilm producing S. aureus via i/mam route and there was 
no significant difference in the level of tissue damage between immunized and 
control mice raising a question on its usefulness as a carrier protein in conjugate 
vaccine formulations in the future. 
 
(m) A vaccine comprising of killed whole cell of S. aureus residing in biofilm and 
delivered via i/mam route was found to induce protective cell mediated immune 
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response against bovine mastitis in caused by S. aureus mouse model and reduced 
the colonization of S. aureus in mammary gland, severity of clinical symptoms and 
tissue damage in mammary gland of mice was lessened. 
 
10.3 Future directions 
(1) Given the finding of this project that biofilm forming S. aureus bacterins induce 
better antibody and cell-mediated immune responses and protection against 
intramammary challenge with the virulent pathogen, it is important to identify the 
nature of the biofilm- associated antigens and determine their relative contribution to 
the colonisation of mammary gland with a view to formulate the most effective 
vaccine capable of giving protection against bovine mastitis. 
 
(2) Given the knowledge that production of high levels of interleukin 6 (IL-6) in 
mice challenged with non-typeable S. aureus isolates may have a role to play in per 
acute death of mice post-challenge as judged by a delay in the time of death upon 
administration of anti-IL-6 or anti IL-6Rβ antibodies, urgent attention on the 
prevention of mortality by treatment with a suitable antibiotic should also be an 
important priority. 
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Appendix A 
A.1 Buffers, Solutions and Media  
 
1xPBS 
Ingredients                Grams 
NaCl                             8 
KCl                            0.2 
Na2HPO4                           1.44 
KH2PO4                     0.24g 
 
The mixture was dissolved in 800 ml of distilled water and PH was adjusted to 7.4. 
The volume was adjusted to 1L adding additional distilled water and autoclaved at 
121°C for 15 minutes. 
 
50 mM sodium acetate buffer 
Ingredients                          Millilitre 
Acetic acid (0.2M)                 7.4 ml 
Sodium acetate (0.2 M)       17.6 ml 
The volume was adjusted to 100 ml using distilled water. 
 
50x TAE (Tris-acetate-EDTA) buffer 
Ingredients                          Gram/Millilitre 
Tris base                                     22241 g 
Glacial acetic acid                      57.1 ml 
EDTA (0.5 M)                           100 ml 
 
The volume was adjusted to 1L by adding distilled water. To make 1xTAE 20ml of 
50xTAE stock to 980 ml of distilled water. 
 
0.5 M EDTA  
93.5 g of Disodium ethylene diamine tetra-acetate, 2H20 was added to 400 ml of 
distilled water. The volume was adjusted to 500 ml by adding distilled water and 
autoclaved at 121°C for 15 minutes. 
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Agar rose gel (1.5%) 
1.5g Agarose  
100 ml 1X TAE buffer 
 
Blocking buffer (ELISA) 
Ingredients                          Gram/Millilitre 
Tris base                                 1.21 g 
Tween-20                                0.50 ml 
 1% PBS                              999.50 ml 
 
The stock was stored at 4ºC. 
 
Carbonate bicarbonate coating buffer (ELISA) 
Ingredients                          Gram/Millilitre 
Na2CO3                                  1.59 g 
NaHCO3                                                   2.94 g 
Distilled water                        900 ml 
 
PH was adjusted to 9.6 and volume was adjusted to 1 L.  
 
Congo red agar 
Ingredients                          Gram/Millilitre 
Congo red                                  0.4 g 
Glucose                                      10 g 
Blood agar base                          40 g 
Distilled water                      1L 
 
Autoclaving was done at 121°C for 15 minutes. 
 
Mueller Hinton agar 
 
Ingredients                       Grams/Litre 
Beef infusion solids                4.0 
Starch                                      1.5 
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Casein hydrolysate                17.5 
Agar                                      15.0 
Final pH was adjusted to 7.4. 
 
Thirty eight  gram of  Mueller Hinton agar was suspended in 1 litre of distilled water, 
brought to the boil for complete dissolving of media and  autoclaved at 121°C for 15 
minutes. 
 
NaCl (0.9%) 
9 g of NaCl was dissolved in 1 L of distilled water and autoclaved at 121°C for 15 
minutes. 
 
Nutrient broth 
 
Ingredients                       Grams/Litre 
Peptone                                    5.0 
NaCl                                        5.0 
Beef extract                             1.5 
Yeast extract                           1.5 
 
Thirteen gram of the mixture was suspended in 1L of distilled water and mixed 
thoroughly to dissolve the medium. Final pH was adjusted to 7.4 and autoclaved at 
121°C for 15 minutes. 
 
Sodium borate buffer (20X) 
NaOH                      8g  
Boric acid             47g  
Distilled water     900 ml 
 
It was mixed thoroughly. The final volume was adjusted to 1 L by adding distilled 
water. 
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Substrate buffer (ELISA) 
Ingredients                          Gram/Millilitre 
Diethanolamine                        106 g 
MgSO4. 7H2O                        0.249 g  
Distilled water                          800 ml 
The PH was adjusted to 10 and the volume was made up to 1L using distilled water. 
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APPENDIX B 
Complementary data for Chapters 3 to 9 
B.1 Chapter 3 
Table 1: List of samples used in the project 
Sl.No Sample Species Organism Sample no 
1 Milk Bovine S.aureus BoAISRF-S.aur25 
2 Milk Bovine S.aureus BoAISRF-S.aur26 
3 Milk Bovine S.aureus BoAISRF-S.aur27 
4 Milk Bovine S.aureus BoAISRF-S.aur30
 
5 Milk Bovine S.aureus BoAISRF-S.aur31 
6 Milk Bovine S.aureus BoAISRF-S.aur32 
7 Milk Bovine S.aureus BoAISRF-S.aur33 
8 Milk Bovine S.aureus BoAISRF-S.aur34 
9 Milk Bovine S.aureus BoAISRF-S.aur35 
10 Milk Bovine S.aureus BoAISRF-S.aur36 
11 Milk Bovine S.aureus BoAISRF-S.aur37 
12 Milk Bovine S.aureus BoAISRF-S.aur38 
13 Milk Bovine S.aureus BoAISRF-S.aur39 
14 Milk Bovine S.aureus BoAISRF-S.aur40 
15 Milk Bovine S.aureus BoAISRF-S.aur41 
16 Milk Bovine S.aureus BoAISRF-S.aur42 
17 Milk Bovine S.aureus BoAISRF-S.aur43 
18 Milk Bovine S.aureus BoAISRF-S.aur44 
19 Milk Bovine S.aureus BoAISRF-S.aur45 
20 Milk Bovine S.aureus BoAISRF-S.aur46 
21 Milk Bovine S.aureus BoAISRF-S.aur47 
22 Milk Bovine S.aureus BoAISRF-S.aur48 
23 Milk Bovine S.aureus BoAISRF-S.aur49 
24 Milk Bovine S.aureus BoAISRF-S.aur50 
25 Milk Bovine S.aureus BoAISRF-S.aur51 
26 Milk Bovine S.aureus BoAISRF-S.aur52 
27 Milk Bovine S.aureus BoAISRF-S.aur53 
28 Milk Bovine S.aureus BoAISRF-S.aur54 
29 Milk Bovine S.aureus BoAISRF-S.aur55 
30 Milk Bovine S.aureus BoAISRF-S.aur56 
31 Milk Bovine S.aureus BoAISRF-S.aur57 
32 Milk Bovine S.aureus BoAISRF-S.aur58 
33 Milk Bovine S.aureus BoAISRF-S.aur59 
34 Milk Bovine S.aureus BoAISRF-S.aur60 
35 Milk Bovine S.aureus BoAISRF-S.aur61 
36 Milk Bovine S.aureus BoAISRF-S.aur62 
37 Milk Bovine S.aureus BoAISRF-S.aur63 
38 Milk Bovine S.aureus BoAISRF-S.aur64 
39 Milk Bovine S.aureus BoAISRF-S.aur65 
40 Milk Bovine S.aureus BoAISRF-S.aur66 
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Sl.No Sample Species Organism Sample no 
41 Milk Bovine S.aureus BoAISRF-S.aur67 
42 Milk Bovine S.aureus BoAISRF-S.aur69 
43 Milk Bovine S.aureus BoAISRF-S.aur70 
44 Milk Bovine S.aureus BoAISRF -S.aur71 
45 Milk Bovine S.aureus BoAISRF -S.aur72 
46 Milk Bovine S.aureus BoAISRF -S.aur73 
47 Milk Bovine S.aureus BoAISRF -S.aur75
 
48 Milk Bovine S.aureus BoAISRF -S.aur76 
49 Milk Bovine S.aureus BoAISRF -S.aur77 
50 Milk Bovine S.aureus BoAISRF -S.aur78 
51 Milk Bovine S.aureus BoAISRF -S.aur79 
52 Milk Bovine S.aureus BoAISRF -S.aur80 
53 Milk Bovine S.aureus BoAISRF-S.aur81 
54 Milk Bovine S.aureus BoAISRF-S.aur82 
55 Milk Bovine S.aureus BoAISRF-S.aur83 
56 Milk Bovine S.aureus BoAISRF-S.aur84 
57 Milk Bovine S.aureus BoAISRF-S.aur85 
58 Milk Bovine S.aureus BoAISRF-S.aur86 
59 Milk Bovine S.aureus BoAISRF-S.aur87 
60 Milk Bovine S.aureus BoAISRF -S.aur88 
61 Milk Bovine S.aureus BoAISRF-S.aur89 
62 Milk Bovine S.aureus BoAISRF-S.aur90 
63 Milk Bovine S.aureus BoAISRF-S.aur91 
64 Milk Bovine S.aureus BoAISRF-S.aur92 
65 Milk Bovine S.aureus BoAISRF-S.aur93 
66 Milk Bovine S.aureus BoAISRF-S.aur94 
67 Milk Bovine S.aureus BoAISRF-S.aur95 
68 Milk Bovine S.aureus BoAISRF-S.aur96 
69 Milk Bovine S.aureus BoAISRF-S.aur97 
70 Milk Bovine S.aureus BoAISRF-S.aur98 
71 Milk Bovine S.aureus BoAISRF-S.aur99 
72 Milk Bovine S.aureus BoAISRF-S.aur100 
73 Milk Bovine S.aureus BoAISRF-S.aur101 
74 Milk Bovine S.aureus BoAISRF-S.aur102 
75 Milk Bovine S.aureus BoAISRF-S.aur103 
76 Milk Bovine S.aureus BoAISRF-S.aur104 
77 Milk Bovine S.aureus BoAISRF-S.aur105 
78 Milk Bovine S.aureus BoAISRF-S.aur106 
79 Milk Bovine S.aureus BoAISRF-S.aur107 
80 Milk Bovine S.aureus BoAISRF-S.aur108 
81 Milk Bovine S.aureus BoAISRF-S.aur109 
82 Milk Bovine S.aureus BoAISRF-S.aur110 
83 Milk Bovine S.aureus BoAISRF-S.aur111 
84 Milk Bovine S.aureus BoAISRF-S.aur112 
85 Milk Bovine S.aureus BoAISRF-S.aur113 
86 Milk Bovine S.aureus BoAISRF-S.aur114 
87 Milk Bovine S.aureus BoAISRF-S.aur115 
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88 Milk Bovine S.aureus BoAISRF-S.aur116 
89 Milk Bovine S.aureus BoAISRF-S.aur117 
90 Milk Bovine S.aureus BoAISRF-S.aur118 
91 Milk Bovine S.aureus BoAISRF-S.aur119 
92 Milk Bovine S.aureus BoAISRF-S.aur120 
93 Milk Bovine S.aureus BoAISRF-S.aur121 
94 Milk Bovine S.aureus BoAISRF-S.aur122 
95 Milk Bovine S.aureus BoAISRF-S.aur123 
96 Milk Bovine S.aureus BoAISRF-S.aur124 
97 Milk Bovine S.aureus BoAISRF-S.aur125 
98 Milk Bovine S.aureus BoAISRF-S.aur126 
99 Milk Bovine S.aureus BoAISRF-S.aur127 
100 Milk Bovine S.aureus BoAISRF-S.aur128 
101 Milk Bovine S.aureus BoAISRF-S.aur129 
102 Milk Bovine S.aureus BoAISRF-S.aur130 
103 Milk Bovine S.aureus BoAISRF-S.aur131 
104 Milk Bovine S.aureus BoAISRF-S.aur132 
105 Milk Bovine S.aureus BoAISRF-S.aur133 
106 Milk Bovine S.aureus BoAISRF-S.aur134 
107 Milk Bovine S.aureus BoAISRF-S.aur135 
108 Milk Bovine S.aureus BoAISRF-S.aur136 
109 Milk Bovine S.aureus BoAISRF-S.aur137 
110 Milk Bovine S.aureus BoAISRF-S.aur138 
111 Milk Bovine S.aureus BoAISRF-S.aur139 
112 Milk Bovine S.aureus BoAISRF-S.aur140 
113 Milk Bovine S.aureus BoAISRF-S.aur141 
114 Milk Bovine S.aureus BoAISRF-S.aur142 
115 Milk Bovine S.aureus BoAISRF-S.aur143 
116 Milk Bovine S.aureus BoAISRF-S.aur144 
117 Milk Bovine S.aureus BoAISRF-S.aur145 
118 Milk Bovine S.aureus BoAISRF-S.aur146 
119 Milk Bovine S.aureus BoAISRF-S.aur147 
120 Milk Bovine S.aureus BoAISRF-S.aur148 
121 Milk Bovine S.aureus BoAISRF-S.aur149 
122 Milk Bovine S.aureus BoAISRF-S.aur150 
123 Milk Bovine S.aureus BoAISRF-S.aur151 
124 Milk Bovine S.aureus BoAISRF-S.aur152 
125 Milk Bovine S.aureus BoAISRF-S.aur153 
126 Milk Bovine S.aureus BoAISRF-S.aur154 
127 Milk Bovine S.aureus BoAISRF-S.aur155 
128 Milk Bovine S.aureus BoAISRF-S.aur156 
129 Milk Bovine S.aureus BoAISRF-S.aur157 
130 Milk Bovine S.aureus BoAISRF-S.aur158 
131 Milk Bovine S.aureus BoAISRF-S.aur159 
132 Milk Bovine S.aureus BoAISRF-S.aur160 
133 Milk Bovine S.aureus BoAISRF-S.aur161 
134 Milk Bovine S.aureus BoAISRF-S.aur162 
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Table 2: List of strains used as positive controls in the project 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl.No Sample Species Organism Sample no 
135 Milk Bovine S.aureus BoAISRF-S.aur163 
136 Milk Bovine S.aureus BoAISRF-S.aur165
 
137 Milk Bovine S.aureus BoAISRF-S.aur166 
138 Milk Bovine S.aureus BoAISRF-S.aur167 
139 Milk Bovine S.aureus BoAISRF-S.aur168 
140 Milk Bovine S.aureus BoAISRF-S.aur169 
141 Milk Bovine S.aureus BoAISRF-S.aur170 
142 Milk Bovine S.aureus BoAISRF-S.aur171 
143 Milk Bovine S.aureus BoAISRF-S.aur172 
144 Milk Bovine S.aureus BoAISRF-S.aur173 
145 Milk Bovine S.aureus BoAISRF-S.aur174 
146 Milk Bovine S.aureus BoAISRF-S.aur175 
147 Milk Bovine S.aureus BoAISRF-S.aur176 
148 Milk Bovine S.aureus BoAISRF-S.aur177 
149 Milk Bovine S.aureus BoAISRF-S.aur178 
150 Milk Bovine S.aureus BoAISRF-S.aur179 
151 Milk Bovine S.aureus BoAISRF-S.aur180 
152 Milk Bovine S.aureus BoAISRF-S.aur181 
153 Milk Bovine S.aureus BoAISRF-S.aur182 
154 Milk Bovine S.aureus BoAISRF-S.aur183 
Sl.No Species Organism Sample no 
1 Human S.aureus Strain M (CP1) 
2 Human S.aureus Strain Smith Diffuse (CP2) 
3 Human S.aureus Strain Newman (CP5) 
4 Human S.aureus NRS 648 (CP5) 
5 Human S.aureus USA 400 (CP8) 
6 Human S.aureus LAC (Non-Capsulated) 
7 Human S.aureus NRS 680 (Non-Capsulated) 
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Table 3: Production of biofilm and detection of icaA and icaD genes in 154 
bovine S. aureus isolates 
 
BOAISRF S. aur    
Strain 
icaA icaD  OD value (TCP 
method) 
25 ✓ ✓ 0.865 
26 ✓ ✓ 0.548 
27 ✓ ✓ 0.346 
30 ✓ ✓ 0.406 
31 ✓ ✓ 0.474 
32 ✓ ✓ 0.515 
33 ✓ ✓ 0.206 
34 ✓ ✓ 0.558 
35 ✓ ✓ 0.941 
36 ✓ ✓ 0.455 
37 ✓ − 0.985 
38 ✓ ✓ 0.332 
39 ✓ ✓ 0.394 
40 ✓ ✓ 0.597 
41 − ✓ 1.413 
42 ✓ ✓ 0.222 
43 ✓ − 0.878 
44 ✓ − 0.347 
45 ✓ − 1.839 
46 ✓ ✓ 0.684 
47 ✓ ✓ 0.611 
48 ✓ ✓ 0.881 
49 ✓ ✓ 0.64 
50 ✓ ✓ 0.779 
51 ✓ ✓ 1.298 
52 − ✓ 0.339 
53 − ✓ 0.494 
54 ✓ ✓ 0.528 
55 ✓ ✓ 0.482 
56 ✓ ✓ 0.344 
57 − ✓ 0.22 
58 ✓ ✓ 0.284 
59 ✓ ✓ 0.448 
60 ✓ ✓ 1.162 
61 ✓ ✓ 0.574 
62 ✓ ✓ 0.491 
63 ✓ ✓ 0.443 
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BOAISRF S. aur    
Strain 
icaA icaD OD value (TCP method) 
64 ✓ ✓ 0.26 
65 ✓ ✓ 0.741 
66 ✓ ✓ 0.434 
67 ✓ ✓ 0.342 
69 ✓ ✓ 0.556 
70 − ✓ 0.217 
71 ✓ ✓ 0.561 
72 ✓ ✓ 0.424 
73 ✓ ✓ 0.572 
75 − ✓ 1.022 
76 − ✓ 0.712 
77 ✓ ✓ 0.42 
78 − ✓ 0.799 
79 − − 0.302 
80 − − 0.907 
81 − − 0.289 
82 − ✓ 0.468 
83 ✓ ✓ 0.775 
84 − ✓ 0.251 
85 − − 0.507 
86 − ✓ 0.404 
87 − − 0.367 
88 − ✓ 0.243 
89 − − 0.328 
90 − − 0.468 
91 − ✓ 0.725 
92 − − 0.251 
93 − ✓ 0.507 
94 − ✓ 0.404 
95 − ✓ 0.368 
96 ✓ ✓ 0.243 
97 ✓ ✓ 0.44 
98 ✓ ✓ 0.313 
99 ✓ ✓ 0.632 
100 ✓ ✓ 0.301 
101 ✓ ✓ 0.448 
102 ✓ ✓ 0.172 
103 ✓ ✓ 0.825 
104 − − 0.494 
105 ✓ ✓ 0.818 
106 ✓ − 0.615 
107 ✓ ✓ 0.295 
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BOAISRF S. 
aur    Strain 
icaA icaD  OD value (TCP 
method) 
108 ✓ ✓ 0.514 
109 ✓ ✓ 0.355 
110 ✓ ✓ 0.613 
111 ✓ ✓ 0.483 
112 ✓ ✓ 0.754 
113 − ✓ 0.24 
114 ✓ ✓ 0.679 
115 ✓ ✓ 0.352 
116 ✓ ✓ 0.239 
117 ✓ ✓ 0.194 
118 ✓ ✓ 0.259 
119 ✓ ✓ 0.172 
120 ✓ ✓ 0.359 
121 ✓ ✓ 0.34 
122 ✓ ✓ 0.63 
123 ✓ ✓ 0.777 
124 ✓ ✓ 0.228 
125 ✓ ✓ 0.231 
126 ✓ ✓ 0.246 
127 ✓ ✓ 0.248 
128 ✓ ✓ 0.304 
129 − − 0.345 
130 − − 0.427 
131 − ✓ 0.325 
132 − − 0.225 
133 ✓ ✓ 0.335 
134 − ✓ 0.294 
135 ✓ ✓ 0.143 
136 ✓ ✓ 0.402 
137 ✓ ✓ 0.398 
138 ✓ ✓ 0.24 
139 ✓ ✓ 0.446 
140 ✓ ✓ 0.425 
141 − ✓ 0.264 
142 ✓ ✓ 0.235 
143 ✓ ✓ 0.303 
144 ✓ ✓ 0.556 
145 − ✓ 0.405 
146 − ✓ 0.273 
147 − − 0.268 
148 ✓ ✓ 0.428 
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The arbitrary cut-off point used for nonbiofilm-producing strains was 0.120 
(Stepanovic et al., 2000). The arbitrary cut-off points used for weakly, intermediate 
or strongly adherent bacterial populations were 0.130–4.00×0.120 A570nm, 4.10–
5.90×0.120 A570nm and greater than 6×0.120 A570nm, respectively. 
 
 
 
 
BOAISRF S. 
aur    Strain 
icaA icaD  OD value (TCP 
method) 
149 ✓ ✓ 0.208 
150 − ✓ 0.13 
151 ✓ ✓ 0.292 
152 ✓ ✓ 0.301 
153 ✓ ✓ 0.393 
154 ✓ ✓ 0.295 
155 − ✓ 0.237 
156 ✓ ✓ 0.191 
157 ✓ ✓ 0.183 
158 ✓ ✓ 0.258 
159 ✓ ✓ 0.316 
160 ✓ ✓ 0.511 
161 ✓ ✓ 0.298 
162 ✓ ✓ 0.432 
163 ✓ ✓ 0.287 
165 − ✓ 0.093 
166 ✓ ✓ 0.199 
167 ✓ ✓ 0.488 
168 − ✓ 0.297 
169 − − 0.162 
170 − − 0.256 
171 − − 0.221 
172 − − 0.137 
173 − − 0.364 
174 ✓ ✓ 0.426 
175 − − 0.275 
176 ✓ ✓ 0.295 
177 − − 0.408 
178 ✓ ✓ 0.269 
179 ✓ ✓ 0.233 
180 ✓ − 0.254 
181 ✓ ✓ 0.491 
182 ✓ ✓ 0.283 
183 ✓ ✓ 0.276 
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Table 4: Detection of bap, blaz and agr types in 154 bovine S. aureus isolates 
 
S.aureus strain  bap gene blaz gene agr type 
25 
- 
+ I 
26 
- 
- I 
27 
- 
- - 
30 
- 
- I 
31 
- 
- III 
32 
- 
- III 
33 
- 
- III 
34 
- 
- III 
35 
- 
- I 
36 
- 
+ I 
37 
- 
+ I 
38 
- 
+ I 
39 
- 
+ I 
40 
- 
- 
 
41 
- 
- III 
42 
- 
- - 
43 
- 
- I 
44 
- 
- I 
45 
- 
- I 
46 
- 
- III 
47 
- 
- III 
48 
- 
- I 
49 
- 
- III 
50 
- 
- III 
51 
- 
- III 
52 
- 
- III 
53 
- 
- - 
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S.aureus strain bap gene blaz gene agr type 
54 
 
- - 
 
- 
 
55 
- - 
 
- 
 
56 
- 
- I 
57 
- 
- I 
58 
- 
- - 
59 
- 
+ I 
60 
- 
- I 
61 
- 
- III 
62 
- 
- I 
63 
- 
+ - 
64 
- 
- I 
65 
- 
- III 
66 
- 
- I 
67 
- 
- I 
69 
- 
- I 
70 
- 
- - 
71 
- 
- - 
72 
- 
- I 
73 
- 
- III 
75 
- 
- III 
76 
- 
- III 
77 
- 
+ I 
78 
- 
+ I 
79 
- 
- II 
80 
- 
- III 
81 
- 
- I 
82 
- 
+ III 
83 
- 
- - 
84 
- 
- I 
85 
- 
- I 
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S.aureus strain  bap gene blaz gene agr type 
86 
- 
- I 
87 
- 
- I 
88 
- 
- I 
89 
- 
- I 
90 
- 
- I 
91 
- 
- I 
92 
- 
- III 
93 
- 
- I 
94 
- 
- I 
95 
- 
- I 
96 
- 
- I 
97 
- 
- - 
98 
- 
- I 
99 
- 
+ I 
100 
- 
- I 
101 
- 
- I 
102 
- 
- III 
103 
- 
- I 
104 
- 
- - 
105 
- 
- I 
106 
- 
- I 
107 
- 
- I 
108 
- 
- I 
109 
- 
- I 
110 
- 
- I 
111 
- 
- III 
112 
- 
- I 
113 
- 
+ I 
114 
- 
- II 
115 
- 
- III 
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S.aureus 
strain bap gene blaz gene agr type 
116 
- 
- III 
117 
- 
+ I 
118 
- 
+ III 
119 
- 
- III 
120 
- 
- I 
121 
- 
- I 
122 
- 
- I 
123 
- 
- I 
124 
- 
- - 
125 
- 
- I 
126 
- 
- III 
127 
- 
- - 
128 
- 
- III 
129 
- 
- I 
130 
- 
- I 
131 
- 
- I & III 
132 
- 
- I 
133 
- 
+ I 
134 
- 
- I 
135 
- 
+ III 
136 
- 
+ III 
137 
- 
- I 
138 
- 
+ I 
139 
- 
- I 
140 
- 
+ I 
141 
- 
+ III 
142 
- 
- I 
143 
- 
- I 
144 
- 
- I 
145 
- 
- I 
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S.aureus 
strain bap gene blaz gene agr type 
146 + - - 
147 
- 
+ - 
148 
- 
- III 
149 
- 
- III 
150 
- 
- I 
151 
- 
+ - 
152 
- 
- III 
153 
- 
- I 
154 
- 
- I 
155 
- 
- I 
156 
- 
- III 
157 
- 
- III 
158 
- 
- III 
159 
- 
- I 
160 
- 
- I 
161 
- 
- III 
162 
- 
- I 
163 
- 
- III 
165 
- 
+ - 
166 
- 
+ III 
167 
- 
+ III 
168 
- 
+ - 
169 
- 
- - 
170 
- 
- - 
171 
- 
+ - 
172 
- 
- - 
173 
- 
+ I 
174 
- 
+ III 
175 
- 
- - 
176 
- 
+ III 
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S.aureus 
strain 
bap gene 
 
 
blaz gene 
 
 
agr type 
 
177 
- 
- - 
178 
- 
+ III 
179 
- 
- III 
180 
- 
- III 
181 
- 
- - 
182 
- 
- - 
183 + - I 
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              B 2: Chapter 4 
 
 
               Table 1: Detection of various toxin genes in 154 bovine S. aureus isolates 
 
S. aureus  strain α-Toxin β-Toxin SEA SEB SEC SED SEE SEG SHE SEI SEJ 
25 + + - - + - - + - + - 
26 + + - - - - - - - - - 
27 + - - - - - - - - - - 
30 + + - - - - - - - - - 
31 + + - - - - - - + - - 
32 + + - - - - - - + - - 
33 + + - - - - - - + - - 
34 + + - - - - - - + - - 
35 + + - - - - - - - - - 
36 + + - - - - - - - - - 
37 + + - - - - - - - - - 
38 + + - - - - - - - - - 
39 + + - - - - - - - - - 
40 + + - - + - - + - + - 
41 + + - - - - - - + - - 
42 + + - - + - - + - + - 
43 + + - - + - - - - - - 
44 + + - - + - - - - - - 
45 + + - - + - - - - - - 
46 + + - - + - - - + - - 
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S. aureus  strain α-Toxin β-Toxin SEA SEB SEC SED SEE SEG SHE SEI SEJ 
47 + + - - - - - - + - - 
48 + + - - - - - - - - - 
49 + + - - - - - - + - - 
50 + + - - - - - - + - - 
51 + + - - - - - - + - - 
52 + - - - - - - - + - - 
53 + + - - - - - - + - - 
54 + - - - + - - + - + - 
55 + + - - - - - - + - - 
56 + + - - - - - - - - - 
57 + + - - - - - - - - - 
58 + - - - - - - + - + - 
59 + + - - - - - - - - - 
60 + - - - - - - - - - - 
61 + + - - - - - - + - - 
62 + + - - - - - - - - - 
63 + - - - - - - - - - - 
64 + + - - - - - - - - - 
65 + + - - - - - - + - - 
66 + + - - - - - - - - - 
67 - + - - - - - - - - - 
69 + + - - - - - - - - - 
70 + - - - - - - + - + - 
71 + + - - + - - + - + - 
72 + + - - - - - - - - - 
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S. aureus  strain α-Toxin β-Toxin SEA SEB SEC SED SEE SEG SHE SEI SEJ 
73 + - - - - - - - + - - 
75 - + - - - - - - + - - 
76 + + - - - - - - + - - 
77 + + - - - - - - - - - 
78 + + - - - - - - - - - 
79 + + - - - + - + - + - 
80 + + - - + - - - + - - 
81 + + - - - - - - - - - 
82 + + - - - - - - + - - 
83 + + - - + + - + - + - 
84 + + - - - - - - - + - 
85 + + - - - - - - - - - 
86 + + - - - - - - - - - 
87 + + - - - - - - - - - 
88 + + - - - - - - - - - 
89 + - - - - - - - - - - 
90 + + - - - - - - - - - 
91 + - - - - - - - + - - 
92 + + - - - - - - + - - 
93 + + - - - - - - - - - 
94 + + - - - - - - + - - 
95 + + - - - - - - - - - 
96 + + - - - - - - - - + 
97 + - - - - - - - - - - 
98 + + - - - - - - + - - 
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S. aureus  strain α-Toxin β-Toxin SEA SEB SEC SED SEE SEG SHE SEI SEJ 
99 + + - - - - - - + - - 
100 + - - - - - - - - - - 
101 + + - - - - - - - - - 
102 + + - - - - - - + - - 
103 + + - - - - - - - - - 
104 + + - - - - - - - - - 
105 + + - - - - - - - - - 
106 + + - - - - - - - - - 
107 + + - - - - - - - - - 
108 + + - - - - - - - - - 
109 + + - - - - - - - - - 
110 + + - - - - - + - - - 
111 + + - - + - - - + - - 
112 + + - - - - - - - - - 
113 + + - - + - - - - - - 
114 + + - - + - - + - + - 
115 + + - - + - - + + - - 
116 + - - - + - - + + - - 
117 + + - - - - - + + + - 
118 + + - - - - - + + + - 
119 + + - - - - - - + - - 
120 + + - - - - - - - - - 
121 + + - - - - - - - - - 
122 + + - - - - - - - - - 
123 + + - - + - - - - - - 
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S. aureus  strain α-Toxin β-Toxin SEA SEB SEC SED SEE SEG SHE SEI SEJ 
124 + + - - + - - + - + - 
125 + + + - - - - + - - + 
126 + - - - - - - - + - - 
127 + + - - + - - + - + - 
128 + - - - + - - - + - - 
129 + + - - - - - - - - - 
130 + + - - - - - - - - - 
131 + + - - - - - - - - - 
132 + + - - - - - - - - - 
133 + + - - + - - - + - - 
134 + + - - + - - - - - - 
135 + - - - + - - + - - - 
136 + + - - + - - + + - - 
137 + + - - + - - - - - - 
138 + + - - + - - - - - - 
139 + + - - - - - + - - - 
140 + + - - - - - - - - - 
141 + + - - + - - + - - - 
142 + + - - - - - - - + - 
143 + + - - + - - + - - - 
144 + + - - + - - - - + - 
145 + + - - + - - - - - - 
146 + + - - - - - + - - - 
147 + + + - - - + - + - - 
148 + + - - - - - - + - - 
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S. aureus  strain α-Toxin β-Toxin SEA SEB SEC SED SEE SEG SHE SEI SEJ 
149 + + - - - - - - + - - 
150 + + + - - - - - - - - 
151 - + + + - - - - - - - 
152 + + - - - - - - + - - 
153 + + - - - - - - - - - 
154 + + - - - - - - - - - 
155 + - - - - - - - - - - 
156 + + - - - - - - + - - 
157 + + - - - - - - - - - 
158 + + - - - - - - + - - 
159 + + - - - - - - - - - 
160 + + - - - - - - - - - 
161 + + - - - - - - - - - 
162 + + - - - - - - + - - 
163 + + - - - - - - - - - 
165 - - - - - - - - - - - 
166 + + - - - - - - - - - 
167 + - - - - - - - - - - 
168 + + - - - - - - - - - 
169 + - - - - - - - - - - 
170 - + - - - - - - - - - 
171 - - - - - - - - - + - 
172 + - - - - - - - - - - 
173 - - - - - - - - - - - 
174 + + - - - - - - - - - 
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S. aureus  strain α-Toxin β-Toxin SEA SEB SEC SED SEE SEG SHE SEI SEJ 
175 - - - - - - - - - - - 
176 + + - - - - - - - - - 
177 + - - - - - - - - - - 
178 - + - - + - - - - - - 
179 + + - - + - - - + + - 
180 + + - - + - - - + - - 
181 + - - - + - - + + - - 
182 + + - - + - - + + + - 
183 + + - - + - - + + - - 
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              Table 2: Detection of MSCRAMMS genes in 154 bovine S. aureus isolates  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. aureus  strain FnBPb FnBPa SpA Cna ClfA ClfB bbp isdA isdB sdrD sdrE 
25 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
26 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
27 ✓ - ✓ - ✓ ✓ - ✓ ✓ - ✓ 
30 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
31 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
32 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
33 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
34 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
35 - ✓ ✓ - - ✓ - ✓ ✓ ✓ ✓ 
36 - ✓ ✓ - - ✓ - ✓ ✓ ✓ ✓ 
37 - ✓ ✓ - - ✓ - ✓ ✓ ✓ ✓ 
38 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
39 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
40 - ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
41 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
42 - - ✓ - ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
43 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
44 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
45 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
46 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
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S. aureus  strain FnBPb FnBPa SpA Cna ClfA ClfB bbp isdA isdB sdrD sdrE 
47 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
48 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
49 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
50 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ - 
51 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
52 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
53 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
54 - ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
55 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
56 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
57 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
58 - - ✓ - ✓ ✓ ✓ ✓ ✓ - ✓ 
59 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ - 
60 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
61 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
62 - - ✓ ✓ ✓ ✓ - - ✓ ✓ ✓ 
63 - ✓ ✓ - ✓ ✓ - - ✓ ✓ ✓ 
64 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
65 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
66 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
67 - ✓ ✓ - ✓ - - ✓ ✓ ✓ ✓ 
69 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
70 - ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
71 - ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
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S. aureus  
strain 
FnBPb FnBPa SpA Cna ClfA ClfB bbp isdA isdB sdrD sdrE 
72 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
73 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
75 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
76 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
77 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
78 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
79 - -  - ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
80 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
81 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
82 - - - - ✓ ✓ - ✓ ✓ ✓ ✓ 
83 - - ✓ - ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
84 - - - - ✓ ✓ - ✓ ✓ ✓ ✓ 
85 - - - - ✓ ✓ - ✓ ✓ ✓ ✓ 
86 - - - - - ✓ - ✓ ✓ ✓ ✓ 
87 - - - - ✓ ✓ - ✓ ✓ ✓ ✓ 
88 - - - - ✓ ✓ - ✓ ✓ ✓ ✓ 
89 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
90 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
91 - - - - ✓ ✓ - ✓ ✓ ✓ ✓ 
92 - - - ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
93 - - - - ✓ ✓ - ✓ ✓ ✓ - 
94 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
95 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
96 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
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S. aureus  
strain 
FnBPb FnBPa SpA Cna ClfA ClfB bbp isdA isdB sdrD sdrE 
97 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
98 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
99 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
100 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
101 - - ✓ - ✓ ✓ - ✓ - ✓ ✓ 
102 - ✓ - ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
103 - ✓ - - ✓ ✓ - ✓ ✓ ✓ ✓ 
104 - - - ✓ - ✓ - ✓ ✓ ✓ ✓ 
105 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
106 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
107 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
108 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
109 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
110 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
111 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
112 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
113 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ - 
114 - ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
115 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
116 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
117 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
118 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
119 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
120 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
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S. aureus  
strain 
FnBPb FnBPa SpA Cna ClfA ClfB bbp isdA isdB sdrD sdrE 
121 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
122 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
123 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
124 - - ✓ - ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
125 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
126 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
127 - - ✓ - ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
128 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
129 - - - - ✓ ✓ - ✓ ✓ ✓ ✓ 
130 - - - - ✓ ✓ - ✓ ✓ ✓ ✓ 
131 - - - - ✓ ✓ - ✓ ✓ ✓ ✓ 
132 - - - - ✓ ✓ - ✓ ✓ ✓ ✓ 
133 - - ✓ ✓ ✓ ✓ - - ✓ ✓ ✓ 
134 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
135 - - - - ✓ ✓ - ✓ ✓ ✓ ✓ 
136 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
137 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
138 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
139 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
140 ✓ - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
141 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
142 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
143 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
144 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
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S. aureus  
strain 
FnBPb FnBPa SpA Cna ClfA ClfB bbp isdA isdB sdrD sdrE 
145 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
146 - - ✓ - - - - ✓ ✓ ✓ - 
147 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
148 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
149 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
150 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
151 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
152 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
153 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
154 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
155 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
156 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
157 - - ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
158 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
159 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
160 - - ✓ ✓ ✓ ✓ - ✓ - ✓ ✓ 
161 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
162 - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 
163 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
165 - - ✓ - ✓ - - ✓ ✓ ✓ - 
166 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
167 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
168 - - ✓ - ✓ - - ✓ ✓ ✓ - 
169 - - ✓ - - - - ✓ ✓ ✓ ✓ 
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S. aureus  
strain 
FnBPb FnBPa SpA Cna ClfA ClfB bbp isdA isdB sdrD sdrE 
170 - - ✓ - - - - ✓ ✓ ✓ ✓ 
171 - - ✓ - - - - ✓ ✓ ✓ ✓ 
172 - - ✓ - - - - ✓ ✓ ✓ ✓ 
173 - - ✓ - - - ✓ ✓ ✓ ✓ ✓ 
174 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
175 - - ✓ - - - - ✓ ✓ ✓ ✓ 
176 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
177 - - ✓ - - - - ✓ ✓ ✓ ✓ 
178 - - ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
179 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
180 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
181 - -  - ✓ ✓ ✓ ✓ ✓ - ✓ 
182 - ✓ ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ 
183 - ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
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B. 3: Chapter 5 
 
Table 1: Table 5.1: Prevalence of capsular/surface polysaccharide genotypes and phenotypes in 154 bovine S. aureus isolates  
                   
Sl. 
No 
S aureus bovine 
strain 
Detection of capsular genotype 
by PCR method 
 Detection of capsular serotype  by 
Slide Agglutination test 
 
CP1 
 
CP2 
 
 
CP5 
 
CP8 
 
 
CP1 
 
CP2 
 
 
CP5 
 
CP8 
 
SP336 
 
1 BoAISRF-S.aur25 - - - - - √ - - - 
2 BoAISRF-S.aur26 - - - √ - - - √ - 
3 BoAISRF-S.aur27 - - - √ - - - √ - 
4 BoAISRF-S.aur30 - - √ - - - √ - - 
5 BoAISRF-S.aur31 - - - √ - - - √ - 
6 BoAISRF-S.aur32 - - - √ - - - √ - 
7 BoAISRF-S.aur33 - - - √ - - - √ - 
8 BoAISRF-S.aur34 - - - √ - - - √ - 
9 BoAISRF-S.aur35 - - √ - - - √ - - 
10 BoAISRF-S.aur36 - - √ - - - √ - - 
11 BoAISRF-S.aur37 - - √ - - - √ - - 
12 BoAISRF-S.aur38 - - √ - - - √ - - 
13 BoAISRF-S.aur39 - - √ - - - √ - - 
14 BoAISRF-S.aur40 - - √ - - - √ - - 
15 BoAISRF-S.aur41 - - - √ - - - √ - 
16 BoAISRF-S.aur42 - - - √ - - - √ - 
17 BoAISRF-S.aur43 - - - √ - - - √ - 
18 BoAISRF-S.aur44 - - √ - - - √ - - 
19 BoAISRF-S.aur45 - - - - - - - - √ 
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20 BoAISRF-S.aur46 - - - √ - - - √ - 
21 BoAISRF-S.aur47 - - - √ - - - √ - 
22 BoAISRF-S.aur48 - - - √ - - - √ - 
23 BoAISRF-S.aur49 - - √ - - - √ - - 
24 BoAISRF-S.aur50 - - - √ - - - √ - 
25 BoAISRF-S.aur51 - - - √ - - - √ - 
26 BoAISRF-S.aur52 - - - - - √ - - - 
27 BoAISRF-S.aur53 - - - √ - - - √ - 
28 BoAISRF-S.aur54 - - - √ - - - √ - 
29 BoAISRF-S.aur55 - - - √ - - - √ - 
30 BoAISRF-S.aur56 - - - √ - - - √ - 
31 BoAISRF-S.aur57 - - - - - - - - - 
32 BoAISRF-S.aur58 - - - √ - - - √ - 
33 BoAISRF-S.aur59 - - √ - - - √ - - 
34 BoAISRF-S.aur60 - - √ - - - - - - 
35 BoAISRF-S.aur61 - - - √ - - - √ - 
36 BoAISRF-S.aur62 - - - - - - - - - 
37 BoAISRF-S.aur63 - - - √ - - - √ - 
38 BoAISRF-S.aur64 - - √ - - - - - - 
39 BoAISRF-S.aur65 - - - √ - - - √ - 
40 BoAISRF-S.aur66 - - - - - - - - - 
41 BoAISRF-S.aur67 - - √ - - - √ - - 
42 BoAISRF-S.aur69 - - - - - - - - - 
43 BoAISRF-S.aur70 - - - √ - - - √ - 
44 BoAISRF -.aur71 - - - √ - - - √ - 
45 BoAISRF-S.aur72 - - - √ - - - √ - 
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46 BoAISRF-S.aur73 - - - √ - - - √ - 
47 BoAISR -S.aur75 - - - √ - - - √ - 
48 BoAISRF-S.aur76 - - - √ - - - √ - 
49 BoAISRF-S.aur77 - - √ - - - √ - - 
50 BoAISRF-S.aur78 - - √ - - - √ - - 
51 BoAISRF-S.aur79 - - - - - √ - - - 
52 BoAISRF-S.aur80 - - - - - √ - - - 
53 BoAISRF-S.aur81 - - - - - √ - - - 
54 BoAISRF-S.aur82 - - - - - - - - √ 
55 BoAISRF-S.aur83 - - - - - - - - - 
56 BoAISRF-S.aur84 - - - - - - - - - 
57 BoAISRF-S.aur85 - - - - - - - - - 
58 BoAISRF-S.aur86 - - - - - - - - √ 
59 BoAISRF-S.aur87 - - - - - - - - - 
60 BoAISRF-S.aur88 - - - - - √ - - - 
61 BoAISRF-S.aur89 - - - - - - - - - 
62 BoAISRF-S.aur90 - - - - - - - - - 
63 BoAISRF-S.aur91 - - - - - √ - - - 
64 BoAISRF-S.aur92 - - - - - - - - - 
65 BoAISRF-S.aur93 - - - - - - - - √ 
66 BoAISRF-S.aur94 - - - - - - - - - 
67 BoAISRF-S.aur95 - - - - - - - - - 
68 BoAISRF-S.aur96 - - - - - - - - - 
69 BoAISRF-S.aur97 - - - - - - - - √ 
70 BoAISRF-S.aur98 - - - - - - - - - 
71 BoAISRF-S.aur99 - - √ - - - √ - - 
72 BoAISRF-S.aur100 - - √ - - - - - - 
73 BoAISRF-S.aur101 - - - - - √ - - - 
74 BoAISRF-S.aur102 - - - √ - - - √ - 
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75 BoAISRF-S.aur103 - - √ - - - √ - - 
76 BoAISRF-S.aur104 - - - √ - - - √ - 
77 BoAISRF-S.aur105 - - - - - √ - - - 
78 BoAISRF-S.aur106 - - - - - - - - - 
79 BoAISRF-S.aur107 - - - - - - - - - 
80 BoAISRF-S.aur108 - - - - - - - - - 
81 BoAISRF-S.aur109 - - √ - - - √ - - 
82 BoAISRF-S.aur110 - - √ - - - √ - - 
83 BoAISRF-S.aur111 - - - √ - - - √ - 
84 BoAISRF-S.aur112 - - - - - - - - - 
85 BoAISRF-S.aur113 - - - - - - - - - 
86 BoAISRF-S.aur114 - - - - - √ - - - 
87 BoAISRF-S.aur115 - - - - - √ - - - 
88 BoAISRF-S.aur116 - - - √ - - - √ - 
89 BoAISRF-S.aur117 - - - √ - - - √ - 
90 BoAISRF-S.aur118 - - - √ - - - √ - 
91 BoAISRF-S.aur119 - - - √ - - - √ - 
92 BoAISRF-S.aur120 - - √ - - - √ - - 
93 BoAISRF-S.aur121 - - √ - - - √ - - 
94 BoAISRF-S.aur122 - - - - - - - - - 
95 BoAISRF-S.aur123 - - - - - - - - √ 
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96 BoAISRF-S.aur124 - - - √ - - - √ - 
97 BoAISRF-S.aur125 - - √ - - - √ - - 
98 BoAISRF-S.aur126 - - - √ - - - √ - 
99 BoAISRF-S.aur127 - - - √ - - - √ - 
100 BoAISRF-S.aur128 - - - - - - - - - 
101 BoAISRF-S.aur129 - - - - - - - - - 
102 BoAISRF-S.aur130 - - - - - √ - - - 
103 BoAISRF-S.aur131 - - - - - - - - - 
104 BoAISRF-S.aur132 - - - - - - - - - 
105 BoAISRF-S.aur133 - - - √ - - - √ - 
106 BoAISRF-S.aur134 - - - - - - - - - 
107 BoAISRF-S.aur135 - - - - - - - - - 
108 BoAISRF-S.aur136 - - - √ - - - √ - 
109 BoAISRF-S.aur137 - - - - - - - - - 
110 BoAISRF-S.aur138 - - √ - - - √ - - 
111 BoAISRF-S.aur139 - - - - - - - - - 
112 BoAISRF-S.aur140 - - √ - - - - - - 
113 BoAISRF-S.aur141 - - - √ - - - √ - 
114 BoAISRF-S.aur142 - - - - - - - - √ 
115 BoAISRF-S.aur143 - - - - - - - - - 
116 BoAISRF-S.aur144 - - - - - - - - - 
117 BoAISRF-S.aur145 - - √ - - - √ - - 
118 BoAISRF-S.aur146 - - √ - - - √ - - 
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119 BoAISRF-S.aur147 - - - - - - - - √ 
120 BoAISRF-S.aur148 - - - √ - - - - - 
121 BoAISRF-S.aur149 - - - √ - - - √ - 
122 BoAISRF-S.aur150 - - √ - - - √ - - 
123 BoAISRF-S.aur151 - - - √ - - - √ - 
124 BoAISRF-S.aur152 - - - √ - - - √ - 
125 BoAISRF-S.aur153 - - √ - - - √ - - 
126 BoAISRF-S.aur154 - - - - - - - - - 
127 BoAISRF-S.aur155 - - √ - - - √ - - 
128 BoAISRF-S.aur156 - - - √ - - - √ - 
129 BoAISRF-S.aur157 - - - √ - - - √ - 
130 BoAISRF-S.aur158 - - - √ - - - √ - 
131 BoAISRF-S.aur159 - - √ - - - √ - - 
132 BoAISRF-S.aur160 - - √ - - - √ - - 
133 BoAISRF-S.aur161 - - √ - - - √ - - 
134 BoAISRF-S.aur162 - - - √ - - - √ - 
135 BoAISRF-S.aur163 - - √ - - - √ - - 
136 BoAISRF-S.aur165 - - - - - √ - - - 
137 BoAISRF-S.aur166 - - √ - - - √ - - 
138 BoAISRF-S.aur167 - - √ - - - √ - - 
139 BoAISRF-S.aur168 - - - - - - - - - 
140 BoAISRF-S.aur169 - - - - - - - - - 
141 BoAISRF-S.aur170 - - - - - - - - - 
142 BoAISRF-S.aur171 - - - - - - - - - 
143 BoAISRF-S.aur172 - - - - - - - - - 
144 BoAISRF-S.aur173 - - - - - - - - - 
145 BoAISRF-S.aur174 - - √ - - - √ - - 
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146 BoAISRF-S.aur175 - - - - - - - - - 
147 BoAISRF-S.aur176 - - √ - - - √ - - 
148 BoAISRF-S.aur177 - - - - - √ - - - 
149 BoAISRF-S.aur178 - - - - - - - - √ 
150 BoAISRF-S.aur179 - - √ - - - - - - 
151 BoAISRF-S.aur180 - - - - - - - - - 
152 BoAISRF-S.aur181 - - √ - - - √ - - 
153 BoAISRF-S.aur182 - - √ - - - √ - - 
154 BoAISRF-S.aur183 - - - √ - - - √ - 
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B. 4: Chapter 6 
 
Table 1A: Total viable counts of S. aureus recovered from mammary glands 48 
h post-harvest 
 
Group Raw 
value 
x80x104 log10 
117.1 67 53600000 7.729165 
117.2 67 53600000 7.729165 
117.3 65 52000000 7.716003 
117.4 66 52800000 7.722634 
48.1 104 83200000 7.920123 
48.2 104 83200000 7.920123 
48.3 103 82400000 7.915927 
48.4 104 83200000 7.920123 
51.1 150 1.2E+08 8.079181 
51.2 153 1.22E+08 8.087781 
51.3 150 1.2E+08 8.079181 
51.4 149 1.19E+08 8.076276 
104.1 43 34400000 7.536558 
104.2 44 35200000 7.546543 
104.3 40 32000000 7.50515 
104.4 41 32800000 7.515874 
 
 
Table 1B: Total viable counts of S. aureus recovered from mammary glands 48 
h post-harvest 
 
Group Average Standard 
deviation 
Standard 
error 
117 7.724242 0.006296271 0.003148136 
48 7.919074 0.002098057 0.001049029 
51 8.080605 0.004976383 0.002488191 
104 7.526031 0.018892152 0.009446076 
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Table 1.C: Statistical analysis of Total viable counts of S. aureus recovered from 
mammary glands 48 h post-harvest 
 
 
 
117                            48                              51                              104 
 
53600000             83200000             120000000           34400000 
53600000             83200000             122400000           35200000 
52000000             82400000             120000000           32000000 
52800000             83200000             119200000           32800000 
 
 
oneway DV Group, bonferroni tabulate 
  
            |            Summary of DV 
      Group |        Mean   Std. Dev.       Freq. 
------------+------------------------------------ 
          1 |    53000000   765941.69           4 
          2 |    83000000      400000           4 
          3 |   1.204e+08   1385640.6           4 
          4 |    33600000   1460593.5           4 
------------+------------------------------------ 
      Total |    72500000    33869239          16 
  
                        Analysis of Variance 
    Source              SS         df      MS            F     Prob > F 
------------------------------------------------------------------------ 
Between groups      1.7192e+16      3   5.7308e+15   4775.69     0.0000 
Within groups      1.4400e+13     12   1.2000e+12 
------------------------------------------------------------------------ 
    Total           1.7207e+16     15   1.1471e+15 
  
Bartlett's test for equal variances:  chi2(3) =   4.4389  Prob>chi2 = 0.218 
  
                          Comparison of DV by Group 
                                (Bonferroni) 
Row Mean-| 
Col Mean |          1          2          3 
---------+--------------------------------- 
       2 |    3.0e+07 
         |      0.000 
         | 
       3 |    6.7e+07    3.7e+07 
         |      0.000      0.000 
         | 
       4 |   -1.9e+07   -4.9e+07   -8.7e+07 
         |      0.000      0.000      0.000 
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Table 2 : Flow cytometry data analysis  
 
IL10 48 51 117 104 
 
12.15587 3.842962 4.127976 6.550594 
 
11.01581 5.054271 3.629202 9.020714 
 
14.49217 3.842962 4.983017 7.76114 
 
12.60332 7.619396 4.49217 5.07726 
     avg 12.70377 5.505543 4.36813 7.286371 
SD 1.44716 1.780386 0.572347 1.685185 
SE 0.72358 0.890193 0.286173 0.842593 
     IL12 13.25523 1.468591 1.094724 7.017558 
 
8.69012 2.767286 0.937307 8.57405 
 
12.80664 0.976661 1.252142 8.69012 
 
14.40049 3.495342 2.452451 10.71687 
avg 12.28812 2.17697 1.434156 8.74965 
SD 2.490775 1.158896 0.690924 1.517067 
SE 1.245388 0.579448 0.345462 0.758533 
     IL17A 2.345293 0.147321 1.112028 2.37838 
 
2.583525 0.150469 1.138691 1.588685 
 
2.998225 0.067911 1.233543 1.571038 
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2.645288 0.068852 1.165161 1.14972 
avg 2.643083 0.108638 1.162356 1.671956 
SD 0.269788 0.046504 0.052181 0.512797 
SE 0.134894 0.023252 0.02609 0.256399 
     IFN-γ 8.114035 12.58865 7.640868 8.04124 
 
8.525782 11.09635 7.888825 8.380191 
 
4.144436 7.952521 8.40294 14.71563 
 
7.548 7.75916 7.117654 13.01632 
avg 7.083063 9.84917 7.762572 11.03835 
SD 1.99967 2.38227 0.534398 3.34082 
SE 0.999835 1.191135 0.267199 1.67041 
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B. 5: Chapter 7 
 
Table 1A: Table 1A: Total viable counts of S. aureus recovered from mammary 
glands 48 h post-harvest 
 
 
 
Group Raw 
value 
x80x104 log10 
83.1 210 1.68E+08 8.225309 
83.2 212 1.7E+08 8.229426 
83.3 209 1.67E+08 8.223236 
83.4 209 1.67E+08 8.223236 
87.1 104 83200000 7.920123 
87.2 102 81600000 7.91169 
87.3 100 80000000 7.90309 
87.4 102 81600000 7.91169 
 
 
Table 1B: Table 1A: Total viable counts of S. aureus recovered from mammary 
glands 48 h post-harvest 
 
 
Group Average Standard 
deviation 
Standard 
error 
83 8.225302 0.002917798 0.001458899 
87 7.911648 0.006953999 0.003476999 
 
Table 2: Flow cytometry data analysis 
 
 IL-10 IL-12 IL-17 IFNgama 
   68.84988 2.67353 33.71914 57.11185 
   65.99973 2.19311 28.13833 64.80309 
   64.47934 3.08212 27.03099 58.01622 
 
s.aur83 
 67.7619 4.164366 25.51337 58.05489 
  avg 66.77271 3.028282 28.60046 59.49651 
  SD 1.927881 0.840029 3.578073 3.564451 
  SE 0.963941 0.420015 1.789036 1.782226 
  
       
 
12.34588 1.094724 18.52964 14.95448 
  
 
12.66485 0.937307 19.20904 8.25735 
  
 
11.60959 1.252142 18.20979 13.6146 
  
 
14.81676 2.452451 16.83775 13.95583 
 
s aur87 
avg 12.85927 1.434156 18.19656 12.69557 
  SD 1.37778 0.690924 0.997095 3.012936 
  SE 0.68889 0.345462 0.498548 1.506468 
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Table 3:  Bacterial load of mammary glands in anti-inflammatory cytokine 
treated mice 
(a) IL-6 control mice group 
 
 
 
(b) Il-6 test mice group 
Mouse CFU Log 
1 50400000 7.702431 
2 45600000 7.658965 
3 49600000 7.695482 
4 37600000 7.575188 
5 44000000 7.643453 
6 34400000 7.536558 
 avg 7.635346 
 SD 0.06651 
 SE 0.027153 
 
           
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Mouse CFU Log 
1 216000000 8.334454 
2 208000000 8.318063 
3 176000000 8.245513 
4 160000000 8.20412 
5 232000000 8.365488 
6 200000000 8.30103 
 avg 8.294778 
 SD 0.059668 
 SE 0.024359 
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(c) IL-6R control mice group 
Mouse CFU Log 
1 160000000 8.20412 
2 168000000 8.225309 
3 200000000 8.30103 
4 168000000 8.225309 
5 256000000 8.40824 
6 112000000 8.049218 
 avg 8.235538 
 SD 0.118344 
 SE 0.048314 
 
 
 
 
(d) IL-6R test mice group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mouse CFU Log 
1 48800000 7.68842 
2 41600000 7.619093 
3 40000000 7.60206 
4 32000000 7.50515 
5 44000000 7.643453 
6 25600000 7.40824 
 avg 7.577736 
 SD 0.102829 
 SE 0.04198 
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B.6: Chapter 8 
 
 
Table 1: Humoral immune response of Planktonic S. aureus vaccine by s/c route 
 
 
 
 
 
Table 2: Humoral immune response Planktonic S. aureus vaccine by i/mam 
route 
 
 
Mouse 
serum 
IgG IgG1 
1 16000 12500 
2 2500 10000 
3 34000 12500 
4 20000 15000 
5 10000 20000 
6 10000 20000 
avg 15416.67 15000 
SD 10883.09 4183.3 
SE 4443.003 1707.825 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mouse 
serum 
IgG IgG1 
1 60000 80000 
2 60000 80000 
3 75000 58000 
4 60000 20000 
5 32000 20000 
6 32000 40000 
avg 53166.67 49666.67 
SD 17394.44 27434.77 
SE 7101.252 11200.2 
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Table 3: Humoral immune response Biofilm S. aureus vaccine by s/c route 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Humoral immune response Biofilm S. aureus vaccine by i/mam route 
 
Mouse 
serum 
IgG IgG1 IgG2a 
1 40000 14000 28000 
2 35000 6000 35000 
3 40000 8000 35000 
4 37500 12000 29500 
5 40000 12000 30000 
6 45000 12000 30000 
avg 39583.33 10666.67 31250 
SD 3322.9 3011.091 2995.83 
SE 1356.568 1229.273 1223.043 
 
 
 
 
 
 
 
 
 
 
Mouse 
serum 
IgG IgG1 IgG2a 
1 26500 20000 6000 
2 28000 21000 14000 
3 25000 13000 14000 
4 16000 20000 4500 
5 15000 20000 4500 
6 16000 7000 6000 
avg 21083.33 16833.33 8166.667 
SD 6020.105 5636.193 4568.005 
SE 2457.698 2300.966 1864.88 
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Table 5: Concentration of IFN-γ produced by killed planktonic S. aureus 
stimulated splenocytes of mice immunized with planktonic S. aureus vaccine 
using different routes 
 
 
 
 
 
 
 
 
 
Table 6: Concentration of IFN-γ produced by killed biofilm S. aureus stimulated 
splenocytes of mice immunized with biofilm S. aureus vaccine using different 
routes 
 
Mouse splenocyte 
sample 
s/c i/mam ConA 
1 0 5246.8 6150 
2 616.4 2830 6200 
3 808.8 3621.2 6000 
4 0 4540.8 6350 
5 616.4 4327.2 6100 
6 723.6 4990 6200 
avg 460.8667 4259.333 6166.667 
SD 364.2153 899.2221 116.9045 
SE 148.6903 367.1059 47.72607 
 
 
Mouse splenocyte 
sample 
s/c 
route 
i/mam 
route 
ConA 
1 77.6 57.2 6100 
2 0 0 6200 
3 77.6 0 6150 
4 56.4 57.2 6200 
5 0 0 6200 
6 77.6 0 6350 
avg 48.2 19.06667 6200 
SD 38.22774 29.53795 83.666 
SE 15.60641 12.05882 34.1565 
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Table 7: Detection of bacterial load of the mammary glands of mice vaccinated 
with S. aureus planktonic and biofilm vaccines 
(a) Planktonic control mice (i/mam route)                                                   
 
Mouse  CFU  Log value 
  1 40000000 7.60206 
2 4000000 6.60206 
3 200000 5.30103 
4 1E+08 8 
5 400000 5.60206 
6 1E+08 8 
 avg 6.851202 
 SD 1.202391 
 SE 0.490874 
  
(b)  Planktonic control mice (s/c route) 
Mouse  CFU Log value 
1 40000000 7.60206 
2 40000000 7.60206 
3 40000000 7.60206 
4 60000000 7.778151 
5 80000000 7.90309 
6 40000000 7.60206 
 avg 7.68158 
 SD 0.129373 
 SE 0.052816 
 
(c) Planktonic test mice (s/c route) 
Mouse  CFU Log value 
1 4000000 6.60206 
2 4000000 6.60206 
3 4000000 6.60206 
4 2000000 6.30103 
5 600000 5.778151 
6 40000000 7.60206 
 avg 6.581237 
 SD 0.594448 
 SE 0.242682 
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(d) Planktonic test mice (i/mam route) 
Mouse  CFU Log value 
1 140000000 8.146128 
2 12000000 7.079181 
3 4000000 6.60206 
4 4000000 6.60206 
5 600000 5.778151 
6 400000 5.60206 
 avg 6.63494 
 SD 0.925649 
 SE 0.377895 
 
(e) Biofilm control mice (s/c route) 
 
Mouse  CFU Log value 
1 20000000 7.30103 
2 4000000 6.60206 
3 200000 5.30103 
4 100000000 8 
5 400000 5.60206 
6 100000000 8 
 avg 6.80103 
 SD 1.170656 
 SE 0.477918 
 
(f) Biofilm control mice (i/mam route) 
 
Mouse  CFU Log value 
1 40000000 7.60206 
2 20000000 7.30103 
3 40000000 7.60206 
4 60000000 7.778151 
5 80000000 7.90309 
6 40000000 7.60206 
 avg 7.631409 
 SD 0.203508 
 SE 0.083082 
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(g) Biofilm test mice (s/c route) 
 
( 
 
 
 
 
 
 
 
(h) Biofilm test mice (i/mam route) 
Mouse  CFU Log value 
1 354000 5.549003 
2 380000 5.579784 
3 400000 5.60206 
4 330000 5.518514 
5 358000 5.553883 
6 400000 5.60206 
 avg 5.567551 
 SD 0.033066 
 SE 0.013499 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mouse  CFU Log value 
1 500000 5.69897 
2 300000 5.477121 
3 340000 5.531479 
4 240000 5.380211 
5 400000 5.60206 
6 440000 5.643453 
 avg 5.555549 
 SD 0.116562 
 SE 0.047586 
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B.7: Chapter 9 
Table 1: Detection of antigen-specific antibody in sera samples of mice 
vaccinated with Protein A 
 
 
 
 
 
 
 
Avg 
SD 
SE 
 
 
 
 
 
                                    
 
 
 
 
 
 
Avg 
SD 
SE 
 
 
 
 
 
 
 
 
Protein A s/c route 
 
          IgG         IgG1       IgG2a 
220 200 80 
400 240 100 
650 480 200 
1200 500 100 
300 220 100 
420 200 120 
531.6667 306.6667 116.6667 
358.1294 142.9219 42.73952 
146.2057 58.34762 17.44834 
ProteinA i/mam  
 
          IgG         IgG1       IgG2a 
280 80 120 
220 40 120 
220 40 140 
255 40 140 
240 40 120 
240 40 120 
242.5 46.66667 126.6667 
22.74863 16.32993 10.32796 
9.287088 6.666667 4.21637 
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Table 2: Concentration of IFN-γ produced by splenocytes of Protein A stimulated mice immunized by Protein A using different 
routes. 
 
 
 
 
 
 
 
 
 Avg 
         SD 
         SE 
 
 
 
 
IFN gama level 
         
           ProteinA s/c 
 
ProteinA i/mam 
  
ProteinA PBS s/c 
 
      PBS      
i/mam 
183.94 
  
163.62 
   
31.56 
  
23.1 
123.52 
  
213.34 
   
33.69 
  
21 
143.3 
  
179.125 
   
30.489 
  
22.2 
166.29 
  
174.845 
   
25.14 
  
22.12 
160.95 
  
120.8473 
   
25.67 
  
20.7 
177.52 
  
266.2756 
   
26.21 
  
23 
159.0233 
  
186.3422 
   
28.79317 
  
22.02 
22.48055 
  
49.21053 
   
3.585603 
  
0.995188 
9.177647 
  
20.09012 
   
1.463816 
  
0.406284 
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Table 3: Detection of bacterial load of the mammary glands of mice 
immunized with Protein A 
 
(a) Protein A s/c route 
                     CFU         Log value 
 
 
 
 
 
 
 
 
 
(b) Protein A i/mam route 
  CFU             Log value 
60000000 7.778151 
1300000 6.113943 
6000000 6.778151 
60000000 7.778151 
60000000 7.778151 
60000000 7.778151 
Avg 7.334117 
SD 0.719248 
SE 0.293632 
 
 
 
 
 
 
 
80000000 7.90309 
100000000 8 
80000000 7.90309 
340000000 8.531479 
460000000 8.662758 
120000000 8.079181 
196666667 8.293731 
     AVG 8.179933 
     SD 0.33242 
     SE 0.13571 
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(c)  Protein A control mice (s/c route) 
 
                   CFU             Log 
2000000000 9.30103 
1000000000 9 
1200000000 9.079181 
1000000000 9 
1000000000 9 
700000000 8.845098 
         Avg 9.037552 
         SD 0.149948 
         SE 0.061216 
 
 
 
(d ) Protein A control mice (i/mam route) 
 
         CFU              Log value 
1700000000 9.230449 
1000000000 9 
1300000000 9.113943 
1000000000 9 
1000000000 9 
900000000 8.954243 
  Avg 9.049772 
SD 0.103266 
SE 0.042158 
 
